

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

=> d his

(FILE 'HOME' ENTERED AT 09:43:05 ON 24 APR 2002)  
TI FILE 'MEDLINE, CAPLUS, EMBASE, 'BIOSIS, CANCERLIT, USPATFULL' ENTERED AT  
09:43:46 ON 24 APR 2002  
L1 11314058 S METHOD OR PROTOCOL?  
L2 12433 S TUMOR INVASION  
L3 3861 S L1 AND L2  
L4 2158 S L3 NOT PY=>1999  
L5 1193 DUP REM L4 (965 DUPLICATES REMOVED)  
L6 6017 S RAGE OR RECEPTOR FOR ADVANCED GLICATION ENDPRODUCTS  
L7 0 S L5 AND L6  
=> s 15 and amphotericin  
L8 0 LS AND AMPHOTERICIN  
=> s 15 and agent?  
L9 239 LS AND AGENT?  
=> d 19 1-239  
L9 ANSWER 1 OF 239 MEDLINE  
AN 199002638 MEDLINE  
DN 99022438 PubMed ID: 9805796  
TI [its laparoscopic evaluation of digestive cancers legitimate? A prospective  
study of 109 cases]  
AU Barrat C; Champault G; Catheline J M  
CS Service de Chirurgie Generale et Digestive, Hopital Jean-verdier, Bondy.  
SO ANNALES DE CHIRURGIE, (1998) 52 (7) 602-6.  
Journal code: 50E; 0140722. ISSN: 0003-3944.  
CY France  
DT Journal; Article; (JOURNAL ARTICLE)  
LA French  
FS Priority Journals  
EM 199812 Entered STN: 19990115  
ED Last Updated on STN: 20000303  
Entered Medline: 19981202  
L9 ANSWER 2 OF 239 MEDLINE  
AN 199844708 MEDLINE  
DN 98445708 PubMed ID: 972531  
TI Effects of TIMP-2 gene transfection on biological behaviors of a  
metastatic human lung carcinoma cell line.  
AU Li H; Fang W; Shi Z  
CS Department of Pathology, Beijing Medical University, CHUNG-HUA I HSUEH TSA CHIH (CHINESE MEDICAL JOURNAL), (1997 Sep) 77 (9) 652-6.  
Journal code: CDG; 751141. ISSN: 0376-2491.  
CY China  
DT Journal; Article; (JOURNAL ARTICLE)  
LA Chinese  
FS Priority Journals  
EM 199811 Entered STN: 19990106  
ED Last Updated on STN: 20000303  
Entered Medline: 19981109  
L9 ANSWER 3 OF 239 MEDLINE  
AN 1998443373 MEDLINE  
DN 98443373 PubMed ID: 97169365  
TI Conservation treatment intensified with tamoxifen and CAF chemotherapy for  
subareolar breast cancers.  
AU Ogawa Y; Nishioka A; Inomata T; Tsiboi N; Hayase N; Fukumoto M; Yoshida S;  
Tochikia N; Tanaka Y; Kumon M  
CS Department of Radiology, Kochi Medical School, Oko-cho, Nankoku-shi,  
Kochi-Prefecture, 783-8505, Japan.  
SO ONCOLOGY REPORTS, (1998 Nov-Dec) 5 (6) 1337-41.  
CY Greece  
TI Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199811 Entered STN: 19990106  
ED Last Updated on STN: 19990106  
Entered Medline: 19981125  
L9 ANSWER 4 OF 239 MEDLINE  
AN 1998187878 MEDLINE  
DN 98187878 PubMed ID: 9529029  
TI Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of  
metalloproteinase-2 expression in bladder cancer.  
AU Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S  
CS Department of Urology, School of Medicine, The University of Tokushima,  
Kuramoto, Japan.  
SO CANCER, (1998 Apr 1) 82 (7) 1359-66.  
Journal code: CLZ; 034236. ISSN: 0008-543X.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 199804 Entered STN: 19980430  
ED Last Updated on STN: 20000303  
Entered Medline: 19980423  
L9 ANSWER 5 OF 239 MEDLINE  
AN 1998120074 MEDLINE  
DN 98120074 PubMed ID: 9467021  
TI [dura thickening adjacent to intracranial, para-dural space-occupying  
lesions in MRI. Histologic correlation].  
AU Hutzemann A; Palmie S; Freund M; Buhl R; Heller M  
CS Klinik fur Radiologische Diagnostik der Christian-Albrechts-Universitt zu  
Kiel.  
SO AKTUELLE RADIOLOGIE, (1997 Nov) 7 (6) 305-8.  
Journal code: AOB; 9102962. ISSN: 0939-267X.  
CY GERMANY; Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA German  
FS Priority Journals  
EM 199803 Entered STN: 19980410  
ED Last Updated on STN: 19980410  
Entered Medline: 19980331  
L9 ANSWER 6 OF 239 MEDLINE  
AN 97070117 MEDLINE  
DN 97070117 PubMed ID: 8913076  
TI A case of embryonal carcinoma successfully treated by neoadjuvant  
chemotherapy: report of a case.  
AU Shibata S; Okumichi T; Kimura A; Nishimura Y; Okamoto H; Kuroaka T; Yuuki

I: Kajiwara H  
CS Department of Surgery, Yoshijima Hospital, Hiroshima, Japan.  
SO KYOU GEKA. JAPANESE JOURNAL OF THORACIC SURGERY, (1996 Oct) 49 (11) 963-5.  
Journal code: KOF; 0413533. ISSN: 0021-5252.

CY Japan  
DT Journal; Article; (JOURNAL ARTICLE)  
LA Japanese  
FS Priority Journals  
EM 199612  
ED Entered STN: 19970128  
Last Updated on STN: 19970128  
Entered Medline: 19961210

L9 ANSWER 7 OF 239 MEDLINE  
LA Japanese  
FS Priority Journals  
EM 199612  
ED Entered STN: 19970128  
Last Updated on STN: 19970128  
Entered Medline: 19961210

L9 ANSWER 7 OF 239 MEDLINE  
AN 9705590 MEDLINE  
DN 9704590 PubMed ID: 8890594  
TI Progress and clinical usefulness of color Doppler method in diagnosing abdominal diseases.  
AU Tomiyama T; Ueno N; Tano S; Nagamine N; Wada S; Miyata T; Aizawa T; Miyata T; Kumakura Y; Kimura K  
CS Department of Gastroenterology, Jichi Medical School, NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, (1996 Sep) 54 (9) 2561-73. Ref: 29  
SO Journal code: KIM; 0420546. ISSN: 0047-1852.  
CY Japan  
DT Journal; Article; (JOURNAL ARTICLE)  
FS General Review; (REVIEW)  
(REVIEW LITERATURE)  
LA Japanese  
FS Priority Journals  
EM 199612  
ED Entered STN: 19970128  
Last Updated on STN: 19970128  
Entered Medline: 19961206

L9 ANSWER 8 OF 239 MEDLINE  
AN 96229311 MEDLINE  
DN 96229311 PubMed ID: 8647672  
TI Local interferon therapy for melanoma patients.  
AU Ikić D; Spaventić S; Padojan I; Kusić Z; Čajkovač V; Ivanković D; Daković N; Nola P  
CS Department of Medicine, Croatian Academy of Sciences and Arts, Zagreb, Croatia.  
SO INTERNATIONAL JOURNAL OF DERMATOLOGY, (1995 Dec) 34 (12) 872-4.  
Journal code: GRZ; 0243704. ISSN: 0011-9959.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199607  
ED Entered STN: 1996005  
Last Updated on STN: 20000303  
Entered Medline: 19960719

L9 ANSWER 9 OF 239 MEDLINE  
AN 96208584 MEDLINE  
DN 96208584 PubMed ID: 8646886  
TI In Vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.  
AU Sokoloff M H; Tsoo C L; Kaboo R; Taneja S; Pang S; deKernion J B; Belldegrun A S  
CS Immunotherapy/Laboratory, Prostate Cancer Program, Division of Urology, Department of Surgery, UCLA School of Medicine, Los Angeles, California

NC 90024, USA.  
SO CA-16024 (NCI)  
CANCER, (1996 May 1) 77 (9) 1862-72.  
Journal code: CIZ; 0374236. ISSN: 0008-543X.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abrridged Index Medicus Journals; Priority Journals  
EM 199607  
ED Entered STN: 19960805  
Last Updated on STN: 20000303  
Entered Medline: 19960722

L9 ANSWER 10 OF 239 MEDLINE  
AN 95395737 MEDLINE  
DN 95395737 PubMed ID: 745228  
TI Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma--a report from the German Cooperative Pediatric Liver Tumor Study HB-99.  
AU von Schweinitz D; Hecker H; Harms D; Bode U; Weinel P; Burger D; Erttmann R; Mildenberger H  
CS Department of Pediatric Surgery, Medical School Hannover, Germany.  
SO JOURNAL OF PEDIATRIC SURGERY, (1995 Jun) 30 (6) 845-52.  
Journal code: JPS; 0025631. ISSN: 0022-3468.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199510  
ED Entered STN: 19951020  
Last Updated on STN: 19960129  
Entered Medline: 19951012

L9 ANSWER 11 OF 239 MEDLINE  
AN 95122813 MEDLINE  
DN 95122813 PubMed ID: 7822556  
TI Staging of colon carcinoma using water enema CT.  
AU Gazelle G S; Gaa J R; Saini S; Shellito P  
CS Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston 02114.  
SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, (1995 Jan-Feb) 19 (1) 87-91.  
Journal code: HVT; 7703942. ISSN: 0363-8715.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199502  
ED Entered STN: 19950223  
Last Updated on STN: 19950223  
Entered Medline: 19950210

L9 ANSWER 12 OF 239 MEDLINE  
AN 94227090 MEDLINE  
DN 94227090 PubMed ID: 8181412  
TI Colon carcinoid tumors. A population-based study.  
AU Spread C; Berkel H; Jewell L; Jenkins H; Yakimets W  
CS Department of Surgery, University Hospital, University of Alberta, Edmonton, Canada.  
SO DISEASES OF THE COLON AND RECTUM, (1994 May) 37 (5) 482-91.  
Journal code: ECR; 0372764. ISSN: 0012-3706.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals

EM 199406 Entered STN: 19940621  
ED Last Updated on STN: 19940621  
Entered Medline: 19940614

L9 ANSWER 13 OF 239 MEDLINE  
AN 94164078 MEDLINE  
DN 94164078 PubMed ID: 8119210  
TI Assessment of response of esophageal carcinoma to induction chemotherapy.

AU Hordijk M L; Rok T C; Wilson J H; Mulder A H  
CS Department of Internal Medicine II, University Hospital Rotterdam  
DIJkzigt, The Netherlands.

SO ENDOSCOPY. (1993 Nov) 25 (9) 592-6.  
Journal code: EHP: 0215166 ISSN: 0013-726X.

CY GERMANY; Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
ED 199404  
Entered STN: 19940412  
Last Updated on STN: 19940412  
Entered Medline: 19940401

L9 ANSWER 14 OF 239 MEDLINE  
AN 94127116 MEDLINE  
DN 94127116 PubMed ID: 8296501  
TI [The contrast enhancement of brain and spinal cord tumors using Gd-DTPA in magnetic resonance tomography with an extra-low magnetic-field intensity].  
Kontrastnaya usilennie opnikhodei golovnogo i spinistogo mozga s pomoshch'iu Gd-DTPA pri magnitnoi-rezonansnoi tomografii so sverkhnizkoi napriazhennost'iu magnitnoi polia.

AU Kornilenko N; Pronin I N; Turkin A M; Fadeeva L M  
SO ZHURNAL VOPROSY NEIROKHIRURGIYI IMENI N. N. BURDENKO. (1993 Oct-Dec) (4) 13-7.  
Journal code: 19Z; 7809757. ISSN: 0042-8817.  
CY RUSSIA; Russian Federation  
DT Journal; Article; (JOURNAL ARTICLE)  
LA Russian  
FS Priority Journals  
EM 19903  
ED Entered STN: 19940314  
Last Updated on STN: 19990129  
Entered Medline: 19940303

L9 ANSWER 15 OF 239 MEDLINE  
AN 93293116 MEDLINE  
DN 93293116 PubMed ID: 1305671  
TI Development of chemopreventive agents for bladder cancer.  
AU Kelloff G J; Boone C W; Malone W F; Steele V E; Boddy L A  
CS Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland  
SO JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT. (1992) 161 1-12. Ref: 48  
Journal code: K8K; 8207539. ISSN: 0733-1959.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA General Review; (REVIEW)  
FS Priority Journals  
ED 199307  
Entered STN: 19930806  
Last Updated on STN: 19930806  
Entered Medline: 19930722

L9 ANSWER 16 OF 239 MEDLINE  
AN 93220208 MEDLINE  
DN 93220208 PubMed ID: 8465580  
TI Intra- and perivesical tumor growth in preoperative staging of bladder cancer: the role of transrectal ultrasonography and high resolution magnetic resonance imaging.  
AU Ruehher U; Guhl L; Schmidt A; Stilz S; Bader H; Nunnensiek C; Rassweiler J; Eisenberger F; Jipp P  
CS Clinic of Internal Medicine, Department of General Internal Medicine, Institute of Pathology, Katharinenhospital, Stuttgart, FRG.  
SO UROLOGIA INTERNATIONALIS. (1993) 50 (3) 141-7.  
CY Switzerland  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
ED 199305  
Entered STN: 19930521  
Last Updated on STN: 19930521  
Entered Medline: 19930504

L9 ANSWER 17 OF 239 MEDLINE  
AN 93215324 MEDLINE  
DN 93215324 PubMed ID: 7681744  
TI Management of malignant pleural effusions.  
AU Lynch T J Jr  
CS Division of Clinical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.  
SO CHEST. (1993 Apr) 103 (4 Suppl) 385S-389S. Ref: 43  
Journal code: DIC: 0231335. ISSN: 0012-3692.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA General Review; (REVIEW)  
FS Abridged Index Medicus Journals; Priority Journals  
EM 199305  
ED Entered STN: 19930521  
Last Updated on STN: 19960129  
Entered Medline: 19930503

L9 ANSWER 18 OF 239 MEDLINE  
AN 93001740 MEDLINE  
DN 93001740 PubMed ID: 1389653  
TI Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation.  
AU Fryholm G; Hemmingsson A; Nyman R; Palmman L; Glimelius B  
CS Department of Oncology, Uppsala University, Sweden.  
SO ACTA RADIOLOGICA. (1992 Sep) 33 (5) 447-52.  
Journal code: ARA; 8706123. ISSN: 0284-1851.  
CY Denmark  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199210  
Entered STN: 19930122  
Last Updated on STN: 19930122  
Entered Medline: 19921029

L9 ANSWER 19 OF 239 MEDLINE  
AN 90208365 MEDLINE  
DN 90208365 PubMed ID: 2181691  
TI Magnetic resonance imaging in the evaluation of lung cancer.  
AU Gefter W B

CS Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104. SEMINARS IN ROENTGENOLOGY, (1990 Jan) 25 (1) 73-84. Ref: 70

SO Journal code: U03; 0053252. ISSN: 0037-198X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM Priority

ED Entered STN: 19900601

Last Updated on STN: 19900601

Entered Medline: 19900508

L9 ANSWER 20 OF 239 MEDLINE

AN 90150098 PubMed ID: 2302078

DN 90150098 PubMed ID: 2302078

TI Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and B16 melanoma.

AU Bousquet P F; Paulsen I A; Fondy C; Lipski K M; Loucy K J; Fondy T P

GS Department of Biology, Syracuse University, New York 13244.

SO CANCER RESEARCH, (1990 Mar 1) 50 (5) 1431-9.

CY Journal code: CNF; 2984705R. ISSN: 0008-5472.

United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM Priority

ED Entered STN: 19900601

Last Updated on STN: 19970203

Entered Medline: 19900321

L9 ANSWER 21 OF 239 MEDLINE

AN 87324971 PubMed ID: 2820315

DN 87324971 PubMed ID: 2820315

TI A case of hepatocellular carcinoma with extrahepatic portal vein obstruction due to tumor invasion, responsive to oral administration of UFT.

AU Nakamichi T; Nishikawa M; Nagase T; Nakayama C; Maeda S; Kuroda K; Tokunaga K

SO GAN TO KAGAKU RIHO (JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY), (1987 Sep) 14 (9) 2183-6.

CY Journal code: GT8; 7810034. ISSN: 0385-0684.

DT Japan; Article; (JOURNAL ARTICLE)

LA Japanese

FS Priority Journals

EM Priority

ED Entered STN: 19900305

Last Updated on STN: 19900305

Entered Medline: 19871008

L9 ANSWER 22 OF 239 MEDLINE

AN 83123387 MEDLINE

DN 83123287 PubMed ID: 6395923

TI [Hemostasis and tumor invasion. Therapeutic implications]. Hemostase et invasion tumorale. Dedications therapeutiques. Cattan A

AU BULLETIN DU CANCER, (1984) 71 (5) 481-93. Ref: 83

SO Journal code: BDZ; 0072416. ISSN: 0007-4551.

CY France

DT (CLINICAL TRIAL)

Journal, Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA French

FS Priority Journals

EN 198304 Entered STN: 19900320

ED Last Updated on STN: 19980206

Entered Medline: 19850404

L9 ANSWER 23 OF 239 MEDLINE

AN 84106383 PubMed ID: 6198070

DN 84106383 PubMed ID: 6198070

TI Retropitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical Stage II nonseminomatous germinal testis tumors.

AU Pizzocaro G; Zanoni F; Milani A; Piva L; Salvioni R; Pasi M; Pilotti S; Monfardini S

SO CANCER, (1984 Mar 15) 53 (6) 1363-8.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 198403 Entered STN: 19900319

ED Last Updated on STN: 19900319

Entered Medline: 19840323

L9 ANSWER 24 OF 239 MEDLINE

AN 82102255 PubMed ID: 7033659

DN 82102255 PubMed ID: 7033659

TI Histochemical localization of cathepsin B at the invasion front of the rabbit v2 carcinoma.

AU Graf M; Baci A; Strauli P

SO LABORATORY INVESTIGATION, (1981 Dec) 45 (6) 587-96.

Journal code: K24; 0376617. ISSN: 0023-6837.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198203 Entered STN: 19900317

ED Last Updated on STN: 19900317

Entered Medline: 19820322

L9 ANSWER 25 OF 239 CAPLUS COPYRIGHT 2002 ACS

AN 1998-138670 CAPLUS

DN 129:92270

TI Clinical study on xenon-enhanced CT and its methodological consideration.

AU Hyoran, Geinachi

CS Dep. Neurol. Surg., Wakayama Med. Coll., Wakayama, 640-0000, Japan

SO Wakayama Iku (1998), 49(2), 223-233

CODEN: WKMRA, ISSN: 0043-0013

BB Wakayama Igakkai

DT Journal

LA Japanese

L9 ANSWER 26 OF 239 CAPLUS COPYRIGHT 2002 ACS

AN 1997-615807 CAPLUS

DN 127:314118

TI Anti-invasive activity of alkaloids and polyphenolics in vitro

AU Parmar, Virinder S.; Bracke, Marc E.; Philippe, Jan; Wengel, Jesper; Jain, Subash C.; Olsen, Carl E.; Bish, Kirpal S.; Sharma, Nawal K.; Courters, Andy; Sharma, Sunil K.; Vennekens, Krist; Van Marck, Veerle; Singh,

Sanjay K.; Kumar, Naresh; Kumar, Ajay; Malhotra, Sanjay; Kumar, Rajesh; Raiwanshi, Vivek K.; Jain, Rajni; Maree, Marc M. Department of Chemistry, University of Delhi, Delhi, 110 007, India

SO Bioorg. Med. Chem. (1997), 5(8), 1609-1619

CS CODEN: BMEC9P; ISSN: 0968-0896

CS Elsevier

CS DT Journal

LA English

LA L9 ANSWER 27 OF 239 CAPLUS COPYRIGHT 2002 ACS

AN 1997:133978 CAPLUS

DN 126-223988

TI Implications for immunosurveillance of altered HLA class I phenotypes in human tumors

AU Garrido, Federico; Ruiz-Cabello, Francisco; Cabrera, Teresa; Perez-Villar, Juan J.; Lopez-Bonet, Miguel; Dugan-Keer, Maggie; Stern, Peter L. 18014, Spain

SO Immunol. Today (1997), 18(2), 89-95

CS Dpto de Analisis Clinicos e Immunologia, Univ. Granada, Granada, 18014, Spain

CS Elsevier

PB CODEN: IMMTOB; ISSN: 0167-4919

DT Journal; General Review

LA English

LA L9 ANSWER 28 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 1998138973 EMBASE

TI Adult T-cell leukemia with predominant skin involvement.

AU Nagatani, T.; Miyazawa, M.; Matsuzaki, T.; Horiuchi, Y.; Temoto, G.; Sugita, Y.; Baba, N.; Sugiyama, A.; Nakajima, H.; Kikumura, H.

CS T. Nagatani, Department of Dermatology, Yokohama City Univ. Sch. of Medicine, 30-9 Fukura, Kanazawa-ku, Yokohama 236, Japan

SO International Journal of Dermatology, (1998) 37/4 (275-277).

Refs: 4 ISSN: 0011-9059 CODEN: IJDEBB

CY United Kingdom

DT Journal; Article

FS 005 General Pathology and Pathological Anatomy

013 Dermatology and Venereology

016 Cancer

037 Drug Literature Index

LA English

LA L9 ANSWER 29 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 1998129984 EMBASE

TI Cytostatic agents in the management of malignant gliomas.

AU Mikkelson, T.

CS Dr. T. Mikkelson, Dept. of Neurology and Neurosurgery, Henry Ford Medical Center, 2799 West Grand Blvd, Detroit, MI 48202-2689, United States

SO Cancer Control, (1998) 5/2 (150-162).

Refs: 114 ISSN: 1073-2748 CODEN: CACOFF

CY United States

DT Journal; Article

FS 008 Neurology and Neurosurgery

037 Drug Literature Index

LA English

LA English

LA L9 ANSWER 30 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 9502228 EMBASE

DN 199502228

TI Magnetic resonance imaging in obstetrics and gynecology: Progress and limitations.

AU Worthington, B.S.

CS Sub-Department of Academic Radiology, Magnetic Resonance Centre, University of Nottingham, Nottingham NG7 2RD, United Kingdom

SO Magnetic Resonance Materials in Physics, Biology, and Medicine, (1994) 2 / 3 (247-251).

CS ISSN: 1352-8661 CODEN: MRBMQ

CY United States

CS DT Journal; Conference Article

FS 010 Obstetrics and Gynecology

FS 014 Radiobiology

FS 016 Cancer

LA 027 Biophysics, Bioengineering and Medical Instrumentation

SL English

LA L9 ANSWER 31 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 93109020 EMBASE

DN 1993109020

TI Development of chemopreventive agents for bladder cancer.

AU Kelloff, G.J.; Boone, C.W.; Malone, W.F.; Steele, V.E.; Doody, L.A.

CS Chemoprevention Branch, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892, United States

SO Journal of Cellular Biochemistry, (1992) 50/SUPPL. 16 I (1-12).

ISSN: 0730-2312 CODEN: JCEDB5

CY United States

DT Journal; Conference Article

FS 016 Cancer

028 Urology and Nephrology

030 Pharmacology

037 Drug Literature Index

LA English

SL English

LA L9 ANSWER 32 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 90090236 EMBASE

DN 1990090236

TI The use of gadolinium enhancement in magnetic resonance imaging of bladder lesions.

AU Hahn, D.; Schmidt, H.

CS Radiologische Klinik und Poliklinik der Universitaet Muenchen, Zentrale Roentgenabteilung, Pettenkoferstr. 8a, 8000 Muenchen 2, Germany

SO Problems in Urology, (1989) 3/4 (782-792).

ISSN: 0889-471X CODEN: PRUREX

CY United States

FS 014 Radiology

016 Cancer

028 Urology and Nephrology

037 Drug Literature Index

LA English

SL English

LA L9 ANSWER 33 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 88002551 EMBASE

DN 1988092551

TI An organ culture system designed to study interaction of fetal rat calvaria with human head and neck squamous cell carcinoma.

AU Wenig, B.L.; Steinberg, B.M.; Scibba, J.J.; Gomes, B.C.; Abramson, A.L.

CS Department of Otolaryngology and Communicative Disorders, The Long Island Jewish Medical Center, New Hyde Park, NY 11042, United States

SO Otolaryngology - Head and Neck Surgery, (1988) 98/3 (235241).

ISSN: 0194-5598 CODEN: OTOLOL

CY United States

DT Journal

FS	005	General Pathology and Pathological Anatomy	DT	Article
011		Otorhinolaryngology	LA	English
016		Cancer	SL	English
L9	ANSWER 34 OF 239	BIOSIS	COPYRIGHT	2002 ELSEVIER SCI. B.V.
AN	1998:80460	BIOSIS		
DN	PREV199800000460			
TI	Novel therapeutic strategies to selectively kill cancer cells.			
AU	Panchal, Rekha G. (1)			
CS	(1) Human Gene Therapy Res. Inst., Iowa Health Syst., 1415 Woodland Ave., Des Moines, IA 50309-2303 USA			
SO	Biochemical Pharmacology, (Feb. 1, 1998) Vol. 55, No. 3, pp. 247-252.			
	ISSN: 0006-2952.			
	Article			
LA	English			
L9	ANSWER 38 OF 239	BIOSIS	COPYRIGHT	2002 BIOLOGICAL ABSTRACTS INC.
AN	1997:40375	BIOSIS		
DN	PREV199705270578			
TI	Mediastinal epithelioid hemangioendothelioma in a patient with type IV Ehlers-Danlos syndrome: A case report and review of the literature.			
AU	Brady, L.W.; Carroll, M.N. (1)			
AU	Dept. Radiat. Ther. Nucl. Med., Hahnemann Med. Coll., Philadelphia, Pa.			
SO	19102, United States			
SO	Skeletal Radiology, (1977) 1/3 (161-167).			
	CODEN: SKRAD1			
CY	German			
DT	Journal			
FS	014	Radiology		
023	Nuclear Medicine			
033	Orthopedic Surgery			
016	Cancer			
LA	English			
L9	ANSWER 35 OF 239	EMBASE	COPYRIGHT	2002 ELSEVIER SCI. B.V.
AN	1977056736	EMBASE		
DN	1977056736			
TI	Carcinoma of the rectum.			
AU	Lee, Y.T.N.			
CS	Dept. Surg., Univ. South. California Sch. Med., Los Angeles, Calif. 90033,			
SO	United States			
	Review of Surgery, (1976) 33/2 (75-95).			
	CODEN: RESUR			
DT	Journal			
FS	006	Internal Medicine		
048	Gastroenterology			
009	Surgery			
016	Cancer			
020	Gerontology and Geriatrics			
LA	English			
L9	ANSWER 36 OF 239	BIOSIS	COPYRIGHT	2002 BIOLOGICAL ABSTRACTS INC.
AN	1998:230653	BIOSIS		
DN	PREV199800230653			
TI	Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasias with squamous phenotype: Actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin.			
AU	Krunic, A. L.; Garrod, D. R. (1); Madani, S.; Buchanan, M. D.; Clark, R.			
CS	(1) Epithelial Morphogenesis Res. Group, Sch. Biol. Sci., Univ. Manchester, 3-29 Storford Build., Oxford Road, Manchester M13 9PT UK			
SO	British Journal of Cancer, (April, 1998) Vol. 77, No. 8, pp. 1275-1279.			
	ISSN: 0007-0920.			
	Article			
DT	Article			
LA	English			
L9	ANSWER 40 OF 239	BIOSIS	COPYRIGHT	2002 BIOLOGICAL ABSTRACTS INC.
AN	1994:490113	BIOSIS		
DN	PREV199409493113			
TI	MR1 manifestations of gastrointestinal wall thickening.			
AU	Chou, C.-K. (1); Chen, L.-T.; Sheu, R.-S.; Wang, M.-L.; Jaw, T.-S.; Liu, G.-C.			
CS	(1) Dep. Radiol., Chi Mei Found. Hosp., No. 901 Chung-Wha Rd., Tainan Taiwan.			
SO	Abdominal Imaging, (1994) Vol. 19, No. 5, pp. 389-394.			
	ISSN: 0892-8925.			
	Article			
DT	Article			
LA	English			
L9	ANSWER 41 OF 239	BIOSIS	COPYRIGHT	2002 BIOLOGICAL ABSTRACTS INC.
AN	1994:349027	BIOSIS		
DN	PREV1994097361027			
TI	Regulation of 92-kD gelatinase release in HL-60 leukemia cells: Tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol ester-induced secretion.			
AU	Ries, Christian; Kolb, Helmut; Petrides, Petro E.			
CS	(1) Mol. Oncol. Lab., Dep. Med. III, Univ. Munich Med. Sch. Grosshadern, Marchioninistr. 15, 81377 Munich Germany			
SO	Blood, (1994) Vol. 83, No. 12, pp. 3638-3646.			
	ISSN: 0006-4971.			
	Article			
DT	Article			
LA	English			
L9	ANSWER 42 OF 239	BIOSIS	COPYRIGHT	2002 BIOLOGICAL ABSTRACTS INC.
AN	1993:346689	BIOSIS		
DN	PREV19930643689			
TI	Tetrapeptide tachykinin antagonists: Synthesis and modulation of the physicochemical and pharmacological properties of a new series of partially cyclic analogs.			
AU	Kucharczak, Nathalie; Thurieu, Christophe; Paladino, Joseph; Morris, James E.; Regolli, Domenico; Bonnet, Jacqueline; Canet, Emmanuel; Krause, Jean-Luc (1)			

CS (1) Inst. Recherches Servier, 11 rue Moulineaux, 92150 Suresnes France  
 SO Journal of Medicinal Chemistry, (1993) Vol. 36, No. 11, pp. 1654-1661.  
 ISSN: 0022-2623.

DT Article  
 LA English

1.9 ANSWER 43 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

DN BA73:84228 TI HISTOCHEMICAL LOCALIZATION OF CATHEPSIN B AT THE INVASION FRONT OF THE RABBIT V-2 CARCINOMA.  
 AU GRAF M; BAICI A; STRAULI P  
 CS DIVISION OF CANCER RESEARCH, INSTITUTE OF PATHOLOGY, UNIV. OF ZURICH, BIRCHSTR. 95, CH-8030 ZURICH, SWITZERLAND.  
 SO LAB INVEST, (1981) (RRCID 19821) 45 (6), 586-596;  
 CODEN: LINAW. ISSN: 0023-6837.  
 BA: OLD  
 FS English  
 LA

L9 ANSWER 44 OF 239 CANCERLIT  
 AN 95608359 DN 95608359  
 TI A membrane-bound metalloendoprotease expressed by C6 glioblastoma cells plays an important role in tumor invasion and cell migration in the CNS (Meeting abstract).  
 AU Hensel T; Amburger V; Schwab M E  
 CS Brain Res Inst., Univ. of Zurich, 8029 Zurich, Switzerland.  
 SO Proc Annu Meet Am Assoc Cancer Res, (1995); Vol. 36, pp. A580.  
 ISSN: 0197-066X.

DT (MEETING ABSTRACTS)  
 FS ICDB  
 LA English  
 EM 199506

L9 ANSWER 45 OF 239 CANCERLIT  
 AN 94699184 DN 94699184  
 TI Transarterial chemoembolization of icteric hepatic tumors (Meeting abstract).  
 AU Wu D K; Tsai T C; Chou C K; Liu G C  
 CS Kachsiung Medical Coll, Kachsiung, China.  
 SO Non-serial, (1993); APECVIR 93: The First Asian-Pacific Congress of Cardiovascular and Interventional Radiology. May 24-27, 1993, Seoul, Korea.  
 DT Journal; Article; (JOURNAL ARTICLE)  
 FS ICDB  
 LA English  
 EM 199410

L9 ANSWER 46 OF 239 CANCERLIT  
 AN 94690810 DN 94690810  
 TI A study of the proteinase, cathepsin L, in the context of tumour invasion.  
 AU Pike R N  
 CS Univ. of Natal, South Africa. Vol. 53, No. 9, pp. 4645.  
 SO Diss Asttr Int [B], (1993). ISSN: 0419-4217.

DT (THESIS)  
 FS ICDB  
 LA English  
 EM 199408

L9 ANSWER 47 OF 239 CANCERLIT  
 AN 90658011

DN 90658011 TT PROTEASES AS MARKERS FOR INVASIVE AND METASTATIC CANCER.  
 AU Wu C-W  
 CS Inst. of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.  
 SO Int Congr Ser, (1989). Vol. 807, pp. 259-73.  
 DT Journal; Article; (JOURNAL ARTICLE)  
 FS ICDB  
 LA English  
 EM 199111

L9 ANSWER 48 OF 239 CANCERLIT  
 AN 90657720 DN 90657720  
 TI OVERVIEW OF CURRENT UNDERSTANDING OF TUMOR SPREAD.  
 AU Goldfarb R; Brunson K W  
 CS Pittsburgh Cancer Inst., 3343 Forbes Ave, Pittsburgh, PA 15213.  
 SO Cancer Growth Prog, (1989). Vol. 1, pp. 28-32.  
 DT Journal; Article; (JOURNAL ARTICLE)  
 (REVIEW, TUTORIAL)  
 General Review; (REVIEW)

FS ICDB  
 LA English  
 EM 199001

L9 ANSWER 49 OF 239 CANCERLIT  
 AN 81695338 DN 81695338  
 TI CANCER PAIN.  
 AU Bonica J J  
 CS Anesthesiology, Univ. Washington Sch. Medicine, Seattle, WA, 98195.  
 SO Monogr Ser Eur Organ Res Treat Cancer, (1981). Vol. 7, pp. 87-115.  
 ISSN: 0146-0497.  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)

FS ICDB  
 LA English  
 EM 198103

L9 ANSWER 50 OF 239 CANCERLIT  
 AN 81688037 DN 81688037  
 TI PLASMINogen ACTIVATOR, PLASMIN, AND COLLAGENASE INTERACTIONS.  
 AU Moscatelli D; Riffin D B; Tisseroff R R; Jaffe E A  
 CS Dept. Cell Biology, New York Univ. Medical Sch., New York, NY, 10016.  
 SO Non-serial, (1980). Proteases and Tumor Invasion. Strauli P, Barrett AJ, Balci A, ed. New York, Raven Press, Monograph Series of the European Organization for Research on Treatment of Cancer, Vol. 6, 215, pp., 1980.

DT Book; (MONOGRAPH)  
 General Review; (REVIEW)

FS ICDB  
 LA English  
 EM 198101

L9 ANSWER 51 OF 239 CANCERLIT  
 AN 81620284 DN 81620284  
 TI HYPERHEMO-HYDROSTATIC PRESSURE THERAPY COMBINED WITH INTRAVESICAL INSTILLATION OF ANTICANCER DRUGS.  
 AU Ishikura G; Morita T; Ishida K  
 CS Dept. Urology, Akita Univ. Sch. Medicine, Hondo, Akita 010, Japan.  
 SO Rinsho Hinyoika, (1980). Vol. 34, No. 10, pp. 955-961.  
 DT Journal; Article; (JOURNAL ARTICLE)

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FS	ICDB	19808	LA	Japanese	EM	19808	ANSWER 52 OF 239 USPATFULL 1998:159986 USPATFULL Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
IN	PA	9510271	PA	The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)	PI	US 585056	19981222
AI	WO	1998-63383	US	1998-63383	DT	US 1994-11492	19980410 (8)
FS	LN CNT	5051	INCL	514/510.000; 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000; 514/567.000	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 54 OF 239 USPATFULL 1998:150674 USPATFULL Isolation of cellular material under microscopic visualization
RLI	AN	1998-159986	AN	Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12 Oct 1993, now patented, Pat. No. US 5635532, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned	TI	IN	1998:150674 USPATFULL Isolation of cellular material under microscopic visualization
IC	ICM:	514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000; 514/567.000	ICM:	514/510.000	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 54 OF 239 USPATFULL 1998:150674 USPATFULL Isolation of cellular material under microscopic visualization
IC	[61]	ICM: A01N037-12	ICM: A01N037-44; A61K031-195; A61K031-24	ICM: A01N001-00; A01N003-00	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
EXF	EXF	514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567	EXF	514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
AN	AN	ANSWER 53 OF 239 USPATFULL Compositions and methods for treating and preventing pathologies including cancer	AN	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe	IN	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
IN	IN	Samid, Dorit, Rockville, MD, United States	IN	514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000; 514/567.000	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
PA	PA	The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)	PA	ANSWER 53 OF 239 USPATFULL Compositions and methods for treating and preventing pathologies including cancer	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
PI	PI	US 5943994	PI	US 1991-778264	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
AI	AI	US 5943994	AI	US 1994-207521, filed on 7 Mar 1994, now patented, Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
DT	DT	Utility	Utility	Utility	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
FS	FS	Granted	Granted	Granted	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
IN	IN	514/510.000	INCL	514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000; 514/567.000	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
IC	[61]	ICM: A01K031-21	ICM: A01K031-21	ICM: A01N0047-40	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
EXF	EXF	514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567	EXF	514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567	INCL	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 55 OF 239 USPATFULL 1998:150662 USPATFULL Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
IN	IN	ANSWER 56 OF 239 USPATFULL 1998:147284 USPATFULL DNA encoding human cysteine protease	IN	ANSWER 56 OF 239 USPATFULL 1998:147284 USPATFULL DNA encoding human cysteine protease	IN	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 56 OF 239 USPATFULL 1998:147284 USPATFULL DNA encoding human cysteine protease
IN	IN	DiP, Dinh, San Francisco, CA, United States	IN	DiP, Dinh, San Francisco, CA, United States	IN	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 56 OF 239 USPATFULL 1998:147284 USPATFULL DNA encoding human cysteine protease
IN	IN	Braxton, Scott Michael, San Mateo, CA, United States	IN	Braxton, Scott Michael, San Mateo, CA, United States	IN	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 56 OF 239 USPATFULL 1998:147284 USPATFULL DNA encoding human cysteine protease
IN	IN	Deleageane, Angelo M., Hayward, CA, United States	IN	Deleageane, Angelo M., Hayward, CA, United States	IN	19960410 PCT 371 date 19960410 PCT 102(e) date	ANSWER 56 OF 239 USPATFULL 1998:147284 USPATFULL DNA encoding human cysteine protease

PA	Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.)	FS	Granted
PI	US 5,080,562	LN/CNT	1439
AI	US 1,977,928,613	INCL	INCIM: 435/029. 000
RLI	o Continuation of Ser. No. US 1,995-567,506, filed on 5 Dec., 1995, now abandoned	INCLS: 435/004-000; 530/300. 000; 530/323. 000; 530/324. 000; 530/325. 000; 530/330. 000;	
DT	Utility	530/326. 000; 530/327. 000; 530/328. 000; 530/329. 000; 530/330. 000;	
FS	Granted	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000; 530/333. 000;	
LN/CNT	1655	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000; 530/333. 000;	
INCIM:	435/212. 000	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000;	
INCLS:	435/320. 100; 435/325. 000; 435/254. 210; 435/252. 330; 536/023. 200;	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000;	
NCLM:	435/023. 500; 536/023. 100	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000;	
NCL:	435/212. 000	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000;	
NCUS:	435/252. 330; 435/254. 210; 435/320. 100; 435/325. 000; 536/023. 100;	530/329. 000; 530/330. 000; 530/332. 000; 530/3328. 000;	
IC	[6] ICM: C12N009-48	CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
ICS:	C07H021-04		
EXF	536/23.2; 536/23.1; 536/23.5; 435/320.1; 435/212; 435/69.1; 435/325;		
TI	535/172.3; 435/252.33; 435/254.21		
IN	CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
L9	ANSWER 57 OF 239 USPATFULL		
AN	1998:147247 USPATFULL		
TI	Nucleic acids, vectors and host cells encoding heregulin		
IN	Vandlen, Richard L., Hillsborough, CA, United States		
PA	Holmes, William E., Pacifica, CA, United States		
PA	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)		
corporation)	US 5841025	19981124	
AI	1995-456241	19950531 (8)	
RLI	Division of Ser. No. US 1,995-126145, filed on 23 Sep 1993, now abandoned		
IN	which is a continuation of Ser. No. US 1,992-880017, filed on 11 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1,992-847743, filed on 6 Mar 1992, now patented, Pat. No. US 5,367,060, issued on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1,991-79001, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1,991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1,991-705256, filed on 24 May 1991, now abandoned		
DT	Utility		
FS	Granted		
LN/CNT	2596		
INCL	INCIM: 514/183.000		
INCL	INCLS: 514/211.000; 514/228.000; 514/241.000; 514/242.000; 514/249.00; 514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/374.000; 514/400.000; 514/425.000; 514/427.000; 514/467.000; 514/314.000; 514/400.000; 514/425.000; 514/427.000; 514/428.000; 514/429.000; 514/430.000; 514/431.000; 514/433.000; 514/435.000; 514/436.000; 514/437.000; 514/438.000; 514/439.000; 514/440.000; 514/441.000; 514/442.000; 514/443.000; 514/444.000; 514/445.000; 514/446.000; 514/447.000; 514/448.000; 514/449.000; 514/450.000; 514/451.000; 514/452.000; 514/453.000; 514/454.000; 514/455.000; 514/456.000; 514/457.000; 514/458.000; 514/459.000; 514/460.000; 514/461.000; 514/462.000; 514/463.000; 514/464.000; 514/465.000; 514/466.000; 514/467.000; 514/468.000; 514/469.000; 514/470.000; 514/471.000; 514/472.000; 514/473.000; 514/474.000; 514/475.000; 514/476.000; 514/477.000; 514/478.000; 514/479.000; 514/480.000; 514/481.000; 514/482.000; 514/483.000; 514/484.000; 514/485.000; 514/486.000; 514/487.000; 514/488.000; 514/489.000; 514/490.000; 514/491.000; 514/492.000; 514/493.000; 514/494.000; 514/495.000; 514/496.000; 514/497.000; 514/498.000; 514/499.000; 514/500.000; 514/501.000; 514/502.000; 514/503.000; 514/504.000; 514/505.000; 514/506.000; 514/507.000; 514/508.000; 514/509.000; 514/510.000; 514/511.000; 514/512.000; 514/513.000; 514/514.000; 514/515.000; 514/516.000; 514/517.000; 514/518.000; 514/519.000; 514/520.000; 514/521.000; 514/522.000; 514/523.000; 514/524.000; 514/525.000; 514/526.000; 514/527.000; 514/528.000; 514/529.000; 514/530.000; 514/531.000; 514/532.000; 514/533.000; 514/534.000; 514/535.000; 514/536.000; 514/537.000; 514/538.000; 514/539.000; 514/540.000; 514/541.000; 514/542.000; 514/543.000; 514/544.000; 514/545.000; 514/546.000; 514/547.000; 514/548.000; 514/549.000; 514/550.000; 514/551.000; 514/552.000; 514/553.000; 514/554.000; 514/555.000; 514/556.000; 514/557.000; 514/558.000; 514/559.000; 514/560.000; 514/561.000; 514/562.000; 514/563.000; 514/564.000; 514/565.000; 514/566.000; 514/567.000; 514/568.000; 514/569.000; 514/570.000; 514/571.000; 514/572.000; 514/573.000; 514/574.000; 514/575.000; 514/576.000; 514/577.000; 514/578.000; 514/579.000; 514/580.000; 514/581.000; 514/582.000; 514/583.000; 514/584.000; 514/585.000; 514/586.000; 514/587.000; 514/588.000; 514/589.000; 514/590.000; 514/591.000; 514/592.000; 514/593.000; 514/594.000; 514/595.000; 514/596.000; 514/597.000; 514/598.000; 514/599.000; 514/600.000; 514/601.000; 514/602.000; 514/603.000; 514/604.000; 514/605.000; 514/606.000; 514/607.000; 514/608.000; 514/609.000; 514/610.000; 514/611.000; 514/612.000; 514/613.000; 514/614.000; 514/615.000; 514/616.000; 514/617.000; 514/618.000; 514/619.000; 514/620.000; 514/621.000; 514/622.000; 514/623.000; 514/624.000; 514/625.000; 514/626.000; 514/627.000; 514/628.000; 514/629.000; 514/630.000; 514/631.000; 514/632.000; 514/633.000; 514/634.000; 514/635.000; 514/636.000; 514/637.000; 514/638.000; 514/639.000; 514/640.000; 514/641.000; 514/642.000; 514/643.000; 514/644.000; 514/645.000; 514/646.000; 514/647.000; 514/648.000; 514/649.000; 514/650.000; 514/651.000; 514/652.000; 514/653.000; 514/654.000; 514/655.000; 514/656.000; 514/657.000; 514/658.000; 514/659.000; 514/660.000; 514/661.000; 514/662.000; 514/663.000; 514/664.000; 514/665.000; 514/666.000; 514/667.000; 514/668.000; 514/669.000; 514/670.000; 514/671.000; 514/672.000; 514/673.000; 514/674.000; 514/675.000; 514/676.000; 514/677.000; 514/678.000; 514/679.000; 514/680.000; 514/681.000; 514/682.000; 514/683.000; 514/684.000; 514/685.000; 514/686.000; 514/687.000; 514/688.000; 514/689.000; 514/690.000; 514/691.000; 514/692.000; 514/693.000; 514/694.000; 514/695.000; 514/696.000; 514/697.000; 514/698.000; 514/699.000; 514/700.000; 514/701.000; 514/702.000; 514/703.000; 514/704.000; 514/705.000; 514/706.000; 514/707.000; 514/708.000; 514/709.000; 514/710.000; 514/711.000; 514/712.000; 514/713.000; 514/714.000; 514/715.000; 514/716.000; 514/717.000; 514/718.000; 514/719.000; 514/720.000; 514/721.000; 514/722.000; 514/723.000; 514/724.000; 514/725.000; 514/726.000; 514/727.000; 514/728.000; 514/729.000; 514/730.000; 514/731.000; 514/732.000; 514/733.000; 514/734.000; 514/735.000; 514/736.000; 514/737.000; 514/738.000; 514/739.000; 514/740.000; 514/741.000; 514/742.000; 514/743.000; 514/744.000; 514/745.000; 514/746.000; 514/747.000; 514/748.000; 514/749.000; 514/750.000; 514/751.000; 514/752.000; 514/753.000; 514/754.000; 514/755.000; 514/756.000; 514/757.000; 514/758.000; 514/759.000; 514/760.000; 514/761.000; 514/762.000; 514/763.000; 514/764.000; 514/765.000; 514/766.000; 514/767.000; 514/768.000; 514/769.000; 514/770.000; 514/771.000; 514/772.000; 514/773.000; 514/774.000; 514/775.000; 514/776.000; 514/777.000; 514/778.000; 514/779.000; 514/780.000; 514/781.000; 514/782.000; 514/783.000; 514/784.000; 514/785.000; 514/786.000; 514/787.000; 514/788.000; 514/789.000; 514/790.000; 514/791.000; 514/792.000; 514/793.000; 514/794.000; 514/795.000; 514/796.000; 514/797.000; 514/798.000; 514/799.000; 514/800.000; 514/801.000; 514/802.000; 514/803.000; 514/804.000; 514/805.000; 514/806.000; 514/807.000; 514/808.000; 514/809.000; 514/810.000; 514/811.000; 514/812.000; 514/813.000; 514/814.000; 514/815.000; 514/816.000; 514/817.000; 514/818.000; 514/819.000; 514/820.000; 514/821.000; 514/822.000; 514/823.000; 514/824.000; 514/825.000; 514/826.000; 514/827.000; 514/828.000; 514/829.000; 514/830.000; 514/831.000; 514/832.000; 514/833.000; 514/834.000; 514/835.000; 514/836.000; 514/837.000; 514/838.000; 514/839.000; 514/840.000; 514/841.000; 514/842.000; 514/843.000; 514/844.000; 514/845.000; 514/846.000; 514/847.000; 514/848.000; 514/849.000; 514/850.000; 514/851.000; 514/852.000; 514/853.000; 514/854.000; 514/855.000; 514/856.000; 514/857.000; 514/858.000; 514/859.000; 514/860.000; 514/861.000; 514/862.000; 514/863.000; 514/864.000; 514/865.000; 514/866.000; 514/867.000; 514/868.000; 514/869.000; 514/870.000; 514/871.000; 514/872.000; 514/873.000; 514/874.000; 514/875.000; 514/876.000; 514/877.000; 514/878.000; 514/879.000; 514/880.000; 514/881.000; 514/882.000; 514/883.000; 514/884.000; 514/885.000; 514/886.000; 514/887.000; 514/888.000; 514/889.000; 514/890.000; 514/891.000; 514/892.000; 514/893.000; 514/894.000; 514/895.000; 514/896.000; 514/897.000; 514/898.000; 514/899.000; 514/900.000; 514/901.000; 514/902.000; 514/903.000; 514/904.000; 514/905.000; 514/906.000; 514/907.000; 514/908.000; 514/909.000; 514/910.000; 514/911.000; 514/912.000; 514/913.000; 514/914.000; 514/915.000; 514/916.000; 514/917.000; 514/918.000; 514/919.000; 514/920.000; 514/921.000; 514/922.000; 514/923.000; 514/924.000; 514/925.000; 514/926.000; 514/927.000; 514/928.000; 514/929.000; 514/930.000; 514/931.000; 514/932.000; 514/933.000; 514/934.000; 514/935.000; 514/936.000; 514/937.000; 514/938.000; 514/939.000; 514/940.000; 514/941.000; 514/942.000; 514/943.000; 514/944.000; 514/945.000; 514/946.000; 514/947.000; 514/948.000; 514/949.000; 514/950.000; 514/951.000; 514/952.000; 514/953.000; 514/954.000; 514/955.000; 514/956.000; 514/957.000; 514/958.000; 514/959.000; 514/960.000; 514/961.000; 514/962.000; 514/963.000; 514/964.000; 514/965.000; 514/966.000; 514/967.000; 514/968.000; 514/969.000; 514/970.000; 514/971.000; 514/972.000; 514/973.000; 514/974.000; 514/975.000; 514/976.000; 514/977.000; 514/978.000; 514/979.000; 514/980.000; 514/981.000; 514/982.000; 514/983.000; 514/984.000; 514/985.000; 514/986.000; 514/987.000; 514/988.000; 514/989.000; 514/990.000; 514/991.000; 514/992.000; 514/993.000; 514/994.000; 514/995.000; 514/996.000; 514/997.000; 514/998.000; 514/999.000; 514/1000.000; 514/1001.000; 514/1002.000; 514/1003.000; 514/1004.000; 514/1005.000; 514/1006.000; 514/1007.000; 514/1008.000; 514/1009.000; 514/1010.000; 514/1011.000; 514/1012.000; 514/1013.000; 514/1014.000; 514/1015.000; 514/1016.000; 514/1017.000; 514/1018.000; 514/1019.000; 514/1020.000; 514/1021.000; 514/1022.000; 514/1023.000; 514/1024.000; 514/1025.000; 514/1026.000; 514/1027.000; 514/1028.000; 514/1029.000; 514/1030.000; 514/1031.000; 514/1032.000; 514/1033.000; 514/1034.000; 514/1035.000; 514/1036.000; 514/1037.000; 514/1038.000; 514/1039.000; 514/1040.000; 514/1041.000; 514/1042.000; 514/1043.000; 514/1044.000; 514/1045.000; 514/1046.000; 514/1047.000; 514/1048.000; 514/1049.000; 514/1050.000; 514/1051.000; 514/1052.000; 514/1053.000; 514/1054.000; 514/1055.000; 514/1056.000; 514/1057.000; 514/1058.000; 514/1059.000; 514/1060.000; 514/1061.000; 514/1062.000; 514/1063.000; 514/1064.000; 514/1065.000; 514/1066.000; 514/1067.000; 514/1068.000; 514/1069.000; 514/1070.000; 514/1071.000; 514/1072.000; 514/1073.000; 514/1074.000; 514/1075.000; 514/1076.000; 514/1077.000; 514/1078.000; 514/1079.000; 514/1080.000; 514/1081.000; 514/1082.000; 514/1083.000; 514/1084.000; 514/1085.000; 514/1086.000; 514/1087.000; 514/1088.000; 514/1089.000; 514/1090.000; 514/1091.000; 514/1092.000; 514/1093.000; 514/1094.000; 514/1095.000; 514/1096.000		

TI Agents affecting thrombosis and hemostasis  
IN Wolf, David L., Palo Alto, CA, United States  
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 583769  
AI US 1995-463301  
RLI Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented,  
Pat. No. US 583107 which is a continuation-in-part of Ser. No. US 1994-29077, filed on 26 May 1994, now patented, Pat. No. US 559779  
which is a continuation of Ser. No. US 1990-808369 which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990,  
now patented, Pat. No. US 5278144  
DT Utility  
FS Granted  
LN.CNT 2092  
INCL INCLM: 514/012.000  
INCIS: 514/008.000; 514/021.000; 514/834.000; 424/094.640; 435/069.600;  
435/212.000; 530/381.000; 530/384.000; 530/395.000; 530/402.000;  
530/830.000  
IC [6] ICM: A61K038-36  
ICL ICM: A61K038-14; C07K014-475; C07K001-06  
EXF ICS: A61K038-14; 514/21; 514/8; 530/384; 530/395; 930/100; 435/350;  
530/402; 530/820; 530/830; 530/331; 530/395; 930/100; 435/69.1;  
435/69.2; 435/69.6; 435/212; 424/94.64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 61 OF 239 USPATFULL  
AN 1998:144076 USPATFULL  
TI Use of scatter factor to enhance angiogenesis  
IN Goldberg, Irzhak D., Englewood, NJ, United States  
Rosen, Eliot M., Port Washington, NY, United States  
PA Long Island Jewish Medical Center, New Hyde Park, NY, United States  
(U.S. corporation)  
PI US 1996-746636 19961113 (8)  
AI Continuation of Ser. No. US 1993-138667, filed on 18 Oct 1993, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 475  
INCL INCLM: 514/008.000  
INCIS: 514/021.000; 530/399.000  
NCL NCIM: 514/008.000  
NCIS: 514/021.000; 530/399.000  
IC [6] ICM: A61K038-18  
EXF ICS: 514/8; 514/21; 530/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 62 OF 239 USPATFULL  
AN 1998:138936 USPATFULL  
TI 3-(2'-halobenzylideny)-2-indolinone compounds for the treatment of  
disease  
IN Tang, Peng Cho, Moraga, CA, United States  
Sun, Li, Foster City, CA, United States  
McMahon, Gerald, Kenwood, CA, United States  
PA Sugen, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5845404 19981110

AI US 1996-655225 19960605 (8)  
RLI Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995  
DT Utility  
FS Granted  
LN.CNT 3662  
INCL INCLM: 514/418.000  
INCIS: 548/486.000  
NCL NCIM: 514/418.000  
NCIS: 548/486.000  
IC [6] ICM: H61K031-40  
ICL ICS: C07D209-34  
EXF 548/486; 514/418  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 63 OF 239 USPATFULL  
AN 1998:136672 USPATFULL  
TI Nucleic acids vectors and host cells encoding and expressing heregulin  
2'-alpha  
IN Vandlen, Richard L., Hillsborough, CA, United States  
Holmes, William E., Pacifica, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 5834229 19981110  
RLI Continuation of Ser. No. US 1993-3530, filed on 22 Mar 1993, now  
abandoned which is a continuation of Ser. No. US 1991-705256, filed on  
24 May 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 3467  
INCL INCLM: 435/069.100  
INCIS: 435/091.200; 435/325.000; 435/252.300; 435/320.100; 435/325.000; 536/023.500;  
536/024.310; 536/024.330  
IC [6] ICM: C12N015-00  
ICL ICS: C12N015-85; C12N007-00; C12N015-63; C07H021-04  
EXF ICS: C12N015-85; C12N007-00; C12N015-63; C07H021-04  
435/91.2; 435/96.1; 435/320.1; 435/240.2; 435/252.3; 435/252.8;  
536/23.5; 536/24.33; 536/24.31  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 64 OF 239 USPATFULL  
AN 1998:135148 USPATFULL  
TI Inhibitors of metalloproteases, pharmaceutical compositions comprising  
same and methods of their use  
IN Campbell, David A., San Mateo, CA, United States  
Patel, Dinesh V., Fremont, CA, United States  
Xiao, Xiao-Yi, San Diego, CA, United States  
PA Affymax Technologies N.V., Greenford, England (non-U.S. corporation)  
PI US 583104 19981003 19981003  
AI US 1995-59345 19951027 (8)  
RLI Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-329420, filed on 27 Oct 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2313  
INCL INCLM: 530/331.000  
INCIS: 514/018.000; 514/019.000; 564/154.000; 546/309.000; 544/159.000  
NCL NCIM: 530/331.000  
NCIS: 544/159.000; 546/309.000; 564/154.000

1C	IC	[61] ICM: C07K005-00 [62] ICM: 530/331; 514/18-19; 564/154; 546/309; 544/159.
19	AN	ANSWER 65 OF 239 USPATFULL
	TI	1998-135050 : USPATFULL
	IN	Phosphinic acid amides as matrix metalloprotease inhibitors
	INCL	Pikul, Stanislaw, Mason, OH, United States
	McDow-Dunham, Kelly Lynn, Loveland, OH, United States	
	DE, B1, Swarath, Cincinnati, OH, United States	
	Tai, Bo, Yettunde Olubisi, West Chester, OH, United States	
	PA	The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
	PI	US 5830915
	AI	US 1997-918950 19981103
	PRAI	US 1996-24765P 19970826 (8)
	DT	US 1996-24765P 19960828 (60)
	FS	Utility Granted
	IN.CNT	18/9
	INCL	INCLIM: 514/620-000
	INCLS:	514/357,000; 514/396,000; 514/415,000; 514/438,000; 514/451,000; 514/824,000; 514/861,000; 514/863,000; 514/864,000; 514/886,000; 514/902,000; 514/903,000; 546/021,000; 546/336,000; 546/337,000; 548/112,000; 549/006,000; 549/216,000
	NCL	NCIM: 514/620-000
	NCIS:	514/357,000; 514/396,000; 514/415,000; 514/438,000; 514/451,000; 514/824,000; 514/861,000; 514/863,000; 514/864,000; 514/886,000; 514/902,000; 514/903,000; 546/021,000; 546/336,000; 546/337,000; 548/112,000; 549/006,000; 549/216,000
	IC	[6]
	ICM:	A61K031-16
	ICS:	A61K031-38; A61K031-40; A61K031-44
	EXF	514/357; 514/396; 514/415; 514/436; 514/451; 514/620; 514/824; 514/861; 514/863; 514/864; 514/886; 514/902; 514/903; 546/21; 546/336; 546/337; 548/112; 549/6; 549/12; 564/12
	CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
19	AN	ANSWER 66 OF 239 USPATFULL
	TI	1998-134796 USPATFULL
	IN	Determining invasiveness of prostatic adenocarcinoma
	PA	Paterno, Steven R., Falls Church, VA, United States
	GEAR	Manvak, Michael, Chevy Chase, MD, United States
	corporation)	George Washington University, Washington, DC, United States (U.S. corporation)
	PI	US 5830640 19981103
	AI	US 1995-86203 19950607 (8)
	RLI	Continuation-in-Part of Ser. No. US 1995-400084, filed on 7 Mar 1995
	DT	Utility Granted
	FS	
	IN.CNT	21/64
	INCL	INCLIM: 435/004,000
	INCLS:	435/007,100; 435/040,500; 435/040,520; 530/386,000; 530/387,100;
	NCL	NCIM: 435/004,000
	NCIS:	435/007,100; 435/040,500; 435/040,520; 530/386,000; 530/387,100;
	IC	[6]
	ICM:	C120001-00
	ISS:	GO1N033-53; C07K016-00
	EXP	424/94-1; 424/184-1; 424/277-1; 5336/23-1; 435/6; 435/7-1; 435/4; 435/40-5; 435/40-52; 530/386; 530/387-1; 530/387,7
	CAS	INDEXING IS AVAILABLE FOR THIS PATENT.

AN	ANSWER 67 OF 239 USPATFULL
IN	Fibrinogen degradation by fibrinolytic matrix metalloproteinase
IN	Bindi, Alessandra, New York, NY, United States
PA	The New York Blood Center, Inc., New York, NY, United States (U.S. Corporation)
PI	US 53830468
AI	AI 1995-446887
DT	Utility
FS	Granted
LN CNT	1483
INCL	INCLM: 424/094.670 INCLS: 424/094.630; 424/094.100; 435/219.000; 530/389.300; 206/210.000;
NCL	NCLM: 424/094.670 NCLS: 426/210.000; 424/094.100; 424/094.630; 435/219.000; 530/389.300; 604/173.000
IC	[61] ICM: A61K038-48 ICSS: C12N009-00; B65D051-24; A61M005-00 EXF: 424/94.67; 424/94.64; 424/94.1; 424/93.21; 206/210; 604/173; 530/389.3; 435/219
CAS	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
19	ANSWER 68 OF 239 USPATFULL
AN	1998:128378 USPATFULL
TT	Human stromelysin-1 promoter
IN	Borden, Paula Ann, Palo Alto, CA, United States Heller, Renu Anand, Stanford, CA, United States
PA	Syntax (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI	US 5824794
AI	US 1994-362706
DT	Utility
FS	Granted
LN CNT	819
INCL	INCLM: 536/024.100 INCLS: 535/172.300; 435/320.100; 435/325.000; 435/366.000; 435/252.300;
NCL	NCLM: 536/023.500 NCLS: 435/252.300; 435/320.100; 435/325.000; 435/366.000; 536/023.500
IC	[61] ICM: C07H021-04 ICSS: C12N005-16; C12N015-12; C12N015-85 EXF: 519/44; 536/23.1; 536/24.1; 536/23.5; 435/320.1; 435/240.2; 435/6; 435/252.3; 435/366; 435/172.3; 435/325; 424/93.21
CAS	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
19	ANSWER 69 OF 239 USPATFULL
AN	1998:128586 USPATFULL
TT	Hydroxamic acid derivatives as inhibitors of cytokine production
IN	Crimmin, Michael John, Oxford, United Kingdom Beckett, Raymond Paul, Oxford, United Kingdom
PA	British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S. corporation)
PI	US 5821262
AI	US 1996-615184 19950413 19981013
DT	Utility
FS	Granted
LN CNT	1077
PRAI	GB 1993-20660 19931007
DT	19961028 PCT 371 date
FS	19961028 PCT 102(e) date

INCL INCLM: 514/455:000; 549/062.000; 562/621.000; 562/623.000  
 INCL INCLM: 514/375.000; 549/062.000; 562/621.000; 562/623.000  
 NCL NCLM: 514/415.000  
 ICL ICM: C07D33-34  
 ICS: C07C323-60; C07C317-44; A61K031-16  
 EXF 514/575; 514/397; 514/399; 514/419; 514/445; 562/621; 562/623;  
 548/315.; 548/325.1; 548/335.5; 548/494; 548/495; 549/62  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 70 OF 239 USPATFULL  
 1998-122568 USPATFULL  
 Certain alpha- $\beta$ -azacycloalkyl substituted arylsulfonamido acethydroxamic acids  
 Nantemmet, Philippe G., Maplewood, NJ, United States  
 Parker, David T., Livingston, NJ, United States  
 MacPherson, Lawrence J., Hampton, NJ, United States  
 Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
 PI US 5817822  
 AI US 1997-79730 19970124 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-475166, filed on 7 Jun 1995, now patented, Pat. No. US 5646167 which is a continuation-in-part of Ser. No. US 1994-33676, filed on 3 Nov 1994, now patented, Pat. No. US 552419 which is a continuation-in-part of Ser. No. US 1994-265296, filed on 24 Jun 1994, now patented, Pat. No. US 5506242

DT Utility  
 FS Granted  
 INL CNT 1865  
 INCL INCLM: 546/194.000  
 INGLS: 546/186.000; 546/190.000; 546/192.000; 546/207.000  
 NCL NCLM: 546/194.000  
 NCUS: 546/186.000; 546/190.000; 546/192.000; 546/207.000  
 IC [6] ICM: C07D401-02  
 EXF 546/186; 546/190; 546/192; 546/194; 546/207  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 71 OF 239 USPATFULL  
 1998-122413 USPATFULL  
 Substituted amino-alkyl compounds  
 Klein, J. Peter, Vashon Island, WA, United States  
 Underiner, Gail E., Brier, WA, United States  
 Leigh, Alastair J., Brier, WA, United States  
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 5817622  
 AI US 1995-468556 19950606 (8)  
 RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9 Nov 1992, now patented, Pat. No. US 5340813

DT Utility  
 FS Granted  
 INL CNT 1358  
 INCL INCLM: 514/263.000  
 INGLS: 424/824.000; 424/825.000; 424/885.000; 424/921.000  
 NCL NCLM: 514/263.300  
 NCUS: 424/824.000; 424/825.000  
 IC [6] ICM: A61K031-52  
 EXF 514/397; 514/263; 424/824; 424/825; 424/885; 424/921  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 72 OF 239 USPATFULL  
 1998-119125 USPATFULL

TI Compositions containing a disintegrin and methods for its use in preventing metastasis and other conditions  
 IN Markland, Jr., Francis S., Manhattan Beach, CA, United States  
 PA Zhou, Qing, Alhambra, CA, United States  
 zhous@alumni.southern.edu (corporation)  
 PI US 5814609 19980929  
 AI US 1996-75603 19961108 (8)  
 RLI Continuation-in-part of Ser. No. US 1996-632691, filed on 15 Apr 1996, now patented, Pat. No. US 5731288 which is a division of Ser. No. US 1995-540423, filed on 10 Oct 1995, now abandoned which is a continuation of Ser. No. US 1993-141321, filed on 22 Oct 1993, now abandoned

DT Utility  
 FS Granted  
 INL CNT 1005  
 INCL INCLM: 514/012.000  
 INGLS: 530/324.000  
 NCL NCLM: 514/012.000  
 NCUS: 530/324.000  
 IC [6] ICM: A61K038-00  
 EXF 514/12; 530/324  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 73 OF 239 USPATFULL  
 1998-111942 USPATFULL  
 Therapeutic compounds containing pyrimidinyl moieties  
 Klein, J. Peter, Vashon, WA, United States  
 Leigh, Alastair J., Brier, WA, United States  
 Underiner, Gail E., Brier, WA, United States  
 PA Kumar, Anil M., Seattle, WA, United States  
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 5807622  
 AI US 1995-478112 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned

DT Utility  
 FS Granted  
 INL CNT 2190  
 INCL INCLM: 514/769.000  
 INGLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000  
 NCL NCLM: 514/269.000  
 NCUS: 544/309.000; 544/310.000; 544/311.000; 544/312.000  
 IC [6] ICM: A61K031-505  
 EXF 514/769; 514/274; 544/309; 544/310; 544/311; 544/312  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 74 OF 239 USPATFULL  
 1998-111941 USPATFULL  
 Amine substituted xanthinyl compounds  
 Klein, J. Peter, Vashon, WA, United States  
 Underiner, Gail E., Brier, WA, United States  
 Kumar, Anil M., Seattle, WA, United States  
 Ridgers, Lance H., Bothell, WA, United States  
 Rice, Gleon C., Seattle, WA, United States  
 Leung, David W., Mercer Island, WA, United States  
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PA US 5807861 19980915  
 PI US 5807861 19980915  
 AI US 1995-476911 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned

DT	Utility	IN	differences between genomic nucleic acid sequences
FS	Granted	IN	Satkowski, Arthur J., Arlington, MA, United States
LN-CNT	1713	Yang, Meiheng, Boston, MA, United States	
INCL	INCLM: 514/263.000	PA	Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States
NCL	NCIM: 514/63.350	PA	(U.S. corporation)
NCIS:	514/081.000; 514/151.000; 514/210.210; 514/263.200;	US	5804382 19980508 (8)
IC	514/263.230	AI	1996-644326
	[6]	DT	Utility
	ICM: A61K031-52	FS	Granted
EXF	514/763	LN-CNT	1251
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	INCL	INCIM: 435/006.000
AN	ANSWER 75 OF 239 USPATFULL	INCL	INCIS: 435/091.200
AN	1998-108432 USPATFULL	NCIM:	435/006.000
TI	Methods of cancer treatment using naaladase inhibitors	NCIS:	435/091.200
IN	Slusher, Barbara S., Kingsville, MD, United States	IC	[6]
PA	Jackson, Paul F., Bel Air, MD, United States	ICM: C12Q001-68	
PA	Gilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)	ICS: C12P015-34	
PI	US 5804602	EXF	435/6; 435/91.2; 935/77; 935/78
AI	US 1996-665775	CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
DT	Utility	AN	ANSWER 78 OF 239 USPATFULL
FS	Granted	1998-104752 USPATFULL	
LN-CNT	1471	TI	Amine substituted compounds
INCL	INCIM: 514/574.000	IN	Klein, J. Peter, Vashon, WA, United States
INCIS:	562/024.000	Underiner, Gail E., Brier, WA, United States	
NCL	NCIM: 514/574.000	Kumar, Anil M., Seattle, WA, United States	
NCIS:	562/024.000	Ridgers, Lance H., Bothell, WA, United States	
IC	[6]	Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)	
ICM: A61K031-66	PA	PI	US 580182 19980901
ICS: C07F009-28	AI	US 1995-485777 19950607 (8)	
EXF	562/24; 514/574	RLI	Continuation-in-Part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	DT	Utility
AN	ANSWER 76 OF 239 USPATFULL	FS	Granted
AN	1998-108415 USPATFULL	LN-CNT	1706
TI	Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms	INCL	INCIM: 514/269.000
IN	Underiner, Gail E., Brier, WA, United States	INCIS:	514/214.000; 544/310.000; 544/311.000; 544/312.000
INCL	Portbeker, David, Seattle, WA, United States	NCIM:	514/265.000
PA	Klein, J. Peter, Vashon Island, WA, United States	NCIS:	514/274.000; 544/310.000; 544/311.000; 544/312.000
PA	Woodson, Paul, Edmonds, WA, United States	IC	[6]
PA	Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)	ICM: A61K031-505	
PI	US 5804584	EXF	544/312; 514/269; 514/274; 514/310; 514/311
AI	US 1995-468659	CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
RLI	Division of Ser. No. US 1993-153556, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070	AN	ANSWER 79 OF 239 USPATFULL
DT	Utility	TI	1998-104751 USPATFULL
FS	Granted	IN	Amino alcohol substituted cyclic compounds
LN-CNT	1554	INCL	Michnick, John, Seattle, WA, United States
INCL	INCIM: 514/269.000	Underiner, Gail E., Brier, WA, United States	
NCL	NCIM: 514/218.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000	Klein, J. Peter, Vashon Island, WA, United States	
NCIS:	514/259.000	Rice, Glenn C., Seattle, WA, United States	
IC	514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000	PA	Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
ICM:	C07D239-54	PI	US 5801181 19980901
ICM: A61K031-52	EXF	AI	US 1995-474820 19950607 (8)
CAS	514/242; 514/243; 514/269; 544/298; 514/299	RLI	Division of Ser. No. US 1993-152650, filed on 12 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993
AN	ANSWER 77 OF 239 USPATFULL	DT	Utility
AN	1998-108219 USPATFULL	FS	Granted
TI	Methods for identifying differentially expressed genes and	LN-CNT	2822
		INCL	INCIM: 514/263.000
		INCIS:	514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000; 514/617.000; 514/619.000;

NCL NCIM: 514/626.000; 514/668.000; 514/669.000

NCL NCIM: 514/263.350

514/315.000; 514/418.000; 514/249.000; 514/266.300; 514/425.000; 514/617.000; 514/619.000;

514/626.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

514/425.000; 514/617.000; 514/668.000; 514/669.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 82 OF 239 USPATFULL

AN 1998/9901 USPATFULL

TI Inhibitors of NALuBase enzyme activity

IN Jackson, Paul F., Bel Air, MD, United States

Tsuker, Barbara S., Kingsville, MD, United States

McLin, Keith M., Baltimore, MD, United States

Guildford Pharmaceuticals Inc., Baltimore, MD, United States (U.S.)

PA Utility (8)

PI US 1996-775586

AI Utility

FS Granted

IN CNT 2019

INCL INCLM: 514/075.000

EXF INCLS: 562/008.000; 562/024.000

NCL NCIM: 514/075.000

NCIS: 562/008.000; 562/024.000

IC [6]

ICM: C07F009-30

EXF C07F009-38; A61K031-66

NCL INCL: 562/8; 562/24; 514/75

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 83 OF 239 USPATFULL

AN 1998/95556 USPATFULL

TI 3-heterocaryl-2-indolinone compounds for the treatment of disease

IN Tang, Peng Cho, Moraga, CA, United States

Sun, Li, Foster City, CA, United States

McMahon, Gerald, Kenwood, CA, United States

Sugen, Inc., Redwood City, CA, United States (U.S. corporation)

PI US 1996-655223

AI Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995

RLI Utility

FS Granted

IN CNT 3788

INCL INCLM: 514/397.000

EXF INCLS: 514/339.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000;

530/388.85; 530/389.7; 530/389.7; 530/389.8;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 81 OF 239 USPATFULL

AN ICM: G01N033-536

EXF ICM: 435/7.1; 435/7.23; 530/3387.7; 530/388.2; 530/388.2; 530/388.9;

530/388.85; 530/389.700; 530/389.700; 530/389.700;

INCL INCLM: 514/007.210; 514/007.210; 514/007.210; 514/007.210;

INCLS: 530/388.85; 530/389.700; 530/389.700; 530/389.700;

IC [6]

ICM: G01N033-536

EXF ICM: 435/007.210; 530/387.700; 530/387.900; 530/388.200; 530/388.800;

530/388.85; 530/389.700; 530/389.700; 530/389.700;

INCL INCLM: 514/007.210; 514/007.210; 514/007.210; 514/007.210;

INCLS: 530/387.700; 530/387.900; 530/388.200; 530/388.800;

IC [6]

ICM: G01N033-536

EXF ICM: 435/007.210; 530/387.700; 530/387.900; 530/388.200; 530/388.800;

INCL INCLM: 514/007.210; 514/007.210; 514/007.210; 514/007.210;

INCLS: 530/387.700; 530/387.900; 530/388.200; 530/388.800;

IC [6]

ICM: G01N033-536

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 84 OF 239 USPATFULL

AN 514/359.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000;

TI 514/365.000; 514/367.000; 514/374.000; 514/374.000; 514/374.000;

IN 514/383.000; 514/406.000; 514/414.000; 514/414.000; 514/414.000;

514/418.000; 514/420.000; 514/420.000; 514/420.000; 514/420.000;

514/422.000; 514/424.000; 514/424.000; 514/424.000; 514/424.000;

514/425.000; 514/427.000; 514/427.000; 514/427.000; 514/427.000;

514/428.000; 514/430.000; 514/430.000; 514/430.000; 514/430.000;

514/431.000; 514/433.000; 514/433.000; 514/433.000; 514/433.000;

514/434.000; 514/436.000; 514/436.000; 514/436.000; 514/436.000;

514/437.000; 514/439.000; 514/439.000; 514/439.000; 514/439.000;

514/440.000; 514/442.000; 514/442.000; 514/442.000; 514/442.000;

514/443.000; 514/445.000; 514/445.000; 514/445.000; 514/445.000;

514/446.000; 514/448.000; 514/448.000; 514/448.000; 514/448.000;

514/449.000; 514/451.000; 514/451.000; 514/451.000; 514/451.000;

514/452.000; 514/454.000; 514/454.000; 514/454.000; 514/454.000;

514/455.000; 514/457.000; 514/457.000; 514/457.000; 514/457.000;

514/458.000; 514/460.000; 514/460.000; 514/460.000; 514/460.000;

514/461.000; 514/463.000; 514/463.000; 514/463.000; 514/463.000;

514/464.000; 514/466.000; 514/466.000; 514/466.000; 514/466.000;

514/467.000; 514/469.000; 514/469.000; 514/469.000; 514/469.000;

514/470.000; 514/472.000; 514/472.000; 514/472.000; 514/472.000;

514/473.000; 514/475.000; 514/475.000; 514/475.000; 514/475.000;

514/476.000; 514/478.000; 514/478.000; 514/478.000; 514/478.000;

514/479.000; 514/481.000; 514/481.000; 514/481.000; 514/481.000;

514/482.000; 514/484.000; 514/484.000; 514/484.000; 514/484.000;

514/485.000; 514/487.000; 514/487.000; 514/487.000; 514/487.000;

514/488.000; 514/490.000; 514/490.000; 514/490.000; 514/490.000;

514/491.000; 514/493.000; 514/493.000; 514/493.000; 514/493.000;

514/494.000; 514/496.000; 514/496.000; 514/496.000; 514/496.000;

514/497.000; 514/499.000; 514/499.000; 514/499.000; 514/499.000;

514/500.000; 514/502.000; 514/502.000; 514/502.000; 514/502.000;

514/503.000; 514/505.000; 514/505.000; 514/505.000; 514/505.000;

514/506.000; 514/508.000; 514/508.000; 514/508.000; 514/508.000;

514/509.000; 514/511.000; 514/511.000; 514/511.000; 514/511.000;

514/512.000; 514/514.000; 514/514.000; 514/514.000; 514/514.000;

514/513.000; 514/515.000; 514/515.000; 514/515.000; 514/515.000;</

AN 1998:91603 USPATFULL  
TI Composition and **method** for enhancing wound healing  
IN Hemlin, R. I., 6601 Brookburn Dr., Bethesda, MD, United States 20817.  
PT US 57839367 1998/08/04  
AI US 1993-480700 1995/06/07 (8)  
RLI Division of Ser. No. US 1993-297083, filed on 26 Aug 1994, now abandoned  
which is a division of Ser. No. US 1993-76058, filed on 14 Jun 1993, now  
patented, Pat. No. US 5384308

DT Utility  
FS Granted  
LN CNT 649  
INCL INCLIM: 424/172.100; INCUS: 424/130.100; NCIM: 424/172.100  
NCL NCUS: 424/1130.100; NCLIM: 424/137.100; NCLUS: 424/130.100;  
IC [6] ICM: A61K039-395  
ICCS: C07K016-000  
EXF 424/130.1; 424/137.1; 530/387.9; 530/387.1; 530/389.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 85 OF 239 USPATFULL  
AN 1998:886037 USPATFULL  
TI Hyaluronan receptor expressed in human umbilical vein endothelial  
IN Hawkins, Phillip R., Mountain View, CA, United States  
Wilde, Craig G., Sunnyvale, CA, United States  
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States  
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
corporation)  
PT US 57033669 1998/07/21  
AI US 1996-700178 1996/08/20 (8)  
RLI Division of Ser. No. US 1995-402217, filed on 10 Mar 1995, now patented,  
Pat. No. US 5587301  
DT Utility  
FS Granted  
LN CNT 1140  
INCL INCLIM: 530/350.000  
INCUS: 435/069.100; NCIM: 530/350.000  
NCL NCUS: 435/069.100; NCLIM: 536/023.500  
IC [6] ICM: C07K014-705  
EXF 530/350; 435/69.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 86 OF 239 USPATFULL  
AN 1998:82763 USPATFULL  
TI Hydroxyl-containing xanthine compounds  
Underiner, Gail E., Brier, WA, United States  
Portubek, Peter, Seattle, WA, United States  
Klein, J. Peter, Vashon Island, WA, United States  
Woodson, Paul, Edmonds, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PT US 5780476 1998/07/14  
AI US 1995-466660 1995/06/05 (8)  
RLI Division of Ser. No. US 1993-152526, filed on 16 Nov 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16  
Nov 1992, now patented, Pat. No. US 5473070  
DT Utility  
FS Granted  
LN CNT 1672  
INCL INCLIM: 514/263.000  
INCUS: 544/267.000  
NCL NCUS: 514/263.360

IC [6] ICM: A61K031-52  
ICCS: C07D43-04  
EXF 514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 87 OF 239 USPATFULL  
AN 1998:79342 USPATFULL  
TI Acetyl- and ketal-substituted pyrimidine compounds  
IN Leigh, Alastair, Brier, WA, United States  
Underiner, Gail, Brier, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PT US 577115 1998/07/07  
AI US 1994-19331 1994/02/07 (8)  
RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now  
abandoned  
DT Utility  
FS Granted  
LN CNT 1632  
INCL INCLIM: 544/242.000  
INCUS: 544/267.000  
NCL NCUS: 544/242.000  
IC [6] ICM: C07B239-26  
ICCS: A61K031-505  
EXF 544/67; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 88 OF 239 USPATFULL  
AN 1998:8867 USPATFULL  
TI Reversible protease inhibitors  
Palmer, James T., San Ramon, CA, United States  
Basmick, David, San Francisco, CA, United States  
Klaus, Jeffrey Lee, Redwood City, CA, United States  
PA Arris Pharmaceutical Corporation, SO, San Francisco, CA, United States  
(U.S. corporation)  
PT US 5776718 1998/07/07  
AI US 1996-618704 1996/03/20 (8)  
RLI Continuation of Ser. No. US 1995-40996, filed on 24 Mar 1995 Ser. No.  
Ser. No. US 1995-09553, filed on 24 Mar 1995 Ser. No. US 1995-40997, filed on 24 Mar 1995  
1995-09997, filed on 24 Mar 1995 And Ser. No. US 1995-41000, filed on  
24 Mar 1995  
DT Utility  
FS Granted  
LN CNT 3717  
INCL INCLIM: 435/023.000  
INCUS: 435/024.000; 435/004.000; 514/208.000; 514/001.000; 514/019.000;  
NCL NCUS: 514/012.000; 514/588.000; 514/600.000; 514/601.000; 424/070.240;  
NCLIM: 435/023.000  
NCL NCUS: 435/023.000  
IC [6] ICM: C12Q001-37  
INCL INCLIM: A01N047-28  
INCUS: C12Q001-00; A01N047-28  
EXF 435/23; 435/24; 435/4; 514/208.000; 514/588.000; 514/600.000; 514/601.000;  
514/019.000; 514/203.000; 514/588.000; 514/600.000; 514/601.000;  
514/019.000; 530/233.000; 530/336.000; 544/106.000  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 89 OF 239 USPATFULL  
AN 1998:75584 USPATFULL  
TI Synthetic matrix metalloprotease inhibitors and use thereof

IN INN: Levy, Daniel E., Alameda, CA, United States  
 Grobely, Denian, Watsonia North, Australia  
 Tang, Cho, Moraka, CA, United States  
 Holme, Kevin R., Alameda, CA, United States  
 Galardy, Richard E., Gulfport, CT, United States  
 Schultz, Gregory S., Gainesville, FL, United States  
 Nematal, Huda, Alameda, CA, United States  
 Musser, John H., San Carlos, CA, United States  
 Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)  
 The University of Florida, Gainesville, FL, United States (U.S. corporation)  
 US 5773438 1994-0630  
 US 5774927 1994-0605 (8)  
 US 1994-184127, filed on 21 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-44334, filed on 7 Apr 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5668304, issued on 7 Dec 1993 which is a continuation-in-part of Ser. No. US 1990-477751, filed on 9 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1981-1775, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 which is a continuation-in-part of Ser. No. US 1990-615738, filed on 21 Nov 1990, now patented, Pat. No. US 5183900, issued on 2 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-881630, filed on 12 May 1992, now patented, Pat. No. US 5270326, issued on 14 Dec 1993 which is a continuation-in-part of Ser. No. US 1990-616201, filed on 21 Nov 1990, now patented, Pat. No. US 5114953, issued on 19 May 1992

DT Utility  
 FS Granted  
 LN.CNT 219  
 INCL INCLM: 514/237.800  
 INCLS: 514/357.000; 514/419.000; 544/168.000; 546/334.000; 548/496.000  
 NCL NCLM: 514/237.800  
 NCLS: 514/357.000; 514/419.000; 544/168.000; 546/334.000; 548/496.000  
 IC [61] ICM: A61K031-535  
 IGS: A61K031-40; C07D265-28; C07D207-32  
 EXP 548/496; 514/419; 514/237.8; 514/357; 546/334; 544/168  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 90 OF 239 USPATFULL  
 AN 1998-72649 USPATFULL  
 TI Certain alpha-substituted arylsulfonamido acetohydroxamic acids  
 IN Parker, David Thomas, Livingston, NJ, United States  
 PA Novartis Corp., Summit, NJ, United States (U.S. corporation)  
 PI US 570624 19980623  
 AI US 1996-763273 19961210 (8)  
 PRAT US 1991-8661P 19951215 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1246  
 INCL INCLM: 514/575.000  
 INCLS: 514/357.000; 514/311.000; 514/428.000; 514/365.000; 514/372.000; 514/374.000; 514/376.000; 514/380.000; 514/378.000; 514/383.000; 514/381.000; 514/399.000; 514/374.000; 514/376.000; 514/378.000; 514/381.000; 514/383.000; 514/399.000; 514/415.000; 514/417.000; 514/419.000; 514/421.000; 514/423.000; 514/425.000; 514/427.000; 514/429.000; 514/431.000; 514/433.000; 514/435.000; 514/437.000; 514/439.000; 514/441.000; 514/443.000; 514/445.000; 514/447.000; 514/449.000; 514/451.000; 514/453.000; 514/455.000; 514/457.000; 514/459.000; 514/461.000; 514/463.000; 514/465.000; 514/467.000; 514/469.000; 514/471.000; 514/473.000; 514/475.000; 514/477.000; 514/479.000; 514/481.000; 514/483.000; 514/485.000; 514/487.000; 514/489.000; 514/491.000; 514/493.000; 514/495.000; 514/497.000; 514/499.000; 514/501.000; 514/503.000; 514/505.000; 514/507.000; 514/509.000; 514/511.000; 514/513.000; 514/515.000; 514/517.000; 514/519.000; 514/521.000; 514/523.000; 514/525.000; 514/527.000; 514/529.000; 514/531.000; 514/533.000; 514/535.000; 514/537.000; 514/539.000; 514/541.000; 514/543.000; 514/545.000; 514/547.000; 514/549.000; 514/551.000; 514/553.000; 514/555.000; 514/557.000; 514/559.000; 514/561.000; 514/563.000; 514/565.000; 514/567.000; 514/569.000; 514/571.000; 514/573.000; 514/575.000; 514/577.000; 514/579.000; 514/581.000; 514/583.000; 514/585.000; 514/587.000; 514/589.000; 514/591.000; 514/593.000; 514/595.000; 514/597.000; 514/599.000; 514/601.000; 514/603.000; 514/605.000; 514/607.000; 514/609.000; 514/611.000; 514/613.000; 514/615.000; 514/617.000; 514/619.000; 514/621.000; 514/623.000; 514/625.000; 514/627.000; 514/629.000; 514/631.000; 514/633.000; 514/635.000; 514/637.000; 514/639.000; 514/641.000; 514/643.000; 514/645.000; 514/647.000; 514/649.000; 514/651.000; 514/653.000; 514/655.000; 514/657.000; 514/659.000; 514/661.000; 514/663.000; 514/665.000; 514/667.000; 514/669.000; 514/671.000; 514/673.000; 514/675.000; 514/677.000; 514/679.000; 514/681.000; 514/683.000; 514/685.000; 514/687.000; 514/689.000; 514/691.000; 514/693.000; 514/695.000; 514/697.000; 514/699.000; 514/701.000; 514/703.000; 514/705.000; 514/707.000; 514/709.000; 514/711.000; 514/713.000; 514/715.000; 514/717.000; 514/719.000; 514/721.000; 514/723.000; 514/725.000; 514/727.000; 514/729.000; 514/731.000; 514/733.000; 514/735.000; 514/737.000; 514/739.000; 514/741.000; 514/743.000; 514/745.000; 514/747.000; 514/749.000; 514/751.000; 514/753.000; 514/755.000; 514/757.000; 514/759.000; 514/761.000; 514/763.000; 514/765.000; 514/767.000; 514/769.000; 514/771.000; 514/773.000; 514/775.000; 514/777.000; 514/779.000; 514/781.000; 514/783.000; 514/785.000; 514/787.000; 514/789.000; 514/791.000; 514/793.000; 514/795.000; 514/797.000; 514/799.000; 514/801.000; 514/803.000; 514/805.000; 514/807.000; 514/809.000; 514/811.000; 514/813.000; 514/815.000; 514/817.000; 514/819.000; 514/821.000; 514/823.000; 514/825.000; 514/827.000; 514/829.000; 514/831.000; 514/833.000; 514/835.000; 514/837.000; 514/839.000; 514/841.000; 514/843.000; 514/845.000; 514/847.000; 514/849.000; 514/851.000; 514/853.000; 514/855.000; 514/857.000; 514/859.000; 514/861.000; 514/863.000; 514/865.000; 514/867.000; 514/869.000; 514/871.000; 514/873.000; 514/875.000; 514/877.000; 514/879.000; 514/881.000; 514/883.000; 514/885.000; 514/887.000; 514/889.000; 514/891.000; 514/893.000; 514/895.000; 514/897.000; 514/899.000; 514/901.000; 514/903.000; 514/905.000; 514/907.000; 514/909.000; 514/911.000; 514/913.000; 514/915.000; 514/917.000; 514/919.000; 514/921.000; 514/923.000; 514/925.000; 514/927.000; 514/929.000; 514/931.000; 514/933.000; 514/935.000; 514/937.000; 514/939.000; 514/941.000; 514/943.000; 514/945.000; 514/947.000; 514/949.000; 514/951.000; 514/953.000; 514/955.000; 514/957.000; 514/959.000; 514/961.000; 514/963.000; 514/965.000; 514/967.000; 514/969.000; 514/971.000; 514/973.000; 514/975.000; 514/977.000; 514/979.000; 514/981.000; 514/983.000; 514/985.000; 514/987.000; 514/989.000; 514/991.000; 514/993.000; 514/995.000; 514/997.000; 514/999.000; 514/1001.000; 514/1003.000; 514/1005.000; 514/1007.000; 514/1009.000; 514/1011.000; 514/1013.000; 514/1015.000; 514/1017.000; 514/1019.000; 514/1021.000; 514/1023.000; 514/1025.000; 514/1027.000; 514/1029.000; 514/1031.000; 514/1033.000; 514/1035.000; 514/1037.000; 514/1039.000; 514/1041.000; 514/1043.000; 514/1045.000; 514/1047.000; 514/1049.000; 514/1051.000; 514/1053.000; 514/1055.000; 514/1057.000; 514/1059.000; 514/1061.000; 514/1063.000; 514/1065.000; 514/1067.000; 514/1069.000; 514/1071.000; 514/1073.000; 514/1075.000; 514/1077.000; 514/1079.000; 514/1081.000; 514/1083.000; 514/1085.000; 514/1087.000; 514/1089.000; 514/1091.000; 514/1093.000; 514/1095.000; 514/1097.000; 514/1099.000; 514/1101.000; 514/1103.000; 514/1105.000; 514/1107.000; 514/1109.000; 514/1111.000; 514/1113.000; 514/1115.000; 514/1117.000; 514/1119.000; 514/1121.000; 514/1123.000; 514/1125.000; 514/1127.000; 514/1129.000; 514/1131.000; 514/1133.000; 514/1135.000; 514/1137.000; 514/1139.000; 514/1141.000; 514/1143.000; 514/1145.000; 514/1147.000; 514/1149.000; 514/1151.000; 514/1153.000; 514/1155.000; 514/1157.000; 514/1159.000; 514/1161.000; 514/1163.000; 514/1165.000; 514/1167.000; 514/1169.000; 514/1171.000; 514/1173.000; 514/1175.000; 514/1177.000; 514/1179.000; 514/1181.000; 514/1183.000; 514/1185.000; 514/1187.000; 514/1189.000; 514/1191.000; 514/1193.000; 514/1195.000; 514/1197.000; 514/1199.000; 514/1201.000; 514/1203.000; 514/1205.000; 514/1207.000; 514/1209.000; 514/1211.000; 514/1213.000; 514/1215.000; 514/1217.000; 514/1219.000; 514/1221.000; 514/1223.000; 514/1225.000; 514/1227.000; 514/1229.000; 514/1231.000; 514/1233.000; 514/1235.000; 514/1237.000; 514/1239.000; 514/1241.000; 514/1243.000; 514/1245.000; 514/1247.000; 514/1249.000; 514/1251.000; 514/1253.000; 514/1255.000; 514/1257.000; 514/1259.000; 514/1261.000; 514/1263.000; 514/1265.000; 514/1267.000; 514/1269.000; 514/1271.000; 514/1273.000; 514/1275.000; 514/1277.000; 514/1279.000; 514/1281.000; 514/1283.000; 514/1285.000; 514/1287.000; 514/1289.000; 514/1291.000; 514/1293.000; 514/1295.000; 514/1297.000; 514/1299.000; 514/1301.000; 514/1303.000; 514/1305.000; 514/1307.000; 514/1309.000; 514/1311.000; 514/1313.000; 514/1315.000; 514/1317.000; 514/1319.000; 514/1321.000; 514/1323.000; 514/1325.000; 514/1327.000; 514/1329.000; 514/1331.000; 514/1333.000; 514/1335.000; 514/1337.000; 514/1339.000; 514/1341.000; 514/1343.000; 514/1345.000; 514/1347.000; 514/1349.000; 514/1351.000; 514/1353.000; 514/1355.000; 514/1357.000; 514/1359.000; 514/1361.000; 514/1363.000; 514/1365.000; 514/1367.000; 514/1369.000; 514/1371.000; 514/1373.000; 514/1375.000; 514/1377.000; 514/1379.000; 514/1381.000; 514/1383.000; 514/1385.000; 514/1387.000; 514/1389.000; 514/1391.000; 514/1393.000; 514/1395.000; 514/1397.000; 514/1399.000; 514/1401.000; 514/1403.000; 514/1405.000; 514/1407.000; 514/1409.000; 514/1411.000; 514/1413.000; 514/1415.000; 514/1417.000; 514/1419.000; 514/1421.000; 514/1423.000; 514/1425.000; 514/1427.000; 514/1429.000; 514/1431.000; 514/1433.000; 514/1435.000; 514/1437.000; 514/1439.000; 514/1441.000; 514/1443.000; 514/1445.000; 514/1447.000; 514/1449.000; 514/1451.000; 514/1453.000; 514/1455.000; 514/1457.000; 514/1459.000; 514/1461.000; 514/1463.000; 514/1465.000; 514/1467.000; 514/1469.000; 514/1471.000; 514/1473.000; 514/1475.000; 514/1477.000; 514/1479.000; 514/1481.000; 514/1483.000; 514/1485.000; 514/1487.000; 514/1489.000; 514/1491.000; 514/1493.000; 514/1495.000; 514/1497.000; 514/1499.000; 514/1501.000; 514/1503.000; 514/1505.000; 514/1507.000; 514/1509.000; 514/1511.000; 514/1513.000; 514/1515.000; 514/1517.000; 514/1519.000; 514/1521.000; 514/1523.000; 514/1525.000; 514/1527.000; 514/1529.000; 514/1531.000; 514/1533.000; 514/1535.000; 514/1537.000; 514/1539.000; 514/1541.000; 514/1543.000; 514/1545.000; 514/1547.000; 514/1549.000; 514/1551.000; 514/1553.000; 514/1555.000; 514/1557.000; 514/1559.000; 514/1561.000; 514/1563.000; 514/1565.000; 514/1567.000; 514/1569.000; 514/1571.000; 514/1573.000; 514/1575.000; 514/1577.000; 514/1579.000; 514/1581.000; 514/1583.000; 514/1585.000; 514/1587.000; 514/1589.000; 514/1591.000; 514/1593.000; 514/1595.000; 514/1597.000; 514/1599.000; 514/1601.000; 514/1603.000; 514/1605.000; 514/1607.000; 514/1609.000; 514/1611.000; 514/1613.000; 514/1615.000; 514/1617.000; 514/1619.000; 514/1621.000; 514/1623.000; 514/1625.000; 514/1627.000; 514/1629.000; 514/1631.000; 514/1633.000; 514/1635.000; 514/1637.000; 514/1639.000; 514/1641.000; 514/1643.000; 514/1645.000; 514/1647.000; 514/1649.000; 514/1651.000; 514/1653.000; 514/1655.000; 514/1657.000; 514/1659.000; 514/1661.000; 514/1663.000; 514/1665.000; 514/1667.000; 514/1669.000; 514/1671.000; 514/1673.000; 514/1675.000; 514/1677.000; 514/1679.000; 514/1681.000; 514/1683.000; 514/1685.000; 514/1687.000; 514/1689.000; 514/1691.000; 514/1693.000; 514/1695.000; 514/1697.000; 514/1699.000; 514/1701.000; 514/1703.000; 514/1705.000; 514/1707.000; 514/1709.000; 514/1711.000; 514/1713.000; 514/1715.000; 514/1717.000; 514/1719.000; 514/1721.000; 514/1723.000; 514/1725.000; 514/1727.000; 514/1729.000; 514/1731.000; 514/1733.000; 514/1735.000; 514/1737.000; 514/1739.000; 514/1741.000; 514/1743.000; 514/1745.000; 514/1747.000; 514/1749.000; 514/1751.000; 514/1753.000; 514/1755.000; 514/1757.000; 514/1759.000; 514/1761.000; 514/1763.000; 514/1765.000; 514/1767.000; 514/1769.000; 514/1771.000; 514/1773.000; 514/1775.000; 514/1777.000; 514/1779.000; 514/1781.000; 514/1783.000; 514/1785.000; 514/1787.000; 514/1789.000; 514/1791.000; 514/1793.000; 514/1795.000; 514/1797.000; 514/1799.000; 514/1801.000; 514/1803.000; 514/1805.000; 514/1807.000; 514/1809.000; 514/1811.000; 514/1813.000; 514/1815.000; 514/1817.000; 514/1819.000; 514/1821.000; 514/1823.000; 514/1825.000; 514/1827.000; 514/1829.000; 514/1831.000; 514/1833.000; 514/1835.000; 514/1837.000; 514/1839.000; 514/1841.000; 514/1843.000; 514/1845.000; 514/1847.000; 514/1849.000; 514/1851.000; 514/1853.000; 514/1855.000; 514/1857.000; 514/1859.000; 514/1861.000; 514/1863.000; 514/1865.000; 514/1867.000; 514/1869.000; 514/1871.000; 514/1873.000; 514/1875.000; 514/1877

corporation)

PI 5755791 19980602

AI US 1990-188426 19940124 (8)

RLT Combination-in-part of Ser. No. US 1993-95908, filed on 26 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-97716, filed on 21 Jul 1992, now abandoned And Ser. No. US 1991-735522, filed on 26 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-622407, filed on 4 Dec 1990, now abandoned which is a continuation of Ser. No. US 1989-298722, filed on 17 Jan 1989, now abandoned

DT Utility

FS Granted

LN CNT 2345

INC1: 435/007. 900; 435/007. 920; 435/975. 000; 435/006. 000; 435/518. 000; 436/623. 100; 536/024. 300

EXF 436/504; 436/518; 436/531; 436/548; 436/15; 436/63; 436/64; 436/86; 436/80; 436/813; 436/819; 435/7. 1; 435/7. 23; 435/7. 9; 435/7. 92; 435/7. 95; 435/28. 6; 435/396; 435/172. 1; 530/324; 530/350; 530/388. 8; 530/389. 7; 530/828; 935/81; 536/23. 1; 536/24. 3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 94 OF 239 USPATFULL

AN 1998-54522 USPATFULL

TI Method for enhancing functional properties of submucosal tissue graft constructs

IN Badyak, Stephen F., W. Lafayette, IN, United States

PA Voitik, Sherry, Lafayette, IN, United States

PI Purdue Research Foundation, West Lafayette, IN, United States (U.S.)

AI US 1995-530001 19950919 (8)

RLI US 5753267 Division of Ser. No. US 1995-386452, filed on 10 Feb 1995, now patented, granted

DT Utility

FS Granted

LN CNT 893

INC1: 424/551. 000; 435/325. 000; 435/366. 000; 435/371. 000; 435/377. 000; 435/402. 000; 623/015. 000

NCL NCLM: 424/551. 000; 435/325. 000; 435/366. 000; 435/371. 000; 435/377. 000; 435/402. 000

IC [6] ICM: A61K035-38 ICS: C12N005-00; A61F002-08 EXF 435/325; 435/366; 435/371; 435/377; 435/402; 424/93. 1; 424/551; 623/15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 95 OF 239 USPATFULL

AN 1998-48332 USPATFULL

TI Metiloprotinase Inhibitors

IN Beckett, Raymond Paul, Cowley, United Kingdom

Whittaker, Mark, Cowley, United Kingdom

Miller, Andrew, Cowley, United Kingdom

Martin, Fiona, Mitchell, Cowley, United Kingdom

PA British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S.)

corporation)

PI 5747514 19980505

AI US 1996-68530 19960719 (8)

RLT GB 1994-1034 19940120

GB 1994-15619 19940802

DT Utility

FS Granted

LN CNT 2561

INC1: 514/7352. 000; 514/363. 000; 514/370. 000; 514/372. 000; 514/477. 000; 514/626. 000; 546/309. 000; 548/135. 000; 548/139. 000; 548/192. 000; 548/206. 000; 549/069. 000; 564/153. 000; 564/155. 000

EXF 514/352. 000; 514/362. 000; 514/363. 000; 514/370. 000; 514/372. 000; 514/477. 000; 514/626. 000; 546/309. 000; 548/139. 000; 548/192. 000; 548/206. 000; 549/069. 000; 564/153. 000; 564/155. 000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 96 OF 239 USPATFULL

AN 1998-45226 USPATFULL

TI Method for inhibiting angiogenesis

IN Kohn, Elise C., Olney, MD, United States

Liotta, Lance A., Potomac, MD, United States

Alessandro, Riccardo, Bethesda, MD, United States

United States of America, Washington, DC, United States (U.S.)

PA government)

PI US 5494492 19980428

AI US 1994-209651 19940310 (8)

RLI Continuation-in-part of Ser. No. US 1993-123614, filed on 17 Sep 1993, now abandoned

DT Utility

FS Granted

LN CNT 775

INC1: 514/359. 000; 514/648. 000; 514/650. 000

NCL NCLM: 514/356. 000; 514/648. 000; 514/650. 000

IC [6] ICM: A61K031-41 ICS: 514/359. 000; 514/648. 000; 514/650. 000

EXF 514/359. 000; 514/648. 000; 514/650. 000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 97 OF 239 USPATFULL

AN 1998-3567 USPATFULL

TI Catherispin O procease

IN Bromme, Dieter, San Bruno, CA, United States

Okamoto, Kathleen, Mountain View, CA, United States

PA Ariis Pharmaceutical, South San Francisco, CA, United States (U.S.)

US 5736357 19980407

AI US 1994-330121 19941027 (8)

DT Utility

FS Granted

LN CNT 1305

INC1: 435/069. 100; 435/320. 100; 435/325. 000; 435/252. 300; 435/254. 110; 536/023. 500

NCL NCLM: 435/069. 100; 435/252. 300; 435/254. 110; 435/320. 100; 435/325. 000; 536/023. 500

IC [6]

ICM: C12N001-21  
 ICS: C12N015-15; C12N015-63; C12P021-02  
 EXF: 536/23.2; 435/219; 435/320.1; 435/240.2; 435/252.3; 435/325  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 **ANSWER 98 OF 239 USPATFULL**

AN 1998:28192 USPATFULL

TI Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis

IN Chung, Leland W. K., Houston, TX, United States  
 Chan, James, Sugarland, TX, United States  
 Logothetis, Christopher, Houston, TX, United States  
 Hisieh, Jer-Tsong, Sugarland, TX, United States  
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

PA US 5728815 19980317 (8)  
 AI US 1991-179569 19940107 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-859228, filed on 30 Mar 1992 now abandoned

DT Utility

FS Granted

IN CNT 2175

INCL INCLM: 530/399.000  
 INCLIS: 530/350.000; 530/412.000; 514/002.000

NCL NCLM: 530/359.000  
 NCLIS: 530/350.000; 530/412.000

IC {61} ICM: C07K04-475  
 EXF 530/350; 530/399; 530/412; 435/240.1; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 **ANSWER 99 OF 239 USPATFULL**

AN 1998-25076 USPATFULL

TI Method to determine metastatic potential of tumor cells

IN Matrisian, Lynn M., Nashville, TN, United States  
 PA Vanderbilt University, Nashville, TN, United States (U.S. corporation)

US 526015 19980310 (8)  
 AI US 1995-371082 19950110 (8)

RLI Continuation of Ser. No. US 1993-61827, filed on 17 May 1993, now abandoned which is a continuation of Ser. No. US 1991-070050, filed on 15 May 1991, now abandoned

DT Utility

FS Granted

LN.GNT INCL INCLM: 435/006.000  
 INCLIS: 536/023.500

NCL NCLM: 435/006.000  
 NCLIS: 536/023.500

IC {61} ICM: C12Q001-68  
 EXF 435/6; 435/7.1; 435/7.2; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 **ANSWER 100 OF 239 USPATFULL**

AN 1998-12007 USPATFULL

TI **Method of inhibiting tumor cell dissemination with a metalloprotease inhibitor**

IN Langley, Keith E., Newbury Park, CA, United States  
 Declerck, Yves A., Los Angeles, CA, United States  
 Boone, Thomas C., Newbury Park, CA, United States  
 Angen Inc., Thousand Oaks, CA, United States (U.S. corporation)

PA US 5714465 19980303 (8)  
 PI US 1994-212660 19940310 (8)

RLI Continuation of Ser. No. US 1993-07021, filed on 6 Jul 1993, now abandoned

DT Utility	INCL LN.CNT 2845	INCLM: 514/012.000 INCLS: 514/002.000; 530/350.000 NCL: 514/012.000 NCLS: 514/002.000; 530/350.000 [6]	abandoned which is a continuation of Ser. No. US 1991-710728, filed on 3 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-501904, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-355027, filed on 19 May 1989
FS Granted			
L9 ANSWER 101 OF 239 USPATFULL 1998-9533 USPATFULL			
TI Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phenylacetic acids and derivatives thereof			
IN PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)			
PI US 5712307 AI US 1993-465924			
RLI Division of Ser. No. US 1993-13661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-71974, filed on 21 Oct 1991			
DT Utility			
FS Granted			
LN.CNT 4169			
INCL INCLM: 514/538.000; 514/567.000 INCLS: 514/563.000; 514/567.000 NCL: 514/538.000; 514/567.000 NCLS: 514/563.000; 514/567.000 [6]			
IC ICM: A01N037-12 ICCS: A01N037-14; A61K031-24 E61K14/538; 514/563; 514/567			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
L9 ANSWER 102 OF 239 USPATFULL 1998-7096 USPATFULL			
TI Compositions and <b>methods</b> for therapy and prevention of pathologies including cancer, AIDS, and anemia			
IN PA Samid, Dvoretz, Rockville, VA, United States			
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)			
PI US 5710178 AI US 1995-669691			
RLI Division of Ser. No. US 1993-13561, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-77974, filed on 21 Oct 1991			
DT Utility			
FS Granted			
LN.CNT 4261			
INCL INCLM: 514/557.000 INCLS: 514/568.000; 514/570.000 NCL: 514/557.000 NCLS: 514/568.000; 514/570.000 [6]			
IC ICM: A01N037-00 ICCS: A61K31-19 E61K 514/568; 514/569; 514/570; 562/405; 562/493; 562/511; 562/473; 562/490 CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L9	ANSWER 103 OF 239 USPATFULL 1998-47011 USPATFULL
TI	Proteocadherin materials and methods
IN	Suzuki, Shintaro, Torrance, CA, United States
PA	Donley Eye Institute, Los Angeles, CA, United States (U.S. corporation)
PT	US 5703143 19980113
AI	US 1995-453695 19950530 (8)
RLI	Division of Ser. No. US 1994-268161, filed on 27 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-98003, filed on 29 Dec 1992 Utility FS Granted
DT	LN CNT 1738
FS	INCL INCLM: 530/350.000 INCLM: 435/069.100; 530/395.000 NCL NCLM: 530/350.000 NCLCIS: 435/069.100; 530/395.000 (6)
IC	ICM: C07K014-435 ICM: C12N011-12
EXF	530/350; 530/395; 435/69.1 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9	ANSWER 104 OF 239 USPATFULL 1998-4624 USPATFULL
AN	Methods for promoting wound healing
TI	Samid, Dvora, Rockville, MD, United States
IN	The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PA	US 5708025 19980113
PI	US 1995-465835 19950606 (8)
AI	Division of Ser. No. US 1993-135691, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-77974, filed on 21 Oct 1991 Utility FS Granted
DT	LN CNT 4206
FS	INCLM: 534/538.000 INCLM: 514/563.000; 514/567.000; 514/885.000; 514/886.000; 514/928.000 NCL NCLM: 514/563.000; 514/567.000; 514/885.000; 514/886.000; 514/928.000 (6)
IC	ICM: A01N037-12 ICM: A01N037-44; A61K031-24
EXF	5314/538; 514/563; 514/567; 514/885; 514/886; 514/928; 560/19 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9	ANSWER 105 OF 239 USPATFULL 1998-1797 USPATFULL
AN	Signal transduction inhibitor compounds
TI	Kohn, Elise C., Oney, MD, United States
IN	Liotte, Lance A., Potomac, MD, United States
PA	Felder, Christian C., Bethesda, MD, United States The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government) US 5705514 19980106
PI	US 1995-455825 19950531 (8)
AI	Division of Ser. No. US 1994-270181, filed on 1 Jul 1994, now Patented Pat. No. US 5492954 which is a division of Ser. No. US 1992-985402, filed on 4 Dec 1992, now patented, Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US 1989-535744, filed on 19 May 1989, now patented, Pat. No. US 5132315 which is a continuation-in-part of Ser. No. US 1992-94003, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-894891, filed

INCLIS: 514/002.000; 514/893.000; 514/894.000; 514/838.000; 530/350.000;

NCL 530/399.000; 535/360.000; 935/013.000;

NCIM: 514/012.000 97:17896 USPATFULL

NCIS: 435/360.000; 514/002.000; 514/838.000; 514/893.000; 514/894.000;

IC [6] ICM: A61K038-18 97:17896 USPATFULL

ICCS: C07K014-475; C12N015-12; C07H021-04

EXF 514/12; 514/893; 514/894; 514/838; 514/2; 424/130.1; 530/350; 530/399;

435/360; 935/13 97:17896 USPATFULL

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 108 OF 239 USPATFULL

AN 97:120654 USPATFULL

TI Hydroxamic acid derivatives as metalloprotease inhibitors

IN Dickens, Jonathan Philip, Cambridge, United Kingdom 97:120654 USPATFULL

Crimmin, Michael John, Cowley, United Kingdom

Beckett, Raymond Paul, Cowley, United Kingdom

PA British Biotech Pharmaceuticals Limited, Oxford, United Kingdom (non-U.S. corporation)

US 5700838 97:120654 USPATFULL

WO 9422497 19940203 97:120654 USPATFULL

US 1995-314602 19930723 19950123 (8)

PI 19950123 PCT 371 date

WO 1993-GB1557 19930723 19950123 PCT 102(e) date

PRAI 1992-15665 19920723

DT Utility

FS Granted

LN CNT 1624

INCL INCLIM: 514/575.000 97:11252 USPATFULL

INCIS: 562/623.000

NCL NCIM: 514/575.000

NCIS: 562/623.000

IC [6] ICM: A61K031-19

EXF 562/623; 514/575

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 109 OF 239 USPATFULL

AN 97-120598 USPATFULL

TI Selection of cells having increased cell adhesion properties

IN Pierischbacher, Michael D., San Diego, CA, United States

Ruosahti, Erkki I., San Diego, CA, United States

Dedhar, Shoukat, North Vancouver, Canada

PA La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S.)

PAI 1995-400084 19950307 (8)

DT Utility

FS Granted

LN CNT 1229

INCL INCLIM: 514/021.000 97:11252 USPATFULL

INCIS: 514/012.000

NCL NCIM: 514/021.000

NCIS: 514/012.000

IC [6] ICM: A61K038-17

EXF 530/350; 530/352; 530/359; 530/386; 530/395; 530/850; 530/851; 530/853; 514/7; 514/8; 514/12; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 112 OF 239 USPATFULL

AN 97:112546 USPATFULL

TI Methods and kits using macrophage stimulating protein

IN Avraham, Hava Karsenty, Brooklyn, NY, United States

Godowski, Paul J., Burlingame, CA, United States

PA Gentetech, Inc., South San Francisco, CA, United States (U.S.)

PAI 1994-334177 19941103 (8)

DT Utility

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 110 OF 239 USPATFULL

AN 97:17896 USPATFULL

TI Method of predicting fetal membrane rupture based on

TI, Straus, III, Jerome Frank, Wyndmoor, PA, United States

IN Vadillo-Ortega, Felipe, La Magdalena, Mexico

PA University of Pennsylvania, Philadelphia, PA, United States (U.S.)

PAI 5598404 1996-227883 19961009 (8)

US 1996-227883 19961009 (8)

PI Continuation of Ser. No. US 1994-246814, filed on 20 May 1994, now

patented, Pat. No. US 5611636

DT Utility

FS Granted

LN CNT 681

INCL INCLIM: 435/074.000 97:11252 USPATFULL

INCIS: 435/018.000; 435/023.000; 435/024.000; 436/518.000; 436/530.000;

NCL NCIM: 435/007.400

NCIS: 435/018.000; 435/023.000; 435/024.000; 436/518.000; 436/530.000;

IC [6] ICM: 601N033-53

EXF 435/7.1; 435/7.4; 435/18; 435/23; 435/24; 436/518; 436/528; 436/529;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 111 OF 239 USPATFULL

AN 97:11252 USPATFULL

TI Methods and compositions for inhibiting metastasis of

epithelial cell-derived cancers

IN Paterno, Steven R., Falls Church, VA, United States

PA Manvak, Michael, Chevy Chase, MD, United States

corporation)

PAI 5698092 19971209

DT Utility

FS Granted

LN CNT 1229

INCL INCLIM: 514/021.000 97:11252 USPATFULL

INCIS: 514/012.000

NCL NCIM: 514/021.000

NCIS: 514/012.000

IC [6] ICM: A61K038-17

EXF 530/350; 530/352; 530/359; 530/386; 530/395; 530/850; 530/851; 530/853; 514/7; 514/8; 514/12; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 112 OF 239 USPATFULL

AN 97:112546 USPATFULL

TI Methods and kits using macrophage stimulating protein

IN Avraham, Hava Karsenty, Brooklyn, NY, United States

Godowski, Paul J., Burlingame, CA, United States

PA Gentetech, Inc., South San Francisco, CA, United States (U.S.)

PAI 1994-334177 19941103 (8)

DT Utility

FS Granted

LN CNT 921

INCLIM: 435/240.210 97:112546 USPATFULL

INCIS: 435/240.200; 435/240.230; 530/350.000; 530/356.000

NCL NCIM: 435/377.000

NCIS: 435/378.000; 530/350.000; 530/356.000

IC [6] ICM: C12N005-06

EXF ICS: C07K014-475; C12N015-12; C07H021-04

PI 435/240.; 435/240.21; 435/240.23; 435/948; 435/70.3; 435/375; 435/377;

US 5698086 1994-334177

DT Utility

FS Granted  
LN CNT 1417  
INCL INCLM: 514/012.000  
INCL INCUS: 530/351.000; 530/380.000  
NCIM: 514/012.000  
NCLS: 530/351.000; 530/380.000  
[6]  
IC ICM: A61K038-16  
ICM: A61K038-19; C07K014-00; C07K014-52  
EXF 530/351; 530/380; 530/12; 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 113 OF 239 USPATFULL  
AN 97:115162 USPATFULL  
TI Submucosa as a growth substrate for islet cells  
Badyak, Stephen F., W. Lafayette, IN, United States  
Boder, George, Martinsville, IN, United States  
Voytik, Sherry, Lafayette, IN, United States  
Demeter, Robert J., Mooresville, IN, United States  
Crittter, John, Carmel, IN, United States  
liu, Chi, Indianapolis, IN, United States  
Purdue Research Foundation, West Lafayette, IN, United States (U.S. corporation)  
Methodist Hospital of Indiana, Inc., Indianapolis, IN, United States (U.S. corporation)  
US 5635998 19971209  
AI US 1995-386452 19950210 (8)  
DT Utility  
FS Granted  
LN CNT 847  
INCL INCLM: 435/391.000  
NCLS: 435/391.000  
[6]  
IC ICM: C12NB05-00  
EXF 435/240.2; 435/240.23; 435/240.24; 435/240.3; 435/391  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 114 OF 239 USPATFULL  
AN 97:109037 USPATFULL  
TI Hydroxamic and carbocyclic acids as metalloprotease inhibitors  
Jacobson, Irina Ciobra, Boothwyn, PA, United States  
Decicco, Carl Peter, Newark, DE, United States  
Chernoy, Robert Joseph, Newark, DE, United States  
The Chiron Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)  
US 5691381 19971125  
AI US 1996-632973 19960416 (8)  
RLI Continuation-in-part of Ser. No. US 1995-423192, filed on 18 Apr 1995, now abandoned  
DT Utility  
FS Granted  
LN CNT 1970  
INCL INCLM: 514/562.000  
INCL INCUS: 514/563.000; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000; 562/455.000; 562/512.000; 562/801.000  
NCL NCLM: 514/562.000  
NCLS: 514/563.000; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000; 562/455.000; 562/512.000; 562/801.000  
[6]  
IC ICM: A61K031-19; C07D211-72  
EXF 562/801; 562/405; 562/512; 562/430; 562/440; 562/444; 562/452; 562/455;  
514/575; 514/562; 514/563; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000; 562/455.000; 562/512.000; 562/801.000  
514/18; 514/19; 514/7; 562/445; 530/331; 530/345.000; 562/445.000  
EXF 514/18; 514/19; 514/7; 562/445; 530/331; 530/345.000  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 115 OF 239 USPATFULL  
AN 97:106931 USPATFULL  
TI Cancer diagnosis using nucleic acid hybridization  
Sager, Ruth, Brookline, MA, United States  
Zou, Zhiqiang, Gaithersburg, MD, United States  
Lee, Sam Whan, Newton, MA, United States  
Tomesko, Catherine Laure, Strasbourg, France  
Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)  
PI US 5688641 1991013 (8)  
AI US 1994-322742 1991013 (8)  
DT Utility  
FS Granted  
LN CNT 1283  
INCL INCLM: 435/006.000  
INCL INCUS: 435/040.500; 436/503.000; 436/811.000  
NCL NCLS: 435/006.000  
[6]  
IC ICM: C12Q001-68  
EXF 436/501; 436/503; 436/811; 435/6; 435/40.5; 530/350; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 116 OF 239 USPATFULL  
AN 97:104449 USPATFULL  
TI Basic .alpha.-aminoalkylphosphonate derivatives  
Powers, James C., Atlanta, GA, United States  
Boduszek, Bogdan, Wroclaw, Poland  
Olekszyn, Jozef, Arlington, MA, United States  
Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)  
PI US 566419 19971111  
AI US 1994-184286 19940211 (8)  
DT Utility  
FS Granted  
LN CNT 1650  
INCL INCLM: 514/018.000  
INCL INCUS: 514/019.000; 514/007.000; 562/445.000; 530/331.000; 530/345.000  
NCL NCLM: 514/018.000  
NCLS: 514/007.000; 514/019.000; 530/331.000; 530/345.000; 562/445.000  
[6]  
IC ICM: A61K038-05  
EXF 514/18; 514/19; 514/7; 562/445; 530/331; 530/345.000  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 117 OF 239 USPATFULL  
AN 97:104323 USPATFULL  
TI Hepatocyte growth factor receptor antagonist antibodies and uses thereof  
Schwall, Ralph H., Pacifica, CA, United States  
Tabor, Kelly Helen, Hillsborough, CA, United States  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
US 5686292 19971111  
AI US 1995-460368 19950602 (8)  
DT Utility  
FS Granted  
LN CNT 1406

INCL INCLM: 435/240.270  
INCL INCIS: 424/133.100; 424/143.100; 530/387.300; 530/387.700; 530/388.100;  
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;  
530/389.700  
NCL NCLM: 424/133.100;  
NCLS: 424/133.100; 435/334.000; 530/387.300; 530/387.700; 530/388.100;  
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;  
530/389.700  
IC [6] ICM: C12N005-12  
IC: A61K039-395; C07K016-28  
EXF ICS: A61K039-395; C07K016-28  
530/387.7; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 530/389.1;  
530/389.7; 530/387.3; 424/143.1; 435/240.27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 118 OF 239 USPATFULL  
AN 97:101902 USPATFULL  
TI preparation of carboxyalkyl derivatives as inhibitors of matrix metalloproteinases  
IN Ponpionom, Mirree M., Branchburg, NJ, United States  
Hagmann, William K., Westfield, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5684152  
AI US 1996-716042  
PRAI US 1995-5272P  
DT Utility  
FS Granted  
LN CNT 1337  
INCL INCLM: 549/242.000  
INCLS: 544/264.000; 544/336.000; 544/358.000; 546/152.000; 546/193.000;  
546/249.000; 548/152.000; 548/206.000; 548/213.000; 548/215.000;  
548/221.000; 548/335.100; 548/433.500; 548/250.000; 548/440.000;  
548/469.000; 548/470.000; 548/89.000; 548/491.000; 548/539.000;  
549/006.000; 549/023.000; 549/033.000; 549/049.000;  
549/229.000; 549/266.000; 549/273.000; 549/307.000; 549/313.000;  
549/735.000; 549/424.000  
NCL NCLM: 544/264.000; 544/336.000; 544/358.000; 546/152.000; 546/193.000;  
546/249.000; 548/152.000; 548/206.000; 548/213.000; 548/215.000;  
548/221.000; 548/250.000; 548/335.100; 548/433.500; 548/440.000;  
548/469.000; 548/470.000; 548/89.000; 548/491.000; 548/539.000;  
549/006.000; 549/023.000; 549/033.000; 549/049.000;  
549/229.000; 549/266.000; 549/273.000; 549/307.000; 549/313.000;  
549/006.000; 549/023.000; 549/033.000  
IC [6] ICM: A61K031-40  
IC: C07C039-225  
ICS: C07D029-02; C07D207-00; C07D263-04; C07D277-04; C07D307-00;  
C07D413-08; C07D279-00  
EXF ICS: C07C039-225  
544/242; 544/336; 544/358; 544/764; 546/152; 546/193; 546/249; 546/152;  
548/206; 548/213; 548/335.1; 548/433.5; 548/250; 548/215; 548/472; 548/215;  
548/440; 548/469; 548/470; 548/491; 548/530; 549/5; 549/23;  
549/40; 549/33; 549/49; 549/229; 549/313; 549/266; 549/273; 549/307;  
568/735  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 119 OF 239 USPATFULL  
AN 97:99272 USPATFULL  
TI Fluorescent 1-peptidylaminokaneephosphonate derivatives  
IN Powers, James C., Atlanta, GA, United States  
AbuIyman, Ahmed S., St. Paul, MN, United States  
PA Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)  
PI US 5681821  
AI US 1994-324809  
DT Utility  
FS Granted  
LN CNT 1620  
INCL INCLM: 514/002.000

IN CNT 927  
INCL INCLM: 514/019.000  
INCL INCIS: 514/018.000; 514/007.000; 530/331.000; 435/004.000  
NCL NCLM: 514/019.000  
NCLS: 435/004.000; 514/007.000; 514/018.000; 530/331.000  
IC [6] ICM: A61K038-05  
EXF ICS: 514/8; 514/19; 514/7; 530/331  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 120 OF 239 USPATFULL  
AN 97:9892 USPATFULL  
TI Substituted phosphinic acid-containing peptidyl derivatives as antiangiogenic agents  
IN Caldwell, Charles G., Scotch Plains, NJ, United States  
Durett, Philippe L., New Providence, NJ, United States  
Goulet, Joung L., Westfield, NJ, United States  
Hagmann, William K., Westfield, NJ, United States  
Sahoo, Soumya P., Old Bridge, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5679700  
AI RLI US 1995-5535  
Continuation of Ser. No. US 1994-25617, filed on 5 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-82113, filed on 15 Jan 1992, now abandoned  
DT Utility  
FS Granted  
LN CNT 1997  
INCL INCLM: 514/416.000  
INCLS: 514/417.000; 514/422.000; 514/429.000; 514/399.000; 514/418.000;  
514/419.000; 548/413.000; 548/414.000; 548/415.000; 548/481.000;  
548/472.000; 548/491.000; 548/492.000; 549/038.000; 549/005.000;  
549/120.000; 549/048.000; 549/112.000; 549/145.000; 546/117.000;  
549/223.000; 544/337.000; 568/015.000; 558/170.000  
NCL NCLM: 514/416.000  
NCLS: 514/399.000; 514/417.000; 514/418.000; 514/419.000; 514/422.000;  
514/428.000; 546/117.000; 546/145.000; 548/112.000; 549/113.000;  
548/414.000; 548/415.000; 548/472.000; 548/481.000; 548/491.000;  
549/005.000; 549/058.000; 549/218.000; 549/220.000; 549/221.000  
IC [6] ICM: A61K031-40  
IC: C07F009-00  
EXF ICS: 514/39; 514/416; 514/419; 514/417; 514/422; 548/481; 548/472;  
548/491; 548/12; 548/414; 548/415; 548/413; 549/58; 549/5; 549/220;  
549/218; 549/221; 546/145; 546/117; 544/243; 549/337; 568/15; 558/170  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 121 OF 239 USPATFULL  
AN 97:96832 USPATFULL  
TI Bone and prostate-derived protein factors affecting prostate cancer  
IN Chung, Leland W. K., Houston, TX, United States  
Chair, James C., Sugarland, TX, United States  
Logothetis, Christopher J., Houston, TX, United States  
PA Board of Regents, The University of Texas, Austin, TX, United States  
(U.S. corporation)  
PI US 5679836  
AI RLI US 1994-341297  
Continuation of Ser. No. US 1992-85928, filed on 30 Mar 1992, now abandoned  
DT Utility  
FS Granted  
LN CNT 1620  
INCL INCLM: 514/002.000



TI IN	lactam-containing hydroxamic acids
De, Biswanath, Cincinnati, OH, United States	
Wahl, Christopher Thomas, Hamilton, OH, United States	
Natchus, Michael George, Cincinnati, OH, United States	
Cheng, Menyan, West Chester, OH, United States	
The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)	
PA	US 5672598
PI	19970330
AI	1996-407839
DT	19950321 (8)
FS	Granted
LN-CNT	3440
INCL	INC1M: 514/019,000 INC1S: 514/020,000; 514/330,000; 514/375,000; 514/367,000; 514/394,000; 519/16,000; 562,450,000; 562,574,000; 548,152,000; 548,217,000; 548/204,400; 548/486,000; 548,400,000; 548/146,000; 548,206,000; 548/252,000; 548/254,000; 548/336,000; 548/357,000; 548/215,000; 548/740,000; 546/245,000; 546,152,000; 549/91,000; 549,498,000; 549/29,000; 549/065,000; 549/069,000; 549/462,000; 549,049,000; 549/296,000; 544/296,000; 544/264,000; 544/375,000; 548/217,000;
IC	[6] INC1M: 514/212,000 INC1S: 514/327,000; 514/424,000; 546/243,000; 548/550,000; 514/327,000; 514/424,000; 514/212,030 NCL: 514/327,000; 546/243,000; 548/550,000; 514/327,000; 514/424,000
IN	[6] INC1M: 514/212,000 INC1S: 514/327,000; 514/424,000; 546/243,000; 548/550,000; 514/327,000; 514/424,000; 514/212,030 NCL: 514/327,000; 546/243,000; 548/550,000; 514/327,000; 514/424,000
TI	C07D23-10
IN	IC5S: A61K031-55
EXF	540/528; 548/443; 548/550; 514/212; 514/327; 514/424
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
L9	ANSWER 127 OF 239 USPATFULL
AN	97:88973 USPATFULL
TI	Certain phosphonomethyl-pentanedioic acid derivatives thereof
IN	Jackson, Paul F., Bel Air, MD, United States
PA	Slusher, Barbara S., Kingsville, MD, United States
PA	Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI	US 5672592
AI	1996-665776
DT	19970930
FS	Granted
LN-CNT	1347
INCL	INC1M: 514/075,000 INC1S: 562/008,000; 562/012,000; 546/021,000; 546/022,000; 548/412,000; 549/005,000; 549/216,000; 549/218,000; 549/005,000; 514/075,000 NCL: 546/021,000; 546/022,000; 548/412,000; 549/013,000; 549/005,000; 549/006,000; 549/216,000; 549/218,000; 562/008,000; 562/012,000
IC	[6] INC1M: A61K031-66 INC1S: 562/008,000; 562/12; 514/75 EXF
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
L9	ANSWER 128 OF 239 USPATFULL
AN	97:88965 USPATFULL
TI	Carboxy-peptidyl derivatives as antidegenerative active agents
IN	Chapman, Kevin, Scotch Plains, NJ, United States
PA	Hagmann, William, Westfield, NJ, United States
PA	Durette, Philippe, New Providence, NJ, United States
PA	Eser, Craig, Belford, NJ, United States
PA	Kopke, Thor, Millburn, NJ, United States
PA	Caldwell, Charles, Scotch Plains, NJ, United States (U.S. corporation)
PI	US 5672593
AI	19940609
DT	19950517 (8)
FS	Granted
LN-CNT	2024
INCL	INC1M: 536/024,300 INC1S: 536/022,100; 535/023,100; 536/024,310; 536/024,320; 536/024,330; 435/006,000; 435/912,000; 435/320,000; 435/325,000; 536/022,100; 536/023,100; 536/024,310; 536/024,320; 536/024,330
IC	[6] INC1M: 536/024,300 INC1S: 536/022,100; 535/091,200; 435/320,100; 435/325,000; 536/022,100; 536/023,100; 536/024,310; 536/024,320; 536/024,330 EXF
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.
L9	ANSWER 130 OF 239 USPATFULL
AN	97:81301 USPATFULL
TI	Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
IN	Fraze, James Simpson, Sewell, NJ, United States
PA	Gleason, John Gerald, Downingtown, PA, United States
PA	Metcalf, Brian Walter, Radnor, PA, United States
PA	SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
RLI	Continuation-in-part of Ser. No. US 1992-981970, filed on 25 Nov 1992, now abandoned



Utility	filed on 16 Sep 1992, now abandoned
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
CNT	ANSWER 136 OF 239 USPATFULL
CL	97:68500 USPATFULL
INC1M:	530/387.300
INC1S:	530/350.000; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: C07K014-435 ICCS: C12P021-08; A61K039-00; A61K038-16 530/389.2; 530/387.3; 530/399; 530/350; 424/138.1; 424/124.1; 424/145.1; 514/12; 524/2
LI	ANSWER 136 OF 239 USPATFULL
AN	97:68500 USPATFULL
TI	Methods for prevention of cancer using phenylacetic acids and derivatives thereof
IN	Samid, Dvorit, Rockville, MD, United States The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PA	Tabor, Kelly Helen, Hillsborough, CA, United States Schwall, Ralph H., Pacifica, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI	US 5546036
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 137 OF 239 USPATFULL
AN	97:56730 USPATFULL
TI	Natural amino acid derivatives as metalloproteinase inhibitors
IN	Dickens, Jonathan Philip, Cambridge, England Crimmin, Michael John, Cowley, England
PA	Beckett, Raymond Paul Cowley, England British Biotech Pharmaceuticals Limited, Cowley, United Kingdom (non-U.S. corporation)
PI	WO 9402446 19940203 #STR1# US 5643964 19970701
AI	US 9402446 19940203 #STR1# US 1993-374601 19950123 (8) WO 1993-GB1556 19930723 19950123 PCT 371 date 19950123 PCT 102(e) date
PRAT	GB 1992-15665
DT	Utility
FS	Granted
LN.CNT	772
INCL	INCLM: 514/575.000
INC1S:	562/623.000
NCL	NC1M: 514/575.000
NC1S:	562/623.000
IC	[61] ICM: A01N037-28
EXF	562/623; 514/575
CAS	ANSWER 140 OF 239 USPATFULL
LN	97156656 USPATFULL
AN	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
TI	IVversen, Patrik L., Raaston, NE, United States
IN	Mata, John E., Omaha, NE, United States
PA	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 138 OF 239 USPATFULL
CL	97:59098 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: C07K014-435 ICCS: C12P021-08; A61K039-00; A61K038-16 530/389.2; 530/387.3; 530/399; 530/350; 424/138.1; 424/124.1; 424/145.1; 514/12; 524/2
LI	ANSWER 138 OF 239 USPATFULL
AN	97:59098 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 139 OF 239 USPATFULL
AN	97:56730 USPATFULL
TI	Natural amino acid derivatives as metalloproteinase inhibitors
IN	Dickens, Jonathan Philip, Cambridge, England Crimmin, Michael John, Cowley, England
PA	Beckett, Raymond Paul Cowley, England British Biotech Pharmaceuticals Limited, Cowley, United Kingdom
PI	WO 9402446 19940203 #STR1# US 5643964 19970701
AI	US 9402446 19940203 #STR1# US 1993-374601 19950123 (8) WO 1993-GB1556 19930723 19950123 PCT 371 date 19950123 PCT 102(e) date
PRAT	GB 1992-15665
DT	Utility
FS	Granted
LN.CNT	772
INCL	INCLM: 514/575.000
INC1S:	562/623.000
NCL	NC1M: 514/575.000
NC1S:	562/623.000
IC	[61] ICM: A01N037-28
EXF	562/623; 514/575
CAS	ANSWER 140 OF 239 USPATFULL
LN	97156656 USPATFULL
AN	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
TI	IVversen, Patrik L., Raaston, NE, United States
IN	Mata, John E., Omaha, NE, United States
PA	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 139 OF 239 USPATFULL
CL	97:59098 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: A61K031-44 ICCS: C07D213-42 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 546/205; 546/84; 564/92;
LI	ANSWER 139 OF 239 USPATFULL
AN	97:59098 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 140 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN	IVversen, Patrik L., Raaston, NE, United States
PA	Mata, John E., Omaha, NE, United States
PI	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 140 OF 239 USPATFULL
CL	97156656 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: A61K031-44 ICCS: C07D213-42 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 546/205; 546/84; 564/92;
LI	ANSWER 140 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 141 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN	IVversen, Patrik L., Raaston, NE, United States
PA	Mata, John E., Omaha, NE, United States
PI	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 141 OF 239 USPATFULL
CL	97156656 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: A61K031-44 ICCS: C07D213-42 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 546/205; 546/84; 564/92;
LI	ANSWER 141 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 142 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN	IVversen, Patrik L., Raaston, NE, United States
PA	Mata, John E., Omaha, NE, United States
PI	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 142 OF 239 USPATFULL
CL	97156656 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: A61K031-44 ICCS: C07D213-42 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 546/205; 546/84; 564/92;
LI	ANSWER 142 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 143 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN	IVversen, Patrik L., Raaston, NE, United States
PA	Mata, John E., Omaha, NE, United States
PI	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 143 OF 239 USPATFULL
CL	97156656 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: A61K031-44 ICCS: C07D213-42 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 546/205; 546/84; 564/92;
LI	ANSWER 143 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;
IC	ICM: C12N015-13 ICCS: C12N015-85; C12N001-21; C07K016-28 [61] 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
EXF	536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85; 530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3
IN	ANSWER 144 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN	IVversen, Patrik L., Raaston, NE, United States
PA	Mata, John E., Omaha, NE, United States
PI	The Board of Regents of the University of Nebraska, Lincoln, NE, United
CNT	ANSWER 144 OF 239 USPATFULL
CL	97156656 USPATFULL
INC1M:	530/350.000
INC1S:	530/338.300; 424/134.100; 424/136.100; 424/178.100
NC1M:	530/338.300
NC1S:	424/134.1100; 424/136.100; 424/178.100; 530/350.000
[61]	ICM: A61K031-44 ICCS: C07D213-42 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 546/205; 546/84; 564/92;
LI	ANSWER 144 OF 239 USPATFULL
AN	97156656 USPATFULL
TI	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
IN	Schwall, Ralph H., Pacifica, CA, United States Tabor, Kelly Helen, Hillsborough, CA, United States denentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PA	US 1995-459388
PI	99950708
AI	US 1995-459388
DT	99950602 (8)
FS	Utility
Granted	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
LN.CNT	1402
INCL	INCLM: 435/252.300
INC1S:	435/240.200; 435/220.100; 536/023.530; 530/387.700; 530/388.220;
NC1M:	530/388.800; 530/388.850; 530/389.100; 530/389.700
NC1S:	435/252.300
NCL	435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/3



PI corporation) 19970624  
US 5641336 19940520 (8)  
AI  
DT Utility  
FS Granted  
LN.CNT 692  
INCL INCLM: 435/007. 400  
INCUS: 435/018. 000; 435/023. 000; 436/065. 000  
NCL NCIM: 435/007. 400  
NCIS: 435/018. 000; 435/023. 000; 436/065. 000  
NCL NCIM: 435/007. 400  
NCIS: 435/018. 000; 435/023. 000; 436/065. 000  
[6] ICM: G01N33-573  
ICS: C12Q001-34; C12Q001-37  
EXF 435/7. 4; 435/24; 435/23; 435/4; 436/518; 436/530; 436/65  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

19 ANSWER 146 OF 239 USPATFULL  
97:51993 USPATFULL  
Hydroxamic acid-containing inhibitors of matrix metalloproteinases  
TI Hydroxamic acid-containing inhibitors of matrix metalloproteinases  
IN Yelm, Kenneth Edward, Fairfield, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S.)  
corporation)  
PI 19970617  
US 5639746 19941229 (8)  
DT Utility  
FS Granted  
LN.CNT 1062  
INCL INCLM: 514/210. 000  
INCUS: 514/212. 000; 514/277. 000; 514/359. 000; 514/507. 000; 546/341. 000;  
NCL NCIM: 548/535. 000; 560/041. 000; 560/049. 000; 562/623. 000  
NCIS: 514/018. 000; 514/210. 020; 514/210. 170; 514/212. 030; 514/217. 110;  
514/227. 000; 514/358. 000; 514/507. 000; 530/331. 000; 546/341. 000;  
548/535. 000; 560/041. 000; 560/049. 000; 562/623. 000  
[6] ICM: A61K031-215  
ICS: C07D207-00; C07C229-00  
EXF 567/623; 560/41; 560/169; 514/507; 514/210; 514/212; 514/277; 514/359;  
548/535; 566/311  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

19 ANSWER 147 OF 239 USPATFULL  
97:49530 USPATFULL  
Method of modulating DNA binding activity of recombinant  
alpha-1 antichymotrypsin and other serine protease inhibitors  
TI alpha-1 antichymotrypsin and other serine protease inhibitors  
IN Rubin, Harvey, Philadelphia, PA, United States  
PA Cooperman, Barry, Penn Valley, PA, United States  
The Trustees of the University of Pennsylvania, Philadelphia, PA, United  
States (U.S. corporation)  
PI 19970610  
US 5637479 19950505 (8)  
RLI Continuation-in-part of Ser. No. US 1994-276936, filed on 19 Jul 1994,  
now patented. Pat. No. US 5612194 which is a continuation-in-part of  
Ser. No. US 1994-222286, filed on 18 Apr 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1994-221078, filed on 31 Mar 1994  
Ser. No. Ser. No. US 1994-221171, filed on 31 Mar 1994 And Ser. No. US  
Ser. No. Ser. No. US 1991-735335, filed on 24 Jul 1991, now  
is a division of Ser. No. US 1991-735335, filed on 15 Jan 1993, now  
patented. Pat. No. US 5352725 which is a division of Ser. No. US 509336,  
1989-370704, filed on 23 Jun 1989, now patented. Pat. No. US 509336,  
said Ser. No. US -221078 which is a continuation-in-part of Ser. No.  
US -5908  
DT Utility  
FS Granted  
LN.CNT 702  
INCL INCLM: 435/069. 200  
INCUS: 435/172. 300; 530/350. 000; 530/395. 000; 536/023. 500  
NCL NCIM: 435/059. 200  
NCIS: 530/350. 000; 530/395. 000; 536/023. 500  
[6] ICM: C07K014-435  
EXF 435/172. 3; 530/335; 530/395; 536/23. 5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

19 ANSWER 148 OF 239 USPATFULL  
97:4511 USPATFULL  
Cathepsin C homolog  
AT Coleman, Roger, Mountain View, CA, United States  
Braxton, Scott M, San Mateo, CA, United States  
Seilheimer, Jeffrey J., Los Altos Hills, CA, United States  
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.)  
US 5637462 19970610  
AT 1995-426428 19950419 (8)  
DT Utility  
FS Granted  
LN.CNT 1076  
INCL INCLM: 435/006. 000  
INCUS: 536/022. 100; 536/023. 100; 536/024. 300; 536/024. 310  
NCL NCIM: 435/006. 000  
NCIS: 435/091. 200  
[6] ICM: C12Q001-68  
EXF 536/22. 1; 536/23. 1; 536/24. 3; 536/24. 31; 435/6; 435/91. 2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

19 ANSWER 149 OF 239 USPATFULL  
97:47505 USPATFULL  
Beta-8 integrin subunit antibodies  
TI Movie, Matthew, Walnut Creek, CA, United States  
IN Molan, John W., San Francisco, CA, United States  
PA Gentech, Inc., South San Francisco, CA, United States  
corporation)  
PI 19970603  
US 5633601 19950530 (8)  
RLI US 1995-45455  
Division of Ser. No. US 1994-193989, filed on 9 Feb 1994 which is a  
continuation of Ser. No. US 1993-4142, filed on 13 Jan 1993, now  
abandoned which is a continuation of Ser. No. US 1991-67607, filed on  
14 Mar 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2642  
INCL INCLM: 530/388. 200  
INCUS: 530/388. 700; 530/389. 600; 435/070. 210; 435/172. 200;  
NCL NCIM: 424/144. 100; 424/158. 100; 424/172. 100  
NCIS: 530/388. 200; 530/388. 700; 530/389. 600  
[6] ICM: A61K039-395  
EXF ICM: C07K015-28; C12P021-08; C12N015-06  
424/139. 1; 424/143. 1; 424/144. 1; 424/158. 1; 424/172. 1; 435/69. 6;  
435/70. 21; 435/172. 2; 435/90. 21; 530/387. 9; 530/388. 2; 530/388. 22;  
530/388. 7; 530/389. 2; 530/389. 6  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 150 OF 239 USPATFULL  
 AN 97:47438 USPATFULL  
 TI Methods for inducing differentiation of a cell using  
 phenylacetic acid and derivatives  
 IN Schmid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5633533 19900603  
 AI RLI 1995-470229  
 DT Division of Ser. No. US 1991-135661, filed on 12 Oct 1993 which is a  
 continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 FS Granted  
 LN CNT 4108  
 INCL INCLM: 514/538.000  
 NCIM: 514/533.000; 514/567.000  
 NCLS: 514/538.000  
 IC [6] ICM: A01N037-12  
 ICS: A01N037-44; A61K031-24  
 EXF 514/538; 514/563; 514/567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 151 OF 239 USPATFULL  
 AN 97:47437 USPATFULL  
 TI Compositions and methods for therapy and prevention of  
 pathologies including cancer, AIDS and anemia  
 IN Samidi, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Secretary of the  
 Department of Health and Human Services, Washington, DC, United States  
 (U.S. government)  
 PI US 5635532 19970603  
 AI RLI Continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 FS Granted  
 LN CNT 4105  
 INCL INCLM: 514/538.00; 514/567.000; 560/019.000  
 NCIM: 514/563.000  
 NCLS: 514/538.00; 514/567.000; 560/019.000  
 IC [6] ICM: A01N037-12  
 ICS: A01N037-44; A61K031-195; A61K031-24  
 EXF 514/538; 514/533; 514/567; 560/19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 152 OF 239 USPATFULL  
 AN 97:40821 USPATFULL  
 TI N-(mercaptoacetyl) peptidyl derivatives as antidegenerative agents  
 IN Hagniann, William, Westfield, NJ, United States  
 PA Kopka, Thor, Millburn, NJ, United States (U.S. corporation)  
 PI US 5623343 19970513  
 AI WO 940481 19940414  
 WO 1993-US9137 19930927 (8)  
 19950223 PCT 371 date  
 19950223 PCT 102(e) date

DT Utility  
 FS Granted  
 LN CNT 1091  
 INCL INCLM: 514/513.000

NCL INCLM: 514/513.000  
 NCIM: 514/562.000; 514/616.000; 558/254.000; 562/426.000  
 NCLS: 514/562.000  
 IC [6] ICM: A61K031-21  
 EXF 564/154; 558/254; 562/426; 514/513; 514/562; 514/616  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 153 OF 239 USPATFULL  
 AN 97:40640 USPATFULL  
 TI Diagnostic assay for inhibitor of tissue-type and urokinase-type  
 plasminogen activators, and gene coding for the inhibitor  
 IN Loskutoff, David J., Solana Beach, CA, United States  
 NY, Tor, Umea, Sweden  
 Sawdayi, Michael, La Jolla, CA, United States  
 The Scripps Clinic and Research Foundation, La Jolla, CA, United States  
 (U.S. corporation)  
 US 56229160 19970513  
 PI US 1994-248348  
 AI RLI Division of Ser. No. US 1992-87721, filed on 29 Apr 1992, now patented,  
 Pat. No. US 5314994 which is a continuation of Ser. No. US 1990-513485,  
 filed on 27 Aug 1990, now abandoned which is a division of Ser. No. US  
 1986-897990, filed on 19 Aug 1986, now patented, Pat. No. US 492512  
 which is a continuation-in-part of Ser. No. US 1984-623357, filed on 22  
 Jun 1984, now patented, Pat. No. US 4791068  
 DT Utility  
 FS Granted  
 LN CNT 2639  
 INCL INCLM: 435/007.100  
 NCIM: 435/007.920; 435/007.930; 435/013.000; 435/059.200; 436/518.000  
 NCLS: 435/007.100  
 IC [6] ICM: G01N033-53  
 EXF 435/7.1; 435/7.9; 435/7.92-7.93; 435/13; 435/69.2; 435/240.1; 436/518  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 154 OF 239 USPATFULL  
 AN 97:38606 USPATFULL  
 TI Integrin-binding peptides  
 IN Ruoslahti, Erkki, Rancho Santa Fe, CA, United States  
 PA Kovalainen, Erkki, San Diego, CA, United States  
 La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S.  
 corporation)  
 PI US 5627263 19970506  
 AI US 1995-425238  
 RLI Continuation of Ser. No. US 1993-158001, filed on 24 Nov 1993, now  
 abandoned  
 DT Utility  
 FS Granted  
 LN CNT 725  
 INCL INCLM: 530/327.000  
 NCIM: 530/328.000  
 NCLS: 530/327.000  
 IC [6] ICM: A61K038-04  
 EXF ICS: C07K007-06; C07K007-08  
 530/327; 530/328; 530/329  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 155 OF 239 USPATFULL  
 AN 97:39499 USPATFULL  
 TI Hydroxamic acid and carboxylic acid derivatives, process for their

IN preparation and use thereof  
 Gomavaram, Madhusudhan R., West Chester, PA, United States  
 Johnson, Jeffrey, Phoenixville, PA, United States  
 Cook, Ewell R., Royersford, PA, United States  
 Wah, Robert C., Collegeville, PA, United States  
 Matlivoetz, Alan M., Schwenksville, PA, United States  
 Tomczuk, Bruce E., Collegeville, PA, United States  
 Saha, Ashis K., Harleysville, PA, United States  
 Sanofi S.A., Paris Cedex, France (non-U.S. corporation)  
 PI US 5618844 1995-0605 (8) I  
 AI 1995-461079 I  
 RLI Division of Ser. No. US 1994-201837, filed on 25 Feb 1994, now patented,  
 Pat. No. US 5514716 I  
 DT  
 FS Granted  
 LN.CNT 1712  
 INCL INCLM: 514/575.000  
 INCLS: 562/621.000  
 NCL NCIM: 514/575.000  
 NCLS: 562/621.000  
 IC [6] ICM: A61K031-19  
 ICS: C07C239-00  
 EXF 562/80; 562/621; 514/575; 514/419; 548/490  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

19 ANSWER 156 OF 239 USPATFULL  
 AN 97-27192 USPATFULL  
 TI Peptide derivatives of collagenase inhibitor  
 IN Gray, Robert D., Louisville, KY, United States  
 Spatola, Arno F., Louisville, KY, United States  
 Darlak, Krzysztof, Louisville, KY, United States  
 Research Corporation Tech., Inc., Tucson, AZ, United States (U.S.  
 corporation)  
 PI US 5616605 19970401  
 AI 1994-287320 I  
 RLI Division of Ser. No. US 1992-98119, filed on 24 Nov 1992, now patented,  
 Pat. No. US 5387610 which is a continuation of Ser. No. US 1991-715948,  
 filed on 14 Jun 1991, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 7722  
 INCL INCLM: 514/510.000  
 INCLS: 514/510.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;  
 NCL NCIM: 514/510.000  
 NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;  
 IC [6] ICM: A61K031-21  
 ICS: A01N037-00; A01N047-40; A01N047-46  
 EXF 514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

19 ANSWER 159 OF 239 USPATFULL  
 AN 96-118315 USPATFULL  
 TI DNA encoding a hyaluronan receptor expressed in human umbilical vein  
 IN Hawkins, Phillip R., Mountain View, CA, United States  
 Middle, Craig G., Sunnyvale, CA, United States  
 Seihamer, Jeffrey J., Los Altos Hills, CA, United States  
 Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
 corporation)  
 PI US 5587301 19961224  
 AI 1995-402217  
 DT Utility  
 FS Granted  
 LN.CNT 1142  
 INCL INCLM: 435/069.100  
 INCLS: 435/252.300; 435/320.100; 536/023.500  
 NCL NCIM: 435/069.100  
 NCLS: 435/252.300; 435/320.100; 536/023.500  
 IC [6] ICM: C12N005-10  
 ICS: C12N015-12

19 ANSWER 157 OF 239 USPATFULL  
 AN 97-27061 USPATFULL  
 TI Effects of growth factors on hair follicle cell proliferation and  
 release of collagenolytic factors  
 IN Yuspa, Stuart H., Bethesda, MD, United States  
 The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5616671 19970401 I  
 AI 1991-650572 19910204 (7)  
 RLI Continuation-in-part of Ser. No. US 1987-48537, filed on 6 May 1987

EXF 435/69.1; 435/282.3; 435/320.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 160 OF 239 USPATFULL  
AN 96:116379 USPATFULL  
TI Tricyclic cefem sulphones  
IN Alpediani, Marco, Milan, Italy  
Bisolino, Pierluigi, San Giorgio di Lomellina, Italy  
Perrone, Ettore, Boffalora Ticino, Italy  
Rizzo, Vincenzo, Arese, Italy (non-U.S. corporation)  
PA, Pharmacia S.p.A., Milan, Italy (non-U.S. corporation)  
PI US 5585372 19941208  
WO 9428003 19941208  
AI WO 1995-367319 19950120 (8)

WO 1994-EP1643 19940517  
19950120 PCT 371 date  
19950120 PCT 102(e) date  
PRAI GB 1993-10428 19930520  
DT Utility Granted  
FS  
LN.CNT 1301  
INCL INCIM: 514/200, 000  
INCL: 514/202, 000; 514/208, 000; 540/216, 000  
NCL NCIM: 514/200, 000  
NCLS: 514/202, 000; 514/208, 000; 540/216, 000  
IC [6] ICM: C07D501-62  
ICM: A61K031-545  
EXF 540/215; 540/221; 540/222; 540/216; 514/202; 514/200; 514/204  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 161 OF 239 USPATFULL  
AN 96:113902 USPATFULL  
TI Agents affecting thrombosis and hemostasis  
IN Wolf, David L., Palo Alto, CA, United States  
Sinha, Uma, San Francisco, CA, United States  
PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5533107 19961210  
US 1994-266003 19940629 (8)  
RLI Continuation-in-part of Ser. No. US 1994-49777, filed on 26 May 1994 which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144  
DT Utility Granted  
FS  
LN.CNT 1955  
INCL INCIM: 514/012, 000  
INCL: 514/021, 000; 424/094, 640; 435/069, 600; 530/381, 000; 530/384, 000;  
NCL NCIM: 530/830, 000  
NCLS: 530/830, 000  
IC [6] ICM: A61K031-60  
ICM: A61K031-64  
EXF 514/094 640; 435/069, 600; 514/021, 000; 530/381, 000; 530/384, 000;  
LN.CNT 530/830, 000  
INCL INCIM: 514/012, 000; 424/094, 640; 435/069, 600; 530/381, 000; 530/384, 000;  
INCL: 530/830, 000  
NCL NCIM: 530/830, 000  
NCLS: 530/830, 000  
IC [6] ICM: A61K038-36  
ICM: A61K035-16; C07K014-435; C07K014-475  
EXF 530/830; 530/380; 530/831; 530/395; 930/100; 435/69.1; 435/69.2;  
435/69.5; 435/712; 424/94, 64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 162 OF 239 USPATFULL  
AN 96:11551 USPATFULL  
TI Single-chain hepatocyte growth factor variants  
IN Godowski, Paul J.; Pacifica, CA, United States  
Lokker, Natalie A.; San Francisco, CA, United States  
Mark, Melanie R.; San Jose, CA, United States  
Generitech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PA PI US 5580953 19961203  
AI RLI US 1994-194088 19940209 (8)  
Division of Ser. No. US 1992-884811, filed on 18 May 1992, now patented,  
Pat. No. US 531621  
DT Utility Granted  
FS  
LN.CNT 1985  
INCL INCIM: 530/399, 000  
NCL NCIM: 530/399, 000  
IC [6] ICM: C07K014-475  
ICM: A61K038-18  
EXF 530/399; 530/351; 435/69, 4; 435/69, 5; 435/106; 435/69, 1; 574/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 163 OF 239 USPATFULL  
AN 96:9138 USPATFULL  
TI Peptides derived from trifluoromethylketones  
de Nanteuil, Guillaume, Suresnes, France  
Portevin, Bernard, Elancourt, France  
Canet, Emmanuel, Paris, France  
Adir et Compagnie, Courbevoie, France (non-U.S. corporation)  
PA PI US 1995-47433 19950505 (8)  
FR 1994-5494 19940505  
DT Utility Granted  
FS  
LN.CNT 522  
INCL INCIM: 530/331, 000  
INCL: 530/345, 000; 530/350, 000; 514/018, 000  
NCL NCIM: 530/331, 000  
NCLS: 530/345, 000; 530/350, 000  
IC [6] ICM: A61K038-05  
ICM: A61K038-05  
EXF 514/18; 530/331; 530/350; 530/323; 530/345  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 164 OF 239 USPATFULL  
AN 96:94559 USPATFULL  
TI Peptides derived from trifluoromethylketones  
Vincent, Michel, Bagneux, France  
de Nanteuil, Guillaume, Suresnes, France  
Portevin, Bernard, Elancourt, France  
Herve, Yolande, Puteaux, France  
Caneil, Emmanuel, Paris, France  
Lorchampt, Michel, Rungis, France  
Adir et Compagnie, Courbevoie, France (non-U.S. corporation)  
PA PI US 5563429 19961015  
AI RLI US 1995-43933 19950511 (8)  
Continuation of Ser. No. US 1993-99915, filed on 30 Jul 1993, now abandoned  
FR 1992-9254 19920728  
DT Utility Granted  
FS  
LN.CNT 1271  
INCL INCIM: 514/018, 000  
INCL: 530/331, 000  
NCL NCIM: 514/018, 000

IC NCIS: 530/331.000  
161  
ICM: A61K038-00  
ICS: C07R005-00; C07R007-00; C07R017-00  
EXF 514/18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 165 OF 239 USPATFULL  
AN 96/39094 USPATFULL  
TI Illudin analogs useful as antitumor agents  
IN Kelner, Michael J., La Jolla, CA, United States  
McMorris, Trevor C., La Jolla, CA, United States  
Taetle, Raymond, Tucson, AZ, United States  
The Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)  
US 5563176 1996/008  
AI US 1954-271619 1994/015 (8)  
RLI Continuation-in-part of Ser. No. US 1993-15179, filed on 9 Feb 1993, now  
patented. Pat. No. US 5439936 which is a continuation-in-part of Ser.  
No. US 1990-606511, filed on 31 Oct 1990, now patented. Pat. No. US  
5439912 which is a continuation-in-part of Ser. No. US 1989-416395,  
filed on 3 Oct 1989, now abandoned

DT Utility  
FS Granted

IN,CNT 1120  
INCIM: 514/691.000  
INCIS: 560/162.000; 560/255.000; 560/256.000; 568/374.000  
NCL: 514/691.000  
IC [6] ICM: A61K031-12  
EXF ICS: C07C049-03  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 166 OF 239 USPATFULL  
AN 96/38026 USPATFULL  
TI Acylsulfonamido-substituted hydroxamic acids  
IN MacPherson, Lawrence J., Hampton, NJ, United States  
Parker, David T., Livingston, NJ, United States  
Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)  
PT US 5532419 1996/093  
AI US 1994-333676 1994/1103 (8)  
RLI Continuation-in-part of Ser. No. US 1994-265296, filed on 24 Jun 1994  
which is a continuation-in-part of Ser. No. US 1993-1136, filed on 6 Jan  
1993, now patented. Pat. No. US 5455258  
PTAI NZ 1993-250517 1993/1220  
DT Utility  
FS Granted

LN,CNT 3589  
INCIM: 514/357.000  
INCIS: 544/058 1.00; 544/168.000; 544/130.000; 544/131.000; 544/133.000;  
540/524.000; 540/531.000; 514/604.000; 546/775.000; 546/194.000;  
546/247.000; 546/299.000; 546/265.000; 546/283.400; 546/282.100;  
546/333.000; 546/337.000; 546/280.400; 546/284.400; 546/281.700;  
546/275.100; 548/205.000; 548/335.100; 548/338.100; 549/013.000;  
549/065.000; 549/426.000; 546/084.000; 564/090.000; 564/092.000;  
564/094.000; 514/237.800; 514/311.000; 514/331.000; 514/332.000;  
514/331.000; 514/365.000; 514/366.000; 514/406.000; 514/432.000;  
514/445.000; 514/451.000; 514/602.000  
NCL NCIM: 514/357.000  
NCL: C07R005-00; C07R017-00; C07K014-475  
NCL: C12N015-18; C07H017-00; C07K014-475  
EXF 530/399; 530/331; 536/23.51; 435/69.4; 435/106; 435/240.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IC NCIS: 530/331.000  
161  
ICM: A61K031-44  
ICS: C07R0213-42  
EXF 546/775; 546/247; 546/265; 546/276; 546/333; 546/337; 544/68; 548/205;  
548/135.1; 548/338.1; 549/113; 549/426; 549/45; 564/84; 564/90; 564/92;  
564/94; 514/237.8; 514/311; 514/332; 514/365; 514/367; 514/406; 514/432; 514/447; 514/491; 514/602; 514/604; 514/357  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 167 OF 239 USPATFULL  
AN 96/71966 USPATFULL  
TI Transgenic animal model system for human cutaneous melanoma  
RLI Mintz, Beatrice, Elkins Park, PA, United States  
PA Fox Chase Cancer Center, Philadelphia, PA, United States (U.S. corporation)  
PI US 5530316 1996/0827  
AI US 1993-11060 1993/0129 (8)  
RLI Continuation-in-part of Ser. No. US 1991-636798, filed on 2 Jan 1991,  
now abandoned

DT Utility  
FS Granted

LN,CNT 1436  
INCIM: 800/002.000  
INCIS: 800/DIG 001; 435/172.3; 536/23.1; 536/23.72; 536/24.1; 424/9  
EXF 800/2; 800/DIG 1; 435/172.3; 536/23.100; 536/023.720; 536/024.100;  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 168 OF 239 USPATFULL  
AN 96/715302 USPATFULL  
TI Hepatocyte growth factor variants  
IN Godowski, Paul J., Burlingame, CA, United States  
Lokker, Natalie A., San Francisco, CA, United States  
Marie, Melanie R., Burlingame, CA, United States  
Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 554/856 1996/0820  
AI US 1993-87783 1993/0713 (8)  
RLI Continuation-in-part of Ser. No. US 1992-884811, filed on 18 May 1992,  
now patented. Pat. No. US 5316921 which is a continuation-in-part of  
Ser. No. US 1992-885971, filed on 18 May 1992, now patented. Pat. No. US  
5320837  
DT Utility  
FS Granted

LN,CNT 2175  
INCIM: 435/694.000  
INCIS: 435/240.100; 435/320.100; 536/023.510; 530/399.000  
NCL NCIM: 435/069.400  
NCL: 435/220.100; 435/325.000; 530/399.000; 536/023.510  
EXF 435/069.400  
IC ICM: C12P021-06  
IC: C12N015-18; C07H017-00; C07K014-475  
IC: C12N015-18; C07H017-00; C07K014-475  
EXF 530/399; 530/331; 536/23.51; 435/69.4; 435/106; 435/240.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 169 OF 239 USPATFULL  
 AN 96:0435 USPATFULL  
 TI Proline phosphonate derivatives, United States  
 Powers, James C., Atlanta, GA, United States  
 Boduszek, Bogdan, Wroclaw, Poland  
 Olekszyn, Jozef, Arlington, MA, United States  
 Georgia Tech Research Corp., Atlanta, GA, United States (U.S.)  
 corporation)  
 PI US 5543396 1994-234181 19960806  
 AI 19940428 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1747  
 INCL INCIM: 514/019.000; 514/087.000; 514/089.000; 514/094.000; 548/412.000; 548/111.000;  
 INCIS: 514/021.000; 540/542.000; 540/450.000; 544/053.000; 544/057.000;  
 NCL NCIM: 514/019.000; 544/088.000; 544/106.000; 558/170.000  
 NCIS: 514/087.000; 514/089.000; 514/094.000; 540/450.000; 540/542.000;  
 544/053.000; 544/057.000; 544/088.000; 544/106.000; 546/021.000;  
 548/111.000; 548/412.000; 558/170.000  
 IC [6] ICM: A61K038-00  
 ICS: A61K031-67; A01N057-00; C07F005-02  
 EXF 514/87; 514/89; 514/90; 514/101; 548/412; 548/111; 546/21; 546/450;  
 540/542; 544/53; 544/57; 544/88; 544/106; 558/170  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 170 OF 239 USPATFULL  
 AN 96:65461 USPATFULL  
 TI Prostate-specific membrane antigen  
 IN Israel, Ron S., Forest Hills, NY, United States  
 Heston, Warren D., New York, NY, United States  
 Fair, William R., New York, NY, United States  
 Sloan-Kettering Institute For Cancer Research, New York, NY, United States (U.S. corporation)  
 PI US 5538866 19960723  
 AI 1994-32553 19941018 (8)  
 RRI Continuation of Ser. No. US 1992-913337, filed on 5 Nov 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1966  
 INCL INCIM: 435/069.300; 435/320.500; 435/240.200; 435/254.200; 935/012.000;  
 INCIS: 435/252.300; 935/023.000; 935/022.000; 935/066.000; 536/023.500  
 NCL NCIM: 435/069.300; 435/254.200; 435/320.100; 435/325.000; 435/348.000;  
 NCIS: 536/023.500  
 IC [6] ICM: C12N015-12  
 ICS: C12N001-21; C12P071-02  
 EXF 435/69.3; 435/320.1; 435/252.3; 435/254.2; 435/240.2; 935/8; 935/12;  
 935/23; 935/24; 935/27; 935/66; 935/70; 935/72; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 171 OF 239 USPATFULL  
 AN 96:653201 USPATFULL  
 TI Integrin-binding peptides  
 IN Ruoslahti, Erkki, Rancho Santa Fe, CA, United States  
 Kovalchenko, San Diego, CA, United States (U.S. corporation)  
 PA La Jolla Cancer Research Foundation, United States (U.S. corporation)  
 PI US 5536814 19960716

AI US 1994-212186 19940311 (8) 19940311 (8)  
 RRI Continuation-in-part of Ser. No. US 1993-127422, filed on 27 Sep 1993,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 847  
 INCL INCIM: 530/329.000; 530/328.000  
 NCL NCIM: 530/329.000; 530/328.000  
 NCIS: 530/317.000; 530/328.000  
 IC [6] ICM: C07R007-64  
 ICS: C07R007-06  
 EXF 530/300; 530/317; 530/321; 530/326; 530/327; 530/328; 530/329; 530/330  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 172 OF 239 USPATFULL  
 AN 96:58109 USPATFULL  
 TI Method for regulating formation of a complex of plasminogen  
 activator, its receptor and inhibitor  
 IN Wang, Ning, Wuhan, China  
 Barlowatz-Memon, Georgia, Paris, France  
 Freberg, Jeffrey J., Sharon, MA, United States  
 President and Fellows of Harvard University, Cambridge, MA, United States (U.S. corporation)  
 University of Paris, France (non-U.S. corporation)  
 PI US 5532132 19960702 19960702  
 AI 1993-127977 19930328 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 984  
 INCL INCIM: 435/007.210  
 INCIS: 435/007.230; 435/007.900; 436/501.000; 436/503.000  
 NCL NCIM: 435/007.210  
 NCIS: 435/007.230; 435/007.900; 436/501.000; 436/503.000  
 IC [6] ICM: G01N033-567  
 EXF 435/7.21; 435/7.23; 435/7.9; 435/13; 435/24; 436/503; 436/501  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

1.9 ANSWER 173 OF 239 USPATFULL  
 AN 96:59115 USPATFULL  
 TI Hydroxamic acid based collagenase inhibitors  
 IN Davidson, Colin H., Oxon, England  
 Dickens, Jonathan P., Buckinghamshire, England  
 Crimmin, Michael J., Ascot, England  
 British Bio-technology Limited, Oxford, England (non-U.S. corporation)  
 PI US 5530161 19960625  
 AI US 1994-195018 19940214 (8)  
 RRI Division of Ser. No. US 1993-48113, filed on 14 Apr 1993, now patented, Pat. No. US 5310763 which is a continuation of Ser. No. US 1991-689818, filed on 8 Jul 1991, now patented, Pat. No. US 5240958  
 DT Utility  
 FS Granted  
 LN.CNT 1525  
 INCL INCIM: 562/623.000  
 NCL NCIM: 562/623.000  
 IC [6] ICM: C07C259-04  
 ICS: A61K031-19  
 EXF 514575; 562/623; 562/621  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 174 OF 239 USPATFULL  
 AN 96:48574 USPATFULL  
 TI Illudin analogs  
 IN Kelner, Michael J., La Jolla, CA, United States  
 McMorris, Trevor C., La Jolla, CA, United States  
 Faetle, Raymond, Tucson, AZ, United States  
 PA The Regents of the University of California, Oakland, CA, United States  
 (U.S. corporation)  
 PI US 5523490 19860604  
 AI US 1994-332940 19941101 (8)  
 RLI Continuation of Ser. No. US 1993-15179, filed on 9 Feb 1993, now  
 patented. Pat. No. US 5439935 which is a continuation-in-part of Ser.  
 No. US 1990-606511, filed on 31 Oct 1990, now patented. Pat. No. US  
 5439942 which is a continuation-in-part of Ser. No. US 1989-416395,  
 filed on 3 Oct 1989, now abandoned  
 DT Utility  
 FS Granted  
 LN CNT 919 INCL NCIM: 568/374.000  
 NCL [6] ICM: C07C211-00  
 EXF 514/56; 514/691; 568/374  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 175 OF 239 USPATFULL  
 AN 96:43170 USPATFULL  
 TI Urokinase-type plasminogen activator receptor antibodies  
 IN Ronne, Keld, Charlottenlund, Denmark  
 Behrendt, Niels, Bagsværd, Denmark  
 Ellis, Vincent, Copenhagen, Denmark  
 Hoyer-Hansen, Gunilla, Gentofte, Denmark  
 Pyke, Charles, Soborg, Denmark  
 Buerner, Nils, Virum, Denmark  
 Canceftorskningsfondet af 1989, Copenhagen, Denmark (non-U.S.  
 corporation)  
 PI US 5519120 19960521  
 AI US 1993-85122 19930617 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-824189, filed on 6 Dec 1991,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1889-37485, filed on 3 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-334613, filed on 7 Apr 1989,  
 now abandoned  
 DT Utility  
 FS Granted

LN CNT 5458 INCL NCIM: 530/388.20  
 INCL NCIM: 530/388.100; 530/388.800; 530/388.260; 530/391.100; 530/391.300;  
 INCL NCIM: 435/240.270  
 NCL NCIM: 530/388.220  
 NCL NCIM: 530/388.100; 530/388.260; 530/388.800; 530/391.100; 530/391.300  
 IC [6] ICM: C07K016-40  
 ICM: C07K016-18; C07K016-00; C12N005-12  
 EXF 530/391.1; 530/391.3; 530/388.22; 530/388.26; 530/388.1; 530/388.8;  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 176 OF 239 USPATFULL  
 AN 96:38938 USPATFULL  
 TI Hydroxamic acid and carboxylic acid derivatives, process for their  
 preparation and use thereof  
 IN Gouravarapu, Madhusudhan R., West Chester, PA, United States

L9 ANSWER 177 OF 239 USPATFULL  
 AN 96:21100 USPATFULL  
 TI Signal transduction inhibitor 1,2,3-triazolo compounds  
 IN Kohn, Elise C., Olney, MD, United States  
 Liotta, Lance A., Potomac, MD, United States  
 Felder, Christian C., Bethesda, MD, United States  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 US 5496620 19960312  
 PI US 1993-455761 19950531 (8)  
 AI RLI Continuation-in-part of Ser. No. US 1992-89491, filed on 8 Jun 1992,  
 now abandoned and a continuation of Ser. No. US 1994-27181, filed on 1  
 Jul 1994 which is a division of Ser. No. US 1992-985402, filed on 4 Dec  
 1992, now patented. Pat. No. US 5359078 which is a continuation-in-part  
 of Ser. No. US 1989-35574, filed on 19 May 1989, now patented. Pat. No.  
 US 5133315. And a continuation-in-part of Ser. No. US 1992-94009, filed  
 on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US  
 1991-637145, filed on 3 Jan 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN CNT 1395 INCL NCIM: 514/359.000  
 INCL NCIM: 548/255.000; 548/264.800; 548/326.500  
 NCL NCIM: 514/359.000  
 NCL NCIM: 548/255.000; 548/264.800; 548/326.500  
 IC [6] ICM: A61K031-41  
 ICM: C07D249-06  
 EXF 548/255; 548/264.8; 548/326.5; 514/359  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 178 OF 239 USPATFULL  
 AN 96:5730 USPATFULL  
 TI Antibodies specific for human stromelysin-3 and a method for  
 detection of stromelysin-3  
 a Bassat, Paul, Strasbourg, France  
 Bellocq, Jean-Pierre, Strasbourg, France  
 PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
 corporation)  
 Institute National de la Santé et de la Recherche Medicale, Paris Cedex,  
 France (non-U.S. government)  
 Centre National de la Recherche Scientifique, Paris Cedex, France  
 (non-U.S. government)  
 Université Louis Pasteur, Strasbourg Cedex, France (non-U.S.  
 corporation)  
 PI US 5484726 19960116  
 AI US 1993-1711 19930107 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-794393, filed on 21 Nov 1991,  
 now patented, Pat. No. US 5336844  
 GB 1990-25326 19901121  
 PRAI DT Utility  
 FS Granted  
 LN CNT 2805 435/007.400  
 INCL INCLM: 530/387.100; 530/388.100; 530/387.700; 530/388.260; 530/388.800  
 NCL NCIM: 435/007.400  
 NCIS: 530/387.100; 530/387.700; 530/388.100; 530/388.260; 530/388.800  
 IC [6] ICM: C12Q001-25  
 ICS: C07K016-40; C07K016-30  
 EXP 435/7.23; 435/7.1; 435/7.4; 530/387.1; 530/388.1; 530/387.7; 530/388.26;  
 530/388.8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 179 OF 239 USPATFULL  
 AN 96:3747 USPATFULL  
 TI Signal transduction inhibitor triazole and diazole compounds  
 IN Kohn, Elise C., Olney, MD, United States  
 Liotte, Lance A., Potomac, MD, United States  
 PA Felder, Christian C., Bethesda, MD, United States  
 The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5422954 19960109  
 AI Division of Ser. No. US 1992-985402, filed on 4 Dec 1992, now patented,  
 Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US  
 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132115 and  
 Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a  
 continuation of Ser. No. US 1991-337145, filed on 3 Jan 1991, now  
 abandoned And a continuation-in-part of Ser. No. US 1992-894891, filed  
 on 8 Jun 1992, now abandoned

DT Utility  
 FS Granted  
 LN CNT 1451 INCLM: 514/359.000  
 INCL INCLM: 514/359.000; 548/264.800; 548/265.400; 548/265.600; 548/326.500;  
 NCIM: 548/255.000; 548/335.100; 548/374.100; 514/383.000; 514/398.000; 514/407.000  
 NCIS: 514/383.000; 514/398.000; 514/407.000; 548/255.000; 548/264.800;  
 IC [6] ICM: A61K031-41  
 ICS: A61K031-415; C07D249-06

EXF 514/255; 514/256; 514/258; 514/261; 514/383; 514/359; 514/398; 514/407;  
 548/255; 548/264.8; 548/265.4; 548/265.6; 548/326.5; 548/335.1;  
 548/374.1

L9 ANSWER 180 OF 239 USPATFULL  
 AN 95:00595 USPATFULL  
 TI Maspin, a sarpin with tumor suppressing activity  
 Sager, Ruth, Brookline, MA, United States  
 Anisowicz, Anthony, West Newton, MA, United States  
 Zou, Zhiqiang, Gaithersburg, MD, United States  
 Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S.  
 corporation)  
 PI US 570970  
 AI US 1993-121714 19951128  
 RLI Continuation-in-part of Ser. No. US 1992-938823, filed on 1 Sep 1992,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1992-844296, filed on 28 Feb 1992, now abandoned which is a  
 continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991,  
 now abandoned

DT Utility  
 FS Granted  
 LN CNT 1403 INCL  
 INCLM: 536/023.500  
 INCL INCLM: 536/024.310; 435/320.100; 435/252.300; 435/240.100; 530/350.000;  
 NCIM: 530/828.000; 930/250.000; 930/010.000; 935/009.000  
 NCIS: 536/023.500  
 IC [6] ICM: C12N001-21  
 ICS: C12N005-10; C12N015-15; C07K014-47  
 EXP 435/6; 435/69.1; 435/69.2; 435/320.1; 536/23.1; 536/23.2;  
 530/828; 930/250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 181 OF 239 USPATFULL  
 AN 95:105868 USPATFULL  
 TI Cell signaling inhibitors  
 IN Michnick, John, Seattle, WA, United States  
 Underiner, Gail E., Brier, WA, United States  
 Klein, J. Peter, Vashon Island, WA, United States  
 Rice, Glenn C., Seattle, WA, United States  
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 470878  
 AI US 1993-164081 19951128  
 RLI US 1993-164081 19931208 (8)  
 Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,  
 now abandoned

DT Utility  
 FS Granted  
 LN CNT 2665 INCL  
 INCLM: 514/558.000  
 INCL INCLM: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;  
 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;  
 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000;  
 544/234.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;  
 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;  
 554/123.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000;  
 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000;  
 514/558.000  
 NCIM: 514/558.000  
 NCIS: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;  
 514/529.000; 514/552.000; 514/613.000; 514/617.000; 544/254.000;  
 514/626.000; 514/629.000; 514/639.000; 544/254.000; 544/285.000;  
 544/301.000; 546/183.000; 546/243.000; 554/108.000; 554/123.000;  
 560/130.000; 560/145.000; 562/553.000; 562/567.000; 564/201.000;  
 564/506.000

IC	[61] ICM: A61K031-20	EXF 564/154; 564/153; 564/80; 564/81; 564/85; 564/154; 514/618; 514/19;
	ICS: C07C231-00	548/485; 548/494; 548/495; 548/340.1
EXF	554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/106; 564/198;	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
	<sup>a</sup> 564/205; 564/201; 564/197; 514/425; 514/629; 514/613; 514/583; 514/552;	ANSWER 184 OF 239 USPATFULL
	514/589; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567;	95:8442 USPATFULL
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	Hydroxamic acid based collagenase inhibitors
L9	ANSWER 182 OF 239 USPATFULL	Campton, Colin, Oxon, England
AN	95:0824 USPATFULL	Davison, Alan H., Oxon, England
TI	Sulfonimine and sulfoximine matrix metalloproteinase inhibitors	Dickens, Jonathan P., Buckinghamshire, England
IN	Schwartz, Martin A., Tallahassee, FL, United States	Crimm, Michael J., Ascot, England
Van Wart, Harold, Los Altos, CA, United States	British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S.)	
PA	Florida State University, Tallahassee, FL, United States (U.S. corporation)	corporation)
PI	US 5670834	WO 9102716 19910307
AI	1993-132411	US 1992-020664
DT	Utility	WO 1990-GB8117 19900720
FS	Granted	19920116 PCR 371 date
LN CNT	4014	19920116 PCR 102(e) date
INC1	INC1M: 514/019,000	PRAI GB 1389-19251 19890824
INC3	INC3M: 514/998,200; 514/397,000; 514/400,000; 514/414,000; 514/415,000;	DT Utility
	514/562,000; 514/607,000; 514/824,000; 514/825,000; 514/843,000;	FS Granted
	514/912,000; 530/331,000; 548/312,100; 548/313,100; 548/313,700;	LN CNT 1170
NCL	NCLM: 514/019,000	INC1: 514/424,000
NC1	NC1M: 514/019,000	INC3: 514/343,000; 514/422,000; 514/269,000; 548/543,000; 548/527,000;
NC3	NC3M: 260/998,200; 514/397,000; 514/400,000; 514/414,000; 514/415,000;	NCL NC1M: 514/424,000
	514/562,000; 514/607,000; 514/824,000; 514/825,000; 514/843,000;	NC3: 514/265,000; 514/343,000; 514/422,000; 544/333,000; 546/278,400;
I1	[61] ICM: A61K038-05	IC [61] ICM: C07D07-27
EXF	ICS: A61K038-06; C07K005-062; C07K005-065; 514/824; 514/843; 514/912; 514/397; 514/400;	EXF ICS: C07D01-12; C07D0409-12; A61K031-505
	514/414; 514/415; 514/562; 530/331; 564/101; 260/998,2; 548/312,1;	AN 95:71386 USPATFULL
	548/313,1; 548/313,7; 548/336,1; 548/455; 548/503; 562/426; 562/427;	TI Method of treating certain tumors using iludin analogs
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	IN Morris, Trevor C., La Jolla, CA, United States
L9	ANSWER 183 OF 239 USPATFULL	IN Keiner, Michael J., La Jolla, CA, United States
AN	95:8877 USPATFULL	IN McMorris, Raymond, Tucson, AZ, United States
TI	Mercatosulfide metalloproteinase inhibitors	PA The Regents of the University of California, Oakland, CA, United States
IN	Schwartz, Martin A., Tallahassee, FL, United States	(U.S. corporation)
PA	Van Wart, Harold, Los Altos, CA, United States (U.S. corporation)	PI US 549936 AI US 1993-15179 19930808
PI	Florida State University, Tallahassee, FL, United States (U.S. corporation)	RLI Continuation-in-part of Ser. No. US 1990-06511, filed on 31 Oct 1990
AI	US 1993-132414	which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned
DT	Utility	DT Utility
FS	Granted	LN CNT 984
LN CNT	4063	INC1: 514/418,000
INC1	INC1M: 514/399,000	INC1: 514/546,000
INC3	INC3M: 514/616,000; 514/618,000; 548/340,100; 548/485,000; 548/494,000;	INC3: 514/678,000; 514/681,000; 514/691,000
	548/495,000; 564/080,000; 564/081,000; 564/085,000; 564/153,000;	NCL NC1M: 514/546,000
NCL	NCLM: 514/418,000	NC1: 514/678,000; 514/681,000; 514/691,000
NC1	NC1M: 514/399,000; 514/419,000; 514/601,000; 514/602,000; 514/604,000;	[61] ICM: A61K031-22
	514/616,000; 514/618,000; 548/340,100; 548/485,000; 548/494,000;	EXF ICS: A61K031-12
	548/495,000; 564/080,000; 564/081,000; 564/085,000; 564/153,000;	AN 95:8442 USPATFULL
I1	[61] ICM: A61K031-40	TI ANSWER 186 OF 239 USPATFULL
EXF	ICS: A61K031-165; C07D209-32; C07C233-05	IN ANSWER 186 OF 239 USPATFULL

TI	P2'-modified hydroxamic acid collagenase inhibitors
IN	Crimmin, M. J., Marlow Bottom, England
DAVIDSON, A. H., Witney, England	
PA	Beckett, R. P., Aston, England
PI	British Bio-Technology Limited, Oxford, England (non-U.S. corporation)
US 5412145	1990/05/02
AI	US 1993-172440
RLI	Division of Ser. No. US 1991-760741, filed on 16 Sep 1991, now patented, Pat. No. US 5300674, issued on 5 Apr 1991
PRAI	GB 1991-12635
DT	1991/02/07
FS	Utility
IN, CNT	Granted
1227	
INC1:	558/414.000
INC2:	558/019.000; 562/444.000
NCL	558/414.000
NC1S:	560/039.000; 562/444.000
IC	561
ICM:	C07C255-50
ICS:	CO7C259-06
EXF	558/414; 560/39; 562/444
EXF INDEXING IS AVAILABLE FOR THIS PATENT.	
L9	ANSWER 187 OF 239 USPATFULL
AN	95:38689 USPATFULL
TI	Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
IN	Laclaisas, Robert, Sancy, France
MCZAR, Elemer, Gif Sur Yvette, France	
Hornebeck, William Georges, Versailles, France	
Kerner, Christiane M., Vitry Sur Seine, France	
Chesterbrook-Ponds USA Co., Division of Conopco, Inc., Greenwich, CT, United States (U.S. corporation)	
PT	US 5411978
AI	1994/02/04
RLI	Division of Ser. No. US 1991-666093, filed on 7 Mar 1991, now patented, Pat. No. US 5338747
PRAI	FR 1990/2951
DT	1990/03/08
FS	Utility
IN, CNT	Granted
833	
INC1:	514/373.000
NC1S:	514/373.000
IC	[6]
ICM:	C07D275-06
EXF	514/373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
L9	ANSWER 188 OF 239 USPATFULL
AN	95:29749 USPATFULL
TI	Substituted cyclic derivatives as novel antidegenerative agents
IN	Hagmann, William, Westfield, NJ, United States
Caldwell, Charles G., Scotch Plains, NJ, United States	
Gooley, Paul R., Westfield, NJ, United States	
Merck & Co., Inc., Rahway, NJ, United States	
PT	US 5403952
AI	US 1993-133493
DT	1995/04/04
FS	Utility
IN, CNT	Granted
1679	
INC1:	510/085.000
INC2:	560/010.000; 560/015.000; 560/018.000; 560/024.000; 560/025.000; 560/026.000; 560/034.000; 560/051.000; 560/053.000; 560/054.000; 560/055.000; 560/056.000; 560/060.000; 560/076.000; 560/080.000; 560/095.000; 560/100.000; 562/433.000; 562/439.000; 562/449.000; 562/470.000; 562/473.000; 562/488.000; 562/490.000
NCL	560/100.000; 562/433.000; 562/439.000; 562/449.000; 562/461.000; 562/470.000; 562/473.000; 562/488.000; 562/490.000
NC1S:	560/085.000
NC2:	560/010.000; 560/015.000; 560/018.000; 560/024.000; 560/025.000; 560/026.000; 560/034.000; 560/051.000; 560/053.000; 560/054.000; 560/055.000; 560/056.000; 560/060.000; 560/076.000; 560/080.000; 560/095.000; 560/100.000; 562/433.000; 562/439.000; 562/449.000; 562/461.000; 562/470.000; 562/473.000; 562/488.000; 562/490.000
IC	561
ICM:	C07K007-100
EXF	560/15; 560/10; 560/15; 560/18; 560/24; 560/25; 560/26; 560/34; 560/51; 560/53; 560/54; 560/55; 560/56; 560/60; 560/76; 560/80; 560/100; 560/122; 562/433; 562/439; 562/461; 562/470; 562/473; 562/488; 562/490; 514/530; 514/562; 514/564; 514/565
IN	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L9	ANSWER 189 OF 239 USPATFULL
AN	95:16247 USPATFULL
TI	Method for inhibition of cell motility by sphingosine-1-phosphate, its derivatives and mimetics and method of synthesizing sphingosine-1-phosphate and its derivatives
IN	Igarashi, Yasuyuki, Seattle, WA, United States
Ruan, Fuqiang, Seattle, WA, United States	
Sadahira, Yoshito, Seattle, WA, United States	
Kawa, Shigeyuki, Seattle, WA, United States	
Harikoshi, Sennitiron, Seattle, WA, United States	
The Biomembrane Institute, Seattle, WA, United States (U.S. corporation)	
PA	US 531800
PI	AI 1993-104504
RLI	US 1993-104504
DT	1993/08/09 (8)
PT	Division of Ser. No. US 1992-863179, filed on 3 Apr 1992, now patented, Pat. No. US 5260288
FS	Utility
IN, CNT	Granted
970	
INC1:	558/145.000
INC2:	558/169.000; 558/170.000
NCL	558/145.000
NC1S:	558/169.000; 558/170.000
IC	[6]
ICM:	C07F009-113
EXF	558/101; 558/145; 558/169
EXF INDEXING IS AVAILABLE FOR THIS PATENT.	
L9	ANSWER 190 OF 239 USPATFULL
AN	95:11626 USPATFULL
TI	Peptide derivatives of collagenase inhibitor
IN	Gray, Robert D., Louisville, KY, United States
Spatola, Arno F., Louisville, KY, United States	
Darla, Keys of, Louisville, KY, United States	
Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)	
PA	US 5387610
PI	AI 1992-981149
RLI	US 1992-981149
DT	1993/02/07
Utility	Continuation of Ser. No. US 1991-715948, filed on 14 Jun 1991, now abandoned
FS	Utility
IN, CNT	Granted
1949	
INC1:	514/575.000
INC2:	514/518.000; 514/507.000; 530/323.000; 530/330.000; 530/331.000; 562/623.000
NCL	514/575.000
NC1S:	514/018.000; 514/507.000; 530/323.000; 530/330.000; 530/331.000; 562/623.000

IC [6] ICM: A61K037-02  
ICS: A61K031-195; C07C259-10  
EXF 530/323; 530/330; 530/331; 562/623; 514/575; 514/507; 514/18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 191 OF 239 USPATFULL  
AN 95-7873 USPATFULL  
TI Composition and method for enhancing wound healing  
IN Henkin, R. I., 6601 Broxburn Dr., Bethesda, MD, United States 20817  
PI US 5384308 1990124  
AI US 1993-76058 19930614 (8)  
DT Utility  
FS Granted  
LN CNT 656  
INCLM: 514/008.000  
INCLS: 514/007.000; 514/969.000; 424/550.000; 530/843.000  
NCIM: 424/550.000; 514/007.000; 514/969.000; 530/843.000  
IC ICM: A61K037-16  
ICS: A61K035-37  
EXF 514/21; 514/938; 514/969; 514/7; 514/8; 424/85.8; 424/550; 530/843  
AN ANSWER 192 OF 239 USPATFULL  
TI Structure, production and use of heregulin  
IN Vandlen, Richard L., Hillsborough, CA, United States  
Holmes, William E., Pacifica, CA, United States  
PA Genentech, Inc., So, San Francisco, CA, United States (U.S. corporation)  
PI US 5367060 19941122  
AI US 1992-847743  
RLI Continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned

DT Granted  
FS Granted  
LN CNT 3658  
INCLM: 530/399.000  
INCLS: 530/350.000  
NCIM: 530/399.000  
NCIS: 530/350.000  
IC [5] ICM: C07K013-00  
ICS: A61K037-36  
EXF 435/69.1; 530/350; 530/399; 530/389.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 193 OF 239 USPATFULL  
AN 94-102319 USPATFULL  
TI Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)  
IN Hession, Catherine A., South Weymouth, MA, United States  
Lobb, Roy R., Westwood, MA, United States  
Goetz, Susan E., Winchester, MA, United States  
Osborn, Laurelee, Brighton, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States  
Rosa, Margaret D., Winchester, MA, United States  
PRA Bigen, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 5367056 19941122  
AI US 1993-35674 19930323 (8)

RLL Division of Ser. No. US 1989-452675, filed on 18 Dec 1989, now patented, Pat. No. US 5272263 which is a continuation-in-part of Ser. No. US 1989-355516, filed on 1 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-345151, filed on 28 Apr 1989, now patented, Pat. No. US 5217870

DT Utility  
FS Granted  
LN CNT 2368  
INCLM: 530/380.000  
INCLS: 530/350.000  
NCIM: 530/380.000  
NCIS: 530/350.000  
IC [15] ICM: C07K013-00  
EXF 530/380; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 194 OF 239 USPATFULL  
AN 94-93457 USPATFULL  
TI Signal transduction inhibitor compounds  
IN Kohn, Elise C., Olney, MD, United States  
Lotta, Lance A., Potomac, MD, United States  
Felder, Christian C., Bethesda, MD, United States  
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
PI US 5359078 19941025  
RLI Continuation-in-part of Ser. No. US 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132315 And a continuation-in-part of Ser. No. US 1992-944005, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned which is a continuation-in-part of Ser. No. US 1992-894891, filed on 8 Jun 1992, now abandoned

DT Granted  
FS Granted  
LN CNT 1287  
INCLM: 548/255.000  
INCLS: 544/238.000; 544/242.000; 544/254.000; 544/264.000; 544/335.000; 548/262.200; 548/262.800; 548/264.800; 548/265.400; 548/265.600; 548/265.800; 548/266.800; 548/267.600  
NCIM: 548/255.000  
NCIS: 548/255.000; 544/242.000; 544/254.000; 544/264.000; 544/335.000; 548/262.200; 548/262.800; 548/264.800; 548/265.400; 548/265.600; 548/265.800; 548/266.800; 548/267.600  
IC [5] ICM: C07D249-05  
EXF 544/258; 544/264; 544/335; 544/336; 544/238; 544/242; 548/255; 548/263.2; 548/265.8; 548/265.8; 548/267.5; 548/267.8; 548/269.4; 548/337; 548/346; 548/262.8; 548/264.8; 548/266.8; 548/262.2; 548/265.6; 548/267.6  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 195 OF 239 USPATFULL  
AN 94-11030 USPATFULL  
TI Benzoisothiazolinone-1-dioxide derivatives as elastase inhibitors  
IN Robert, Ladislis, Sente, France  
Mozzar, Elmer, Gif sur Yvette, France  
Hornbeck, William G., Versailles, France  
Kerneur, Christiane M. P., Vitry sur Seine, France  
PRA Cheesborough-Pond USA Co., Division of Conopco, Inc., Greenwich, CT  
PI US 5338747 19940816  
AI US 1991-666093 19910307 (7)  
PRAI FR 1990-2951 19900308

DT	Utility	PA	Genentech, Inc., South San Francisco, CA, United States (U.S.)
FS		PI	corporation)
Granted		AI	US 5316921
		AI	1992-884811
LN CNT	797	DT	19920518 (7)
INCL		FS	Granted
INCIM:	514/373.000	LN CNT	1870
INCLIS:	548/210.000	INCL	
NCIM:	514/373.000	INCIM:	435/069.400
NCILS:	548/210.000	NCIM:	435/069.400
NCLS:	548/210.000	NCILS:	530/399.000; 536/023.510
IC		IC	[5]:
EXF	[5]: C07D75-06	ICM:	C12P021-06
ANSWER 196 OF 239 USPATFULL	ICN:	ICN:	A61K037-36
94-60089 USPATFULL	ICN:	EXF	530/399; 536/23.51; 435/69.1; 435/69.4
Hepatocyte growth factor protease domain variants	INCIM:	CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
Godowski, Paul J., Pacifica, CA, United States	INCIM: 435/069.400	LN CNT	2544
Lokker, Natalie A., San Francisco, CA, United States	INCIM: 514/373.000	INCL	
Mark, Melanie R., San Jose, CA, United States (U.S.)	INCIM: 548/210.000	INCL	
Genentech, Inc., South San Francisco, CA, United States (corporation)	INCIM: 548/210.000	INCL	
US 5328837	INCIM: 530/399.000; 536/023.510	INCL	
AT 1881	INCIM: 435/069.400	INCL	
DT Utility	INCIM: 530/399.000; 536/023.510	INCL	
FS Granted	INCIM: 435/069.400	INCL	
LN CNT 1881	INCIM: 530/399.000; 536/023.510	INCL	
ICM: C12P021-06	INCIM: 530/399.000; 536/023.510	INCL	
ICM: A61K037-36	INCIM: 530/399.000; 536/023.510	INCL	
EXF 530/399; 536/23.51; 435/69.1; 435/69.4	INCIM: 530/399.000; 536/023.510	INCL	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	INCIM: 530/399.000; 536/023.510	INCL	
L9 ANSWER 197 OF 239 USPATFULL	INCIM: 530/399.000; 536/023.510	INCL	
AN 94-47042 USPATFULL	INCIM: 530/399.000; 536/023.510	INCL	
Cysteine proteinase inhibitors and inhibitor precursors	INCIM: 530/399.000; 536/023.510	INCL	
IN Barrilett, Paul A., Kensington, CA, United States	INCIM: 530/399.000; 536/023.510	INCL	
PA Mader, Mary M., El Cerrito, CA, United States (U.S. corporation)	INCIM: 530/399.000; 536/023.510	INCL	
PI US 1992-848377	INCIM: 530/399.000; 536/023.510	INCL	
AI 19920309 (7)	INCIM: 530/399.000; 536/023.510	INCL	
DT Utility	INCIM: 530/399.000; 536/023.510	INCL	
FS Granted	INCIM: 530/399.000; 536/023.510	INCL	
LN CNT 555	INCIM: 530/327.000	INCL	
INCL INCIM: 530/327.000	INCIM: 530/327.000	INCL	
NCL NCIM: 530/327.000	INCIM: 530/327.000	INCL	
NCILS: 530/328.000; 530/329.000; 530/330.000; 530/331.000	INCIM: 530/327.000	INCL	
IC (5): ICM: C07K005-00	INCIM: 530/327.000	INCL	
ICM: C07K007-00; A61K037-00	INCIM: 530/327.000	INCL	
EXF 514/19; 514/18; 514/17; 514/16; 514/15; 514/14; 530/331; 530/330;	INCIM: 530/327.000	INCL	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	INCIM: 530/327.000	INCL	
L9 ANSWER 198 OF 239 USPATFULL	INCIM: 530/327.000	INCL	
AN 94-46878 USPATFULL	INCIM: 530/327.000	INCL	
Single-chain hepatocyte growth factor variants	INCIM: 530/327.000	INCL	
Godowski, Paul J., Pacifica, CA, United States	INCIM: 530/327.000	INCL	
Lokker, Natalie A., San Francisco, CA, United States	INCIM: 530/327.000	INCL	
Mark, Melanie R., San Jose, CA, United States	INCIM: 530/327.000	INCL	
DT Utility	INCIM: 530/327.000	INCL	
FS Granted	INCIM: 530/327.000	INCL	
LN CNT 1437	INCIM: 514/575.000	INCL	
INCL INCIM: 514/575.000	INCIM: 514/575.000	INCL	
INCI: C07K007-00; A61K037-00	INCIM: 514/575.000	INCL	
EXF 514/19; 514/18; 514/17; 514/16; 514/15; 514/14; 530/331; 530/330;	INCIM: 514/575.000	INCL	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	INCIM: 514/575.000	INCL	
L9 ANSWER 199 OF 239 USPATFULL	INCIM: 514/575.000	INCL	
AN 94-44735 USPATFULL	INCIM: 514/575.000	INCL	
Inhibitor of tissue-type and urokinase-type plasminogen activators	INCIM: 514/575.000	INCL	
PA Sjogren, Michael, La Jolla, CA, United States	INCIM: 514/575.000	INCL	
PI ICM: C12P021-06	INCIM: 514/575.000	INCL	
AI 5314934	INCIM: 514/575.000	INCL	
RLI US 1992-877211	INCIM: 514/575.000	INCL	
Continuation of Ser. No. US 1990-57385, filed on 27 Aug 1990, now abandoned which is a division of Ser. No. US 1986-887990, filed on 19 Aug 1986, now patented, Pat. No. US 4952512 which is a continuation-in-part of Ser. No. US 1984-623357, filed on 22 Jun 1984, now patented, Pat. No. US 4791068	INCIM: 514/575.000	INCL	
DT Utility	INCIM: 514/575.000	INCL	
FS Granted	INCIM: 514/575.000	INCL	
LN CNT 2544	INCIM: 514/575.000	INCL	
INCL INCIM: 530/350.000	INCIM: 530/350.000	INCL	
NCL NCIM: 530/350.000	INCIM: 530/350.000	INCL	
NCILS: 530/395.000	INCIM: 530/350.000	INCL	
IC (5): ICM: C07K013-00	INCIM: 530/350.000	INCL	
EXF 435/69.2; 530/350; 530/395; 930/250	INCIM: 530/350.000	INCL	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	INCIM: 530/350.000	INCL	
L9 ANSWER 200 OF 239 USPATFULL	INCIM: 530/350.000	INCL	
AN 94-40082 USPATFULL	INCIM: 530/350.000	INCL	
TI Hydroxamic acid based collagenase inhibitors	INCIM: 530/350.000	INCL	
Davison, Alan H., Oxon, England	INCIM: 530/350.000	INCL	
Dickens, Jonathan P., Buckinghamshire, England	INCIM: 530/350.000	INCL	
PA Crimmin, Michael J., Ascot, England	INCIM: 530/350.000	INCL	
British Biotechnology Limited, Oxford, England (non-U.S. corporation)	INCIM: 530/350.000	INCL	
PI US 5310763	INCIM: 530/350.000	INCL	
AI 1993-4413	INCIM: 530/350.000	INCL	
RLI US 1993-689848, filed on 8 Jul 1991, now patented, Pat. No. US 5249058	INCIM: 530/350.000	INCL	
PAI GB 1988-27305	INCIM: 530/350.000	INCL	
DT Utility	INCIM: 530/350.000	INCL	
FS Granted	INCIM: 530/350.000	INCL	
LN CNT 1437	INCIM: 514/575.000	INCL	
INCL INCIM: 514/575.000	INCIM: 514/575.000	INCL	
INCI: C07K007-00; A61K037-00	INCIM: 514/575.000	INCL	
EXF 514/19; 514/18; 514/17; 514/16; 514/15; 514/14; 530/331; 530/330;	INCIM: 514/575.000	INCL	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	INCIM: 514/575.000	INCL	
L9 ANSWER 198 OF 239 USPATFULL	INCIM: 514/575.000	INCL	
AN 94-46878 USPATFULL	INCIM: 514/575.000	INCL	
Single-chain hepatocyte growth factor variants	INCIM: 514/575.000	INCL	
Godowski, Paul J., Pacifica, CA, United States	INCIM: 514/575.000	INCL	
Lokker, Natalie A., San Francisco, CA, United States	INCIM: 514/575.000	INCL	
Mark, Melanie R., San Jose, CA, United States	INCIM: 514/575.000	INCL	

IC [5] ICM: A61K031-19  
ICS: A61K031-16; C07C327-04  
EXF 514/575; 514/616; 538/230; 552/621; 562/623  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 201 OF 239 USPATFULL

IN DNA sequences encoding vascular cell adhesion molecules (VCAMS)  
Hession, Catherine A., South Weymouth, MA, United States  
Lobb, Roy R., Westwood, MA, United States  
Goelz, Susan E., Winchester, MA, United States  
Osborn, Laureleen, Brighton, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States  
Rosa, Margaret D., Winchester, MA, United States  
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
US 5272263

PA AI US 1989-52675 19891218 (7)  
Continuation-in-Part of Ser. No. US 1989-359516, filed on 1 Jun 1989,  
now abandoned which is a continuation-in-part of Ser. No. US 1989-345151, filed on 28 Apr 1989

DT Utility FS Granted  
LN CNT 2440  
INCL INCLM: 536/023. 500  
INCLS: 530/380. 000; 435/069. 600; 435/320. 100  
NCL NCIM: 536/023. 500  
NCIS: 435/069. 600; 435/320. 100; 530/380. 000

IC [5] ICM: C07K013-00  
ICS: C12N015-00; C12R021-06  
EXF 435/69. 1; 435/69. 9; 435/320. 1; 530/380; 536/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 202 OF 239 USPATFULL  
93/96120 USPATFULL  
IN Glycosaminoglycan derivatives and their use as inhibitors of tumor  
invasiveness of metastatic profusion-III  
Nicolson, Garth L., Kingwood, TX, United States  
Irimura, Tatsuro, Tokyo, Japan  
Nakajima, Motoo, Kamagaya, Japan  
PA States (U.S. corporation)  
US 5262403 19931116

PI AI US 1989-526827 19900710 (7)  
RLI Continuation-in-part of Ser. No. US 1989-342627, filed on 8 Apr 1989,  
now abandoned which is a continuation of Ser. No. US 1986-899511, filed  
on 21 Aug 1986, now abandoned and a continuation-in-part of Ser. No. US  
1986-339890, filed on 7 Mar 1986, now abandoned

DT Utility FS Granted  
LN CNT 1188  
INCL INCLM: 514/056. 000  
INCLS: 514/054. 000; 536/021. 000  
NCL NCIM: 514/056. 000  
NCIS: 514/054. 000; 536/021. 000

IC [5] ICM: A61K031-25  
ICS: C08B037-10  
EXF 514/45; 514/56; 536/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 203 OF 239 USPATFULL  
93/93778 USPATFULL

TI phosphate and derivatives  
Ingarashi, Yasuyuki, Seattle, WA, United States  
Ruan, Fupjiang, Seattle, WA, United States  
Sadairia, Yoshito, Seattle, WA, United States  
Kawa, Shigeyuki, Seattle, WA, United States  
Hakomori, Sen-itiroh, Seattle, WA, United States  
The Biomembrane Institute, Seattle, WA, United States (U.S. corporation)

PA PI AI US 1992-863179 19920403 (7)  
Utility FS Granted  
LN CNT 889  
INCL INCLM: 514/114. 000  
INCLS: 514/119. 000  
NCL NCIM: 514/114. 000  
NCIS: 514/119. 000

IC [5] ICM: A61K031-66  
EXF 514/114; 514/119  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 204 OF 239 USPATFULL  
93/67545 USPATFULL  
TI Analytical markers for malignant breast cancer  
IN Basset, Paul, Strasbourg, France  
Bellocq, Jean-Pierre, Strasbourg, France  
Chambon, Pierre, Blaesheim, France  
Institut National de la Sante et de la Recherche Medicale, France  
(non-U.S. government)  
Centre National de Recherche Scientifique, France (non-U.S. government)  
Universite Louis Pasteur Strasbourg, France (non-U.S. corporation)

PA PI AI US 1991-794393 19930817  
US 23684  
PRAI GB 1990-22326 19901121 (7)  
DT Utility FS Granted  
LN CNT 1495  
INCL INCLM: 435/320. 100  
INCLS: 536/023. 500  
NCL NCIM: 435/320. 100  
NCIS: 536/023. 500

IC [5] ICM: C12N015-70  
ICS: C07H021-04  
EXF 435/6; 435/320. 1; 536/27; 536/23. 5; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 205 OF 239 USPATFULL  
93/18572 USPATFULL  
TI Method of ophthalmic testing  
IN Salonen, Eva-Marjatta, Espoo, Finland  
PA LabSystems, OY, Helsinki, Finland (non-U.S. corporation)  
PI US 5192665 19930309  
AI US 1989-336249 19890411 (7)  
RLI Division of Ser. No. US 1986-838339, filed on 11 Mar 1986, now patented,  
Pat. No. US 4849406  
DT Utility FS Granted  
LN CNT 663  
INCL INCLM: 435/018. 000  
INCLS: 422/000. 000; 435/023. 000  
NCL NCIM: 435/018. 000  
NCIS: 435/023. 000

IC [5] ICM: C12Q001-34  
EXF 435/18; 435/23; 424/9  
ANSWER 206 OF 239 USPATFULL  
L9 93/5469 USPATFULL  
AN Adhesion receptor for laminin and its use  
TI <sup>1</sup>Rusolani, Erkki I., Rancho Santa Fe, CA, United States  
Engsahl, Eva, Rancho Santa Fe, CA, United States  
Gehlsen, Kurt R., San Diego, CA, United States  
La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S.  
corporation)  
PI US 5180809  
AI US 1989-35754  
RLI Continuation-in-Part of Ser. No. US 1988-196986, filed on 20 May 1988,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 849  
INCL INCLM: 530/350.000; 530/355.000; 530/413.000; 530/810.000; 530/388.220; 530/389.100;  
INCIS: 424/450.000  
NCL NCIM: 530/350.000  
NCLS: 424/450.000; 530/388.220; 530/389.100; 530/395.000; 530/413.000;  
IC [5] ICM: C07K015-06  
ICCS: C07K003-20; C07K017-02  
EXF 436/501; 436/503; 436/518; 436/534; 436/547; 436/548; 436/829; 435/7-21;  
435/7-23; 424/450; 530/350; 530/387; 530/395; 530/413; 530/810;  
514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 207 OF 239 USPATFULL  
AN 92/76614 USPATFULL  
TI Inhibition of tumor growth by blockade of the protein C system  
IN Esmon, Charles T., Oklahoma City, OK, United States  
PA Comp', Philip C., Oklahoma City, OK, United States  
Oklahoma Medical Research Foundation, Oklahoma City, OK, United States  
(U.S. corporation)  
PI US 517638  
AI US 1989-39617  
RLI Continuation-in-Part of Ser. No. US 1988-292447, filed on 30 Dec 1988,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1023  
INCL INCLM: 424/085.800  
INCIS: 424/085.100; 424/085.200; 424/085.400; 424/085.500; 435/212.000;  
514/002.000; 514/008.000; 514/012.000; 530/351.000; 530/381.000;  
530/388.250; 530/389.300  
NCL NCIM: 424/085.100  
NCIS: 424/085.200; 424/085.400; 424/085.500; 424/152.100; 424/172.100;  
424/282.100; 435/212.000; 514/002.000; 514/008.000; 514/012.000;  
530/351.000; 530/381.000; 530/388.250; 530/389.300  
IC [5] ICM: A61K037-00  
ISS: A61K037-66; A61K039-00  
EXF 424/85.2; 424/85.5; 424/85.8; 514/2; 514/12; 530/387  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 208 OF 239 USPATFULL  
AN 92/66111 USPATFULL

TI Cyclopeptide derivatives usable as selective inhibitors with respect to  
proteases with active serine  
IN Wakeman, Michel, Paris, France  
Mazzleyeau, Jean-Paul, Choisy-le-Roi, France  
Reboud-Bavaux, Michele, Paris, France  
Centre National de la Recherche Scientifique, Paris, France (non-U.S.  
corporation)  
PA US 1990-47820  
PI FR 1988-11520  
AI US 1990-035  
RLI 19920811  
DT Utility  
FS Granted  
LN.CNT 1074  
INCL INCLM: 530/317.000  
NCL NCIM: 530/317.000  
IC [5] ICM: C07K005-12  
ICCS: A61K037-00  
EXF 530/317; 514/9  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 209 OF 239 USPATFULL  
AN 92/59884 USPATFULL  
TI Therapeutic application of an anti-invasive compound  
IN Kohn, Elise C., Olney, MD, United States  
Liotta, Lance A., Potomac, MD, United States  
PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5132315  
AI US 1989-355744  
RLI 19920721  
DT Utility  
FS Granted  
LN.CNT 460  
INCL INCLM: 514/359.000  
INCIS: 514/650.000; 514/648.000; 514/650.000; 548/257.000  
NCL NCIM: 514/359.000  
NCLS: 514/648.000; 514/650.000; 548/257.000  
IC [5] ICM: A61K031-41  
EXF 514/243; 514/863; 514/648; 514/359; 514/650; 548/257  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 210 OF 239 USPATFULL  
AN 92/59483 USPATFULL  
TI Method of treating a synthetic naturally occurring surface  
with a collagen laminate to support microvascular endothelial cell  
growth, and the surface itself  
IN Williams, Stuart K., Wilmington, DE, United States  
Jarrell, Bruce E., Philadelphia, PA, United States  
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S.  
corporation)  
PI US 5131907  
RLI 19920721  
AI US 1991-66475  
RLI 19910306 (7)  
TI Continuation of Ser. No. US 1986-818453, filed on 4 Apr 1986, now  
abandoned which is a continuation-in-part of Ser. No. US 1985-742086,  
filed on 6 Jun 1985, now patented, Pat. No. US 4820626  
DT Utility  
FS Granted  
LN.CNT 1848  
INCL INCLM: 600/036.000  
INCIS: 623/001.000; 427/040.000; 427/041.000; 424/093.000; 435/001.000;  
435/240.241  
NCL NCIM: 600/036.000  
NCLS: 424/093.700; 427/534.000; 427/538.000; 435/001.100; 435/375.000;

IC 435/399.000; 623/921.000

[5] ICM: A61F002-04

ICCS: A61F002-02; B050003-06; C12N005-06

EXF: 435/240-241; 623/1; 424/93; 427/40; 427/41; 620/36

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 211 OF 239 USPATFULL

92:38510 USPATFULL

Method of stabilizing plasminogen activator inhibitor by treatment with vitronectin

Wun, Tze-Chen, St. Louis, MO, United States

PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)

PI US 5112955 19920512

AI US 1991-181304 1990408 (7)

Division of Ser. No. US 1990-532410, filed on 4 Jun 1990, now patented, Pat. No. US 5073626 which is a continuation-in-part of Ser. No. US 1988-268916, filed on 9 Nov 1988, now abandoned

DT Utility

FS Granted

LN.CNT 714

INCL INCIM: 530/409.000

INCIS: 530/350.000; 530/402.000; 530/395.000

NCL NCIM: 530/409.000

NCIS: 530/350.000; 530/395.000; 530/402.000

IC [5] ICM: A61K037-64

ICCS: C07K03-04

EXF 530/402; 530/409; 530/350; 530/395; 514/2; 514/13; 514/21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 212 OF 239 USPATFULL

92:38661 USPATFULL

Pharmaceutical preparation for promoting epithelial healing and prevention of epithelial destruction

Salonen, Beva-Mariatta, Espoo, Finland

PA Labsystems, Oy, Helsinki, Finland (non-U.S. corporation)

PI US 5122805 19920312

AI US 1989-336231 19890411 (7)

Continuation of Ser. No. US 1986-338339, filed on 11 Mar 1986, now patented, Pat. No. US 4849406

DT Utility

FS Granted

LN.CNT 655

INCL INCIM: 514/008.000

INCIS: 514/012.000; 514/802.000

NCL NCIM: 514/008.000

NCIS: 514/012.000; 514/802.000

IC [5] ICM: A61K037-02

ICCS: A61K037-64

EXF 424/101; 424/530; 514/802; 514/12; 514/8; 514/912

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 213 OF 239 USPATFULL

AN 911-102392 USPATFULL

TI Affinity purification of plasminogen activator inhibitor I using a modified urokinase

IN Wun, Tze-Chen, St. Louis, MO, United States (U.S. corporation)

PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)

PI US 5073626 19911217

AI US 1990-533410 19900604 (7)

Continuation-in-part of Ser. No. US 1988-268916, filed on 9 Nov 1988, now abandoned

DT Utility

FS Granted

LN.CNT 748

INCL INCIM: 530/350.000

INCIS: 530/413.000; 435/069.200; 435/212.000; 435/215.000

NCL NCIM: 530/350.000

NCIS: 435/069.200; 435/212.000; 435/215.000; 530/413.000

IC [5] ICM: C07K003-18

ICCS: C07K03-06

EXF 530/412; 530/413; 530/350; 435/69.2; 435/212; 435/215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 214 OF 239 USPATFULL

91:162238 USPATFULL

Bioactive metabolites from cribrochalinia vasculum

TI Gunakakera, Sarath P., Vero Beach, FL, United States

PA Faircloth, Glynn T., Ft. Pierce, FL, United States

PI Wright, Amy E., Ft. Pierce, FL, United States

AI US 1980-481475 19900216 (7)

DT Utility

FS Granted

LN.CNT 501

INCL INCIM: 514/739.000

INCIS: 514/544.000; 514/546.000; 514/552.000; 560/113.000; 560/261.000

NCL NCIM: 514/739.000

NCIS: 514/544.000; 514/546.000; 514/552.000; 560/113.000; 560/261.000

IC [5] ICM: C07C033-02

ICCS: C07C033-03; A61K031-045; A61K031-22

EXF 568/873; 560/113; 560/261; 514/739; 514/544; 514/546; 514/552

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 215 OF 239 USPATFULL

AN 911-02160 USPATFULL

TI Synergistic composition for endothelial cell growth

IN Chen, Chung-Ho, Phoenix, MD, United States

PA Chen, Sumi C., Phoenix, MD, United States

The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)

PI US 5073492 19911217

AI US 1987-1844 19870109 (7)

DT Utility

FS Granted

LN.CNT 624

INCL INCIM: 435/240.200

INCIS: 435/240.300; 435/240.310; 435/240.230

NCL NCIM: 435/384.000

NCIS: 435/392.000; 435/405.000

IC [5] ICM: C12N005-00

EXF 435/240.1; 435/240.2; 435/240.3; 435/240.21; 435/240.23; 435/240.31; 530/849; 424/95; 424/531; 424/71; 514/2; 514/21; 514/42; 514/43

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 216 OF 239 USPATFULL

AN 911-73352 USPATFULL

TI : Tripeptide compounds having a nitrogenous polycyclic structure  
 IN : Vincent, Michel, Bagneux, France  
 Remond, Georges, Versailles, France  
 Portevin, Bernard, Eancourt, France  
 Cuendeuc, Claude, La Celle St-Cloud, France  
 Adir et Cie, Neuilly-sur-Seine, France (non-U.S. corporation)  
 PA : US 1987-20710 1990/0910 1989/0616 (7)  
 PI : US 5047400  
 AI : PRAT FR 1987-8350 1987/0616  
 DT : Utility  
 FS : Granted  
 IN,CNT : INC4 773  
 INCLM : INCL: 514/018.000  
 INCL : 514/018.000; 546/146.000; 546/147.000; 546/164.000; 546/165.000;  
 NCL : NCIM: 514/018.000  
 NCL : 546/169.000; 546/175.000; 548/472.000; 548/515.000  
 IC : [5] ICM: A61K031-40  
 ICS: C07D21-02; C07D217-00; C07D209-46  
 EXF : EXF: 546/46; 546/147; 546/112; 546/164; 546/165; 546/169; 546/175; 548/472;  
 548/515; 514/18  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 217 OF 239 USPATFULL  
 AN 91:13045 USPATFULL  
 TT DNA encoding 92-kDa type IV collagenase  
 TI Goldberg, Gregory I., St. Louis, MO, United States  
 Eissen, Arthur Z., St. Louis, MO, United States  
 PA Washington University, St. Louis, MO, United States (U.S. corporation)  
 PI US 4922537 1990/012 1989/0515 (7)  
 AI US 1989-352078  
 DT Utility  
 FS Granted  
 IN,CNT : INC4 562  
 INCLM : INCL: 536/027.000  
 INCL : 435/069.100; 435/172.300; 530/219.000; 530/226.000  
 NCL : NCIM: 536/028.200  
 NCL : 435/069.100; 530/219.000; 530/226.000  
 IC : [5] ICM: C12N015-00  
 EXF EXF: 536/27; 435/69.1; 435/172.3; 530/219; 530/226  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 218 OF 239 USPATFULL  
 AN 90:81777 USPATFULL  
 TT Peptide compounds having a nitrogenous polycyclic structure  
 IN Vincent, Michel, Bagneux, France  
 Remond, Georges, Versailles, France  
 Cuendeuc, Claude, La Celle St-Cloud, France  
 Adir et Cie, Neuilly-sur-Seine, France (non-U.S. corporation)  
 PA : US 4962520 1990/0123 1988/14027 (7)  
 AI : US 4962520  
 PRAT FR 1987-1810 1987/0213  
 DT Utility  
 FS Granted  
 IN,CNT : INC4 692  
 INCLM : INCL: 514/018.000  
 INCL : 514/018.000; 530/330.000  
 NCL : NCIM: 514/018.000  
 NCL : 514/885.000; 530/330.000  
 IC : [5] ICM: A61K037-02

EXF ICS: C07K005-10  
 IN 530/130; 514/18; 514/885  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 219 OF 239 USPATFULL  
 AN 90:7993 USPATFULL  
 TI Boron analogs of amino acid/peptide protease inhibitors  
 Kinder, David H., Rochester, MN, United States  
 Ames, Matthew M., Rochester, MN, United States  
 Mayo Foundation for Medical Education and Research, Rochester, MN  
 PA : US 4963655 1990/0116 1988/0527 (7)  
 AI : US 1988-199891  
 DT Utility  
 FS Granted  
 IN,CNT : INC4 376  
 INCLM : INCL: 530/331.000  
 INCL : 548/110.000; 549/213.000; 560/029.000; 564/008.000  
 NCL : NCIM: 530/331.000  
 NCL : 548/110.000; 549/213.000; 560/029.000; 564/008.000  
 IC : [5] ICM: C07K005-08  
 EXF EXF: 514/64; 514/18; 514/19; 530/331; 548/110; 549/213; 560/29; 564/8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 220 OF 239 USPATFULL  
 AN 90:67565 USPATFULL  
 TT Gene encoding an inhibitor of tissue-type and urokinase-type plasminogen  
 activators  
 Loskutoff, David J., 426 Glencrest Dr., Solana Beach, CA, United States  
 IN 92075  
 NY, Tor, Lodjinsvagen 11, Umea, Sweden  
 Swedey, Michael, 9232 (C) Regents Rd., La Jolla, CA, United States  
 92037  
 PI : US 4932512 1990/0228  
 AI : US 1986-89990 1986/0819 (6)  
 RLI Continuation-in-part of Ser. No. US 1984-623357, filed on 22 Jun 1984,  
 now patented, Pat. No. US 4791068  
 DT Utility  
 FS Granted  
 IN,CNT : INC4 2547  
 INCLM : INCL: 435/320.000  
 INCL : 435/091.100; 435/172.300; 435/069.200; 435/212.000; 435/219.000;  
 NCL : NCIM: 435/320.100  
 NCL : 435/069.200; 435/212.000; 435/219.000; 536/023.200; 536/023.500;  
 NCL : 435/024.310  
 IC : [5] ICM: C12N015-12  
 ICS: C12N015-58  
 EXF EXF: 435/91; 435/172.3; 435/68; 435/253; 435/240.2; 435/320; 435/219;  
 435/212; 435/91.1; 935/11; 935/29; 935/73; 935/9; 935/60; 536/27  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 221 OF 239 USPATFULL  
 AN 90:54619 USPATFULL  
 TI Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat  
 arthritis  
 IN Tidwell, Richard R., Chapel Hill, NC, United States  
 Geratz, Joachim D., Chapel Hill, NC, United States  
 Schwab, John H., Chapel Hill, NC, United States  
 Prywansky, Katherine B., Chapel Hill, NC, United States  
 Anderele, Sonia K., Chapel Hill, NC, United States  
 PA University of North Carolina, Chapel Hill, Chapel Hill, NC, United

States (U.S. corporation) 19900710  
 PI: US 49410723 19900710 (7)  
 AI: US 1988-260056 19881020 (7)  
 DT: Utility Granted  
 FS:   
 LN-CNT: 489  
 INC: INCL: 514/396.000  
 NC: NCIS: 514/401.000  
 NCIS: 514/396.000  
 NCIS: 514/401.000  
 ICM: A61K031-415  
 EXE: 514/401; 514/396  
 CAS: INDEXING IS AVAILABLE FOR THIS PATENT.

L9  
 ANSWER 222 OF 239 USPATFULL  
 AN  
 TI  
 Protease inhibitors  
 IN  
 Bachorcin, William W., Melrose, MA, United States  
 Plaut, Andrew G., Lexington, MA, United States  
 PA  
 Kettner, Charles A., Wilmington, DE, United States  
 E. I. Du Pont de Nemours and Company, Wilmington, DE, United States  
 (U.S. corporation)  
 New England Medical Center Hospitals, Inc., Boston, MA, United States  
 (U.S. corporation)  
 Tufts University, Medford, MA, United States (U.S. corporation)  
 US 4935493  
 US 1987-105768  
 DT Utility  
 FS Granted  
 LN-CNT 524  
 INCL INCLM: 530/331.000  
 INCL: 530/330.000  
 NCIS: NCIM: 530/331.000  
 NCIS: 530/330.000  
 ICM: A61K037-02  
 ICS: C07K005-08; C07K005-10  
 EXF 514/19; 514/19; 530/330; 530/331  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9  
 ANSWER 223 OF 239 USPATFULL  
 AN  
 TI  
 Cancer therapy system for effecting oncolysis of malignant neoplasms  
 Cone, Jr., Clarence D., Yorktown, VA, United States  
 PA Therapeutic Systems Corporation, Yorktown, VA, United States (U.S. corporation)  
 US 4935450  
 US 1988-234036 19880822 (7)  
 RLI Continuation-in-part of Ser. No. US 1987-130563, filed on 8 Dec 1987, now abandoned And Ser. No. US 1987-130280, filed on 8 Dec 1987, now abandoned which is a continuation of Ser. No. US 1985-92257, filed on 28 Oct 1985, now patented, Pat. No. US 4721234, issued on 9 Feb 1988 which is a continuation of Ser. No. US 1982-41324, filed on 17 Sep 1982, now abandoned, said Ser. No. 130563 which is a continuation of Ser. No. US 1984-634267, filed on 25 Jul 1984, now patented, Pat. No. US 4724230, issued on 9 Feb 1988 which is a continuation-in-part of Ser. No. 419324  
 DT Utility  
 FS Granted  
 LN-CNT 4266  
 INCL INCLM: 514/728.000  
 INCL: 514/558.000; 514/561.000  
 NCIS: 514/728.000

LC  
 NCIS: 514/558.000; 514/561.000  
 [5] ICM: A61K031-045  
 ICS: A61K031-20; A61K031-195  
 EXF 514/728; 514/558; 514/561  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9  
 ANSWER 224 OF 239 USPATFULL  
 AN  
 TI  
 Immobilized fluorogenic substrates for enzymes; and processes for their preparation  
 Brynes, Paul J., Libertyville, IL, United States  
 Andrade-Gordon, Patricia, Port Jefferson, NY, United States  
 PA The Research Foundation of the State University of New York, Albany, NY, United States (U.S. corporation)  
 PI US 4937444  
 AI US 1985-740706 19850803 (6)  
 RLI Continuation-in-part of Ser. No. US 1985-739746, filed on 31 May 1985, now abandoned  
 DR Utility  
 FS Granted  
 LN-CNT 1569  
 INCL INCLM: 525/054.100  
 INCL: 435/022.000; 435/024.000; 530/330.000; 530/331.000; 530/330.000  
 NCIS: 525/054.100  
 NCIS: 435/023.000; 435/024.000; 530/330.000; 530/331.000  
 ICM: [4] C08L089-00  
 EXF 530/380; 530/330; 530/331; 525/54.1; 435/23; 435/24  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9  
 ANSWER 225 OF 239 USPATFULL  
 AN  
 TI  
 Device and method for separating leucocytes from platelet concentrate  
 IN  
 Pall, David B., Roslyn Estates, NY, United States  
 PA Pall Corporation, Glen Cove, NY, United States (U.S. corporation)  
 PI US 480548  
 AI US 1988-183993 19880425 (7)  
 RLI Continuation-in-part of Ser. No. US 1988-156894, filed on 17 Feb 1988, now abandoned  
 DT Utility  
 FS Granted  
 LN-CNT 2857  
 INCL INCLM: 210/767.000  
 INCL: 210/435.000; 210/504.000; 210/508.000  
 NCIS: 210/435.000; 210/504.000; 210/508.000  
 ICM: [4] B01D039-04  
 EXF 210/651; 210/767; 210/435; 210/446; 210/506; 210/507; 210/508; 210/503; 210/504; 210/505; 210/648  
 L9  
 ANSWER 226 OF 239 USPATFULL  
 AN  
 TI  
 Method of isolating tumor-secreted products using a novel protein-free medium  
 IN  
 Alderman, Edward M., Dedham, MA, United States  
 Fetter, James W., Waltham, MA, United States  
 Valley, Bert L., Brookline, MA, United States  
 PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)  
 PI US 4879222 19891107

AI US 1986-901101 19860828 (6)  
DT Granted  
LN CNT 619  
INCL INCLM: 435/068.000  
INCIS: 435/20.200; 435/240.310  
NCL NCIM: 435/068.100  
IC ICM: C12R021-00  
EXF ICS: C12R005-00  
435/240.31; 435/8; 435/240.31  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 227 OF 239 USPATFULL  
AN 89:69/09 USPATFULL  
DT Affinity column and process for detection of low molecular weight toxic  
FS substances  
IN Groopman, John D., Lynnfield, MA, United States  
Mogan, Gerald N., Belmont, MA, United States  
Bergot, Frederick G., Wellesley, MA, United States  
Ferrari, Christopher, Marlborough, MA, United States  
PA Massachusetts Institute of Technology, Cambridge, MA, United States  
(U.S. corporation)  
Boston University, Boston, MA, United States (U.S. corporation)

PI US 4818687 19850404 (2)  
AI US 4818687 19850404 (2)  
RLI US 4818687 19850228 (2)

DT Utility  
FS Granted  
LN CNT 633  
INCL INCLM: 436/518.000  
INCIS: 436/520.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;  
NCL 436/525.000  
NCIS: 436/513.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000  
IC ICM: G01N033-543  
ISS: G01N033-577  
EXF 436/518; 436/529; 436/815; 436/824;  
NCIS: 436/513.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000  
ICL ICM: G01N033-543  
ISS: G01N033-577  
EXF 436/825; 436/172; 436/548; 530/413  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 228 OF 239 USPATFULL  
AN 89:58/116 USPATFULL  
DT Method for promoting epithelial healing and prevention of  
epithelial destruction  
IN Salonen, Eva-Mariatta, Espoo, Finland  
PA Labsystems Oy, Helsinki, Finland (non-U.S. corporation)  
PI US 4849406 19860718 (6)  
AI US 1986-83339 19860311 (6)  
PAI FI 1985-4634 19851122  
DT Utility  
FS Granted  
LN CNT 661  
INCL INCLM: 514/008.000  
INCIS: 514/012.000; 514/802.000; 424/101.000  
NCL NCIM: 514/008.000; 514/802.000  
IC ICM: 514/012.000; 514/802.000  
EXF ICM: A61K037-02  
424/101; 514/802; 514/12; 514/8  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 229 OF 239 USPATFULL  
DT Affinity column and process for detection of low molecular weight toxic  
FS substances  
IN Groopman, John D., Essex, County, MA, United States  
Mogan, Gerald N., Middlesex County, MA, United States  
Massachusetts Institute of Technology, Cambridge, MA, United States  
(U.S. corporation)  
Boston University, Boston, MA, United States (U.S. corporation)

PI US 4818687 19850404 (2)  
AI US 4818687 19850404 (2)  
RLI US 4818687 19850228 (2)

DT Utility  
FS Granted  
LN CNT 633  
INCL INCLM: 436/518.000  
INCIS: 436/520.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;  
NCL 436/525.000  
NCIS: 436/513.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;  
IC ICM: G01N033-543  
ISS: G01N033-577  
EXF 436/518; 436/529; 436/815; 436/824;  
NCIS: 436/513.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000  
ICL ICM: G01N033-543  
ISS: G01N033-577  
EXF 436/825; 436/172; 436/548; 530/413  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 230 OF 239 USPATFULL  
AN 89:73/737 USPATFULL  
DT Serine protease inhibitors and methods for isolation of same  
IN Thompson, Robert C., Boulder, CO, United States  
Ohlsson, Kjell, Glemmingebo, Sweden  
Synercon Biologicals, Inc., Boulder, CO, United States (U.S.  
corporation)

PI US 4760130 19880726  
AI US 4760130 19880726  
RLI Continuation-in-part of Ser. No. US 1984-678823, filed on 6 Dec 1984,  
now abandoned  
DT Utility  
FS Granted  
LN CNT 805  
INCL INCLM: 530/350.000  
INCIS: 530/350.000  
NCIS: 930/010.000; 930/250.000; 930/DIG.821  
IC ICM: C07K013-00  
EXF 530/334; 530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 231 OF 239 USPATFULL  
AN 88-29409 USPATFULL  
DT Hydroxamic acid based collagenase inhibitors  
IN Dickens, Jonathan P., High Wycombe, England  
Donald, David K., High Wycombe, England  
Kneen, Geoffrey, West Wycombe, England  
McKay, William R., High Wycombe, England  
G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

PI US 4743587 19860510  
AI US 1986-880130 19860707 (6)  
RLI Continuation-in-part of Ser. No. US 1985-774491, filed on 10 Sep 1985,  
now patented, Pat. No. US 4599361  
DT Utility  
FS Granted  
LN CNT 1007  
INCL INCLM: 514/575.000  
INCIS: 260/500.500H

NCL	NCIM:	514/575.000	DT	Utility
IC	NCLS:	562/623.000	FS	Granted
[4]	ICM:	C07K031-10	LN.CNT	631
EXF	IC:	A61K031-165; A61K031-185	INCL	INCIM: 514/018.000
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				
19	ANSWER 232 OF 239 USPATFULL	IC:	INCIS: 514/44.000; 510/330.000; 530/331.000	
AN	88:477 USPATFULL	EXF	INCIM: 514/018.000	
TI	Method of inhibiting vertebrate collagenase activity using peptide hydroxamic acid derivatives	NCIM:	514/018.000	
IN	Spilburg, Curtis A., Chesterfield, MO, United States	NCLS:	514/844.000; 530/330.000; 530/331.000	
PA	Moore, William M., St. Charles, MO, United States	IC:	930/250.000; 930/DIG.785	
PI	Monsanto Company, St. Louis, MO, United States (U.S. corporation)	ICM:	A61K037-02	
PI	US 4720486	IC:	C07K005-08; C07K005-10	
AI	US 1987-1265	EXF	424/177; 260/112.5R; 514/112; 514/18; 514/844; 530/330; 530/331	
RLI	Pat. No. US 4687841	CAS INDEXING IS AVAILABLE FOR THIS PATENT.	930/250.000; 930/DIG.785	
DT	Utility	19	ANSWER 233 OF 239 USPATFULL	
FS	Granted	AN	86:71655 USPATFULL	
LN.CNT	INCIM: 514/018.000	TI	Hydroxamic acid based collagenase inhibitors	
INCIL	INCIS: 525.054.100	IN	Dickens, Jonathan P., High Wycombe, England	
NCL	NCIM: 514/018.000	PA	Donald, David K., High Wycombe, England	
NCLS:	525.054.100	PI	Kneen, Geoffrey, West Wycombe, England	
[4]	ICM: A61K037-02	AI	McKay, William R., High Wycombe, England	
EXF	IC: C08F283-00	DT	G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)	
5.4/18; 545.1	EXF	Utility	US 499361 19860708 19850910 (6)	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	19	ANSWER 233 OF 239 USPATFULL		
AN	87:58255 USPATFULL	AN	ANSWER 233 OF 239 USPATFULL	
TI	Peptide hydroxamic acid derivatives	AN	86:6621 USPATFULL	
IN	Spilburg, Curtis A., Chesterfield, MO, United States	TI	Carboxylalkyl Peptide derivatives	
PA	Moore, William McC., St. Charles, MO, United States (U.S. corporation)	IN	McCuilagh, Keith G., Princes Risborough, United Kingdom	
PI	US 467841	PA	Wadsworth, Harry J., High Wycombe, United Kingdom	
AI	19870818	PI	Hann, Michael M., Watlington, United Kingdom	
DT	19851018 (6)	AI	G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)	
FS	Utility	US 4588666 19860204 19841018 (6)		
LN.CNT	Granted	DT	Utility	
INCIL	INCIM: 530/331.000	FS	Granted	
INCIL	INCIS: 530/810.000; 530/813.000	LN.CNT	3163	
NCL	NCIM: 530/331.000	INCL	INCIM: 514/020.000	
NCLS:	530/810.000; 530/813.000	INCIL	INCIS: 260/112.500R	
IC	[4]	NCL	NCIM: 260/001.000; 562/443.000; 930/250.000	
ICM:	CO7C03-52	IC	NCLS: 260/001.000; 562/443.000; 930/250.000	
EXF	530/331; 530/810; 530/813	[4]	ICM: A61K037-00	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	EXF	IC:	CO7C03-52	
19	ANSWER 234 OF 239 USPATFULL	EXF	514/120; 260/112.5R	
AN	87:34104 USPATFULL	CAS INDEXING IS AVAILABLE FOR THIS PATENT.	930/250.000; 930/DIG.785	
TI	Peptide derivatives, the preparation and their use as elastase inhibitors	19	ANSWER 235 OF 239 USPATFULL	
IN	Robert, Ladislas, Santeny, France	AN	84:664289 USPATFULL	
IN	Hornbeck, William, Saint Cyr l'Ecole, France	TI	Therapeutic hypothermia instrument	
PA	Mozza, Elmer, Gif-sur-Yvette, France	IN	Wittels, Eleonora M., Rancho Palos Verdes, CA, United States	
PA	Centre National de la Recherche Scientifique, Paris, France (non-U.S. government)	PA	Atlantic Richfield Company, Los Angeles, CA, United States (U.S. corporation)	
PI	US 4656053	FR	1983-8052 19830516	

PI : US 4483341 19841120  
AI : US 1982-448114 19821209 (6)  
DT : Utility  
FS : Granted  
LN CNT: 805  
INC1: INCLM: 128/402.000  
INCUS: 128/303.100; 128/784.000; 062/003.000  
NCL : NCIM: 606/021.000  
NCLS: 062/003.100; 062/003.200  
IC : (3) ICM: A61R007-00  
EXF : 128/303.1; 128/399-403; 128/DIG.27; 128/784; 062/3; 062/335  
AN : ANSWER 238 OF 239 USPATFULL  
AN : 77:51189 USPATFULL  
TI : Steroidal erythropoietic agents and therapeutic compositions  
and methods  
IN : Strade, Henry A., Montville, NJ, United States  
PA : Akron Incorporated, Ashville, NC, United States (U.S. corporation)  
PI : 4049805 19770920  
AI : US 1976-593249 19760604 (5)  
RLI : Continuation-in-Part of Ser. No. US 1975-618176, filed on 30 Sep 1975,  
now patented, Pat. No. US 4004005  
DT : Utility  
FS : Granted  
LN.CNT : INCLM: 424/243.000  
NCL : 255  
IC : NCIM: 514/178.000  
[2] ICM: A61K031-565  
EXF : 424/243  
AN : ANSWER 239 OF 239 USPATFULL  
AN : 77:3777 USPATFULL  
TI : Steroidal erythropoietic agents and therapeutic compositions  
and methods  
IN : Strade, Henry A., Montville, NJ, United States  
PA : Akron Incorporated, Ashville, NC, United States (U.S. corporation)  
PI : 4004005 19770118  
AI : US 1975-618176 19750930 (5)  
DT : Utility  
FS : Granted  
LN.CNT : INCLM: 424/243.000  
NCL : 188  
IC : NCIM: 514/178.000  
[2] ICM: A61K031-565  
IC : A61K031-575  
EXF : 424/243  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.